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 Neurodegenerative diseases are a major cause of disability and 
premature death worldwide (Brettschneider et al. 2015). The prevalence of 
neurodegenerative disorders is increasing rapidly while disease-modifying 
therapies remain missing (Palop et al. 2006). Hence, understanding how 
neurodegenerative pathology spreads throughout the brain is integral to 
prevention and/or the discovery of disease-modifying therapies. Hallmark 
patterns of disease are well-characterized from converging animal model, post 
mortem and human neuroimaging evidence. However, predictive whole-brain 
models of neurodegeneration are much less studied.  
 This thesis utilizes complex graph theoretic methodology and multimodal 
human neuroimaging data to construct and evaluate predictive models of 
disease spread in several debilitating disorders, including Alzheimer’s Disease, 
Huntington’s Disease and Schizophrenia. By probing the two dimensions of 
network neuroscience (dynamics on networks vs. dynamics of networks), the 
current work seeks to elucidate mechanisms of neurodegeneration.  
 Chapter one gives biological background to the two dimensions of 
network neuroscience and current hypotheses of neurodegeneration in 
Alzheimer’s Disease (AD), Huntington’s Disease (HD) and Schizophrenia (SZ). 
Chapter two asks if Alzheimer’s Disease is a disorder encompassing dynamics 
on networks or dynamics of networks by using a predictive pathology spread 
model to assess whether the structural network undergoes degeneration or 
remains intact to simply serve as a conduit for degenerative pathology in AD. 
Chapter three expands on work presented in Chapter two by elucidating 
mechanisms at play atop the static structural network to determine the 
relationship between rate of neurodegeneration and CSF biomarkers. Chapter 
four focuses purely on dynamics on networks by constructing several models 
of pathology spread in Huntington’s Disease in an unprecedented dataset and 
is the first work to empirically evaluate predictive ability of popular 
neurodegenerative hypotheses in vivo. Chapter five analyzes dynamics of 
networks by exploring age-related organizational changes in the WM network 
and the relationship to gene expression in chronic schizophrenia. Together, 
these distinct studies elucidate the role of structural network organization in the 
dynamics of neurodegeneration and suggest an umbrella approach to modeling 
pathology spread.  Chapter six integrates findings across all three original 
studies and discusses the therapeutic implications of the current thesis, 
methodological considerations and future work.       
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Chapter 1: 
 An Introduction to Structural Network Dynamics and its 
Application to Neurodegeneration 
Introduction 
 Neurodegenerative diseases are a major cause of disability and 
premature death worldwide (Bird et al., 2003; Huisman et al., 2011; Savica et 
al., 2013). The prevalence of neurodegenerative disorders is increasing rapidly 
while disease-modifying therapies remain missing (Palop et al., 2006). Hence, 
understanding how neurodegenerative pathology spreads throughout the brain 
is integral to prevention and/or the discovery of disease-modifying therapies. 
While hallmark patterns of specific diseases are well-characterized from 
converging animal model, post mortem and human neuroimaging evidence, 
predictive whole-brain models of neurodegeneration are largely absent.  
 Recent advances in non-invasive neuroimaging and the application of 
graph theory, a method modeling pairwise relationships between objects in a 
graph, to neural networks constitute a rapidly evolving field known as network 
neuroscience. Broadly speaking, network neuroscience pursues new ways to 
map, record, analyze and model the elements and interactions of 
neurobiological systems (Bassett and Sporns, 2017). The current thesis 
applies tenets of network neuroscience to build and test predictive models of 
disease spread, with the goal of elucidating mechanisms of 
neurodegeneration. This chapter will provide background to the field of 
network neuroscience and explain how it can be applied to evaluate popular 
hypotheses of disease spread in three disorders, which include Alzheimer’s 
Disease, Huntington’s Disease and Schizophrenia.  
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Visualizing the brain as a network  
 Brain systems span multiple levels of organization. Starting as a single 
neuron, neurons communicate to form circuits, synapses are formed between 
circuits that lead to systems and, collectively, distinct but interrelated systems 
constitute the whole brain.  
 Until recently, whole brain studies in humans were rare and limited in 
scope. Previously, neuropathological studies were the only viable approach to 
whole brain mapping in humans, but required large autopsy cohorts or 
laborious methods for whole-brain sectioning and staining (Seeley, 2017). 
Recent advances in non-invasive neuroimaging offer the ability to visualize 
and test models in vivo that have long been restricted to post mortem, mouse 
model and cell culture methods. The current work capitalizes on such 
advances by utilizing neuroimaging data to build new models.   
 In 2005, Sporns and colleagues coined the phrase “the connectome” as 
the complete description of structural connections between elements of a 
nervous system (Sporns et al., 2005). However, visualization of a complete 
nervous system was by no means a novel concept. In 1974, all 302 neurons 
and respective connections encompassing the nervous system was mapped in 
C. Elegans (Brenner, 1974). The field of connectomics is unique in that it is 
rooted in the tenet that brain function is contingent on brain-network 
interactions, and that elucidating of higher brain function requires an 
understanding of brain-network organization (Sporns, 2012; Sporns et al., 
2005).   
 Quickly following the birth of the connectome came pathoconnectomics, 
which focuses on mapping abnormal brain networks, both elements and 
interaction (Rubinov and Bullmore, 2013a). As a logical extension of 
 3 
connectomics, the overall goal of pathoconnectomics is “to understand brain 
disorders at the casual mechanistic level, to be leveraged for therapeutic 
intervention” (Deco and Kringelbach, 2014). Given the progressive nature of 
neurodegenerative disease, pathoconnectomics represents an excellent 
approach to further understand progressive brain changes at the whole-brain 
level in neurodegeneration. 
 The intersection of sophisticated empirical methods for mapping 
neurobiological data with theoretical and computational advances in data 
analysis and modeling of brain networks has led to rise of network 
neuroscience (Bassett and Sporns, 2017). In network neuroscience, the brain 
is visualized as a network by constructing a graph consisting of vertices 
representing brain regions and edges as connections between them. Edges 
can be constructed from a wide array of non-invasive human neuroimaging 
methodology to represent both structural and functional networks. Anatomical 
and structural networks can be constructed from magnetic resonance imaging 
(MRI) and diffusion MRI, respectively (Bassett et al., 2008; Wang et al., 2012).   
Functional networks can be visualized using functional magnetic resonance 
imaging (fMRI) as well as electrophysiological methods such as EEG and 
MEG (de Haan et al., 2009; Redcay et al., 2013). The current thesis focuses 
on the construction of DTI-based graphs as the basis for structural networks.   
 Graph theory is rooted in the physical world (Bullmore and Sporns, 
2009). For example, air travel is an area where graph theory has been widely 
applied and further developed. Guimerra and colleagues showed that 
worldwide flight paths exhibit small world architecture of both simultaneous 
clustering and segregation, similar to that of the human brain (Guimera et al., 
2005).  
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 In network neuroscience, quantification of topological metrics such as 
modularity, path length, centrality and the distribution of hubs provides an 
understanding of brain organization (Figure 1.1) (Rubinov and Sporns, 2010; 
Stam and Reijneveld, 2007). 
 To illustrate an original example of graph theory as it applies to airport 
networks, JFK is an airport (vertex) in the graph that constitutes all daily flights 
in the United States (network). Flight path (distance) represents connections 
(edges) between the vertices (airports). Incidentally, JFK could be 
conceptualized as a hub, because, say, 70% of flights in the US stop through 
JFK en route to small cities and international destinations. When flying from 
JFK to LAX, a direct flight from JFK to LAX represents shortest path length, 
whereas flying from JFK to Houston to LAX represents a longer, less efficient 
path.  
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Figure 1.1. Measures of network topology. Adapted from Rubinov and 
Sporns, 2010. An illustration of key complex network measures (in italics) 
described in this thesis. These measures are typically based on basic 
properties of network connectivity (in bold type). Thus, measures of integration 
are based on shortest path lengths (green), while measures of segregation are 
often based on triangle counts (blue) but also include more sophisticated 
decomposition into modules (ovals). Measures of centrality may be based on 
node degree (red) or on the length and number of shortest paths between 
nodes. Hub nodes (black) often lie on a high number of shortest paths and 
consequently often have high betweenness centrality. Patterns of local 
connectivity are quantified by network motifs (yellow). An example three-node 
and four-link anatomical motif contains six possible functional motifs, of which 
two are shown—one motif containing dashed links, and one motif containing 
crossed links. 
 
 Organizational differences can be viewed both on the global level of 
characteristic metrics as well as the local level, which reflect the role of how 
individual regions fit into the larger network. Moreover, differences in global 
measures become more informative when supplemented by more detailed 
analyses that pinpoint specific network element of local measurements of 
network topology (Wig et al., 2011). The current thesis makes use of both 
global and local widespread topological properties such as path length, degree 
and clustering as well as additional, more complex properties of network 
graphs, which will be expounded upon in later chapters.  
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Dynamics in network neuroscience  
 An emerging frontier of network neuroscience is the investigation of 
network dynamics, which is defined as how networks change over time 
(Bassett and Sporns, 2017). Importantly, the mechanistic role of structural 
brain networks for shaping brain dynamics is a key rationale for mapping the 
human connectome (Sporns, 2014). The current thesis defines structural 
network as the interconnected system of nodes and vertices defined from 
white matter fiber pathways. Hence, the current work will focus on mapping 
structural network dynamics, which are changes involving the structural 
network over time,  as a means to elucidate neurodegenerative processes.  
 Though static differences between diseased and healthy structural 
networks are well-characterized, the study of network dynamics is increasingly 
important in order to build comprehensive models of neurodegeneration. 
Neurodegeneration, by definition, is characterized by dynamic, progressive 
changes the brain (Jucker and Walker, 2013). Thus, predictive models of 
neurodegeneration must correspondingly capture elements of dynamicity.  
 Basset and Sporns identify two important dimensions of how networks 
change: 1) How activity patterns can change on top of a fixed structural 
network and 2) How structural network edges themselves can reconfigure. 
These dimensions are, respectively, referred to as 1) Dynamics on structural 
networks and 2) Dynamics of structural networks (Bassett and Sporns, 2017; 
Holme and Saramäki, 2012) (Figure 1.2). The current work carries out original 
studies that investigates dynamics on structural networks, dynamics of 
structural networks and also incorporates methodology to test both 
simultaneously. The subsequent paragraphs will provide specific examples 
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illustrating dynamics on vs. of structural networks and how it relates to current 
models of neurodegeneration.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. Dynamic network models. Adapted from Bassett and Sporns, 
2017. In the field of network science, two types of dynamic processes are 
studied in some detail: dynamics on networks and dynamics of networks. (a) 
Dynamics on networks indicates that the activity (or some other property of 
interest) of nodes changes as a function of time. Here we illustrate decreasing 
activity (pink), increasing activity (gray) and changes in the pattern of activity 
(blue) over time in distinct network modules or communities. (b) Dynamics of 
networks indicates that the edges of the network themselves change either in 
their existence/absence or in their strength. Here we illustrate the coalescence 
of modules (blue and yellow), as well as the transfer of allegiance of a single 
region from one module (pink) to another (yellow) over time.  
 
 
Dynamics on structural networks in neurodegeneration  
 Neurodegeneration is broadly classified as a progressive loss of 
function or structure of neurons. Nearly all neurodegenerative disorders are 
classified by stereotypical patterns of disease progression related to clinical 
symptomatology (Brettschneider et al., 2015). These patterns suggest 
pathology is not only simply propagated between neighboring cell bodies, but 
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that it also spreads along axonal pathways either away from (anterogradely) or 
toward (retrogradely) the cell body (Brundin et al., 2010). Though there exists 
heterogeneity among specific cellular and genetic mechanisms implicated in 
pathophysiological processes, we observe unifying patterns of broader 
neurodegeneration on the whole-brain scale.  
 A multitude of hypotheses describe the neurodegenerative process as 
as dynamics on structural networks. Such examples include the cascade 
hypothesis, dual-hit hypothesis, network failure hypothesis and the prion 
hypothesis (Heinemann et al., 2016; Jucker and Walker, 2013; Karran et al., 
2011; Palop et al., 2006). When examining dynamics on structural networks, 
the current thesis will limit its scope to prion hypothesis.  
 The prion hypothesis posits specific proteins aggregate and misfold, 
propagating trans-synaptically throughout the brain in a template-directed 
manner (Jucker and Walker, 2013). There is considerable evidence for the 
prion hypothesis in several neurodegenerative disorders, including Alzheimer’s 
Disease (AD), Frontotemporal Dementia (FTD), Amyotrophic Lateral Sclerosis 
(ALS), Huntington’s Disease (HD) and Parkinson’s Disease (PD) (Lee et al., 
2001; Neumann et al., 2006; Ren et al., 2009; Spillantini et al., 1998).  
 However, these hypotheses have been developed and evaluated 
extensively in human post mortem studies, animal models and cell culture. 
Rarely have these models have been tested and validated in vivo on human 
neuroimaging data. In Chapter 2 - 4, the present thesis will evaluate and 
construct dynamics on structural network models to empirically test 
hypotheses of pathology spread in AD and HD as a means to elucidate 
mechanisms of trans-synaptic pathology spread.   
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The Network Diffusion Model  
 The Network Diffusion Model (NDM) is one of the few published 
predictive computational tools recapitulating the prion hypothesis in vivo and 
will be used as a tool in the current work. The NDM is an example of how 
whole-brain computational models can generate and predict dynamic brain 
interactions and consequences over many timescales (Rubinov and Bullmore, 
2013a). 
 The principal investigator overseeing the current thesis developed the 
Network Diffusion Model in 2012 as a means to model tau pathology spread 
on a healthy structural connectome in Alzheimer’s Disease (Raj et al., 2012). 
Subsequently, the model was validated, showing high predictive ability in 418 
subjects on the AD spectrum from the publicly available Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) dataset (Raj et al., 2015) (Figure 1.3). The 
Network Diffusion Model represents dynamics on structural networks, as it 
assumes a static white matter network on which tau pathology spreads. 
 In the Network Diffusion Model, atrophy is used a surrogate for tau, as 
prior work shows a close association between the two (Attems et al., 2012; 
Reitz et al., 2009). From a baseline pattern of atrophy (pathology), an end 
state level of atrophy (pathology) can be predicted using linear algebra and 
complex graph theory.  
 To provide a more granular description, the NDM is an equation that 
describes the following process: From a baseline regional pattern of 
pathology, a diffusion kernel is calculated, which modifies pathology over time. 
The diffusion kernel calculation is based on eigen-decomposition of the 
Laplacian matrix. Eigenmode is a non-linear graph theoretic measure 
reflective of a region’s “hubness” (Raj et al., 2012). Ultimately, the topological 
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metric of structural eigenmode governs disease spread. The original NDM 
does not assume directionality of disease spread and structural connections 
between regions are positive and the same in either direction.  
 The current thesis will evaluate the network diffusion model (NDM) on 
structural network associated with different disease states in AD (Chapter 2-3). 
In Chapter 4, several modifications to the model will be made in order to 
create new applications and models of pathology spread in HD.  
 
Figure 1.3. The Network Diffusion Model., adapted from Raj et al. 2012.  
Predicted atrophy of an AD subject, t=0, 5, 10 years from baseline. Predicted 
atrophy correlates strongly to observed end state atrophy (not pictured). The 
spheres are proportional to effect size, and color-coded by lobe: frontal = blue, 
parietal = purple, occipital = green, temporal = red, and subcortical = yellow.  
 
Neurodegeneration: Dynamics of structural networks  
 Further hypotheses of neurodegeneration posit that because brain 
function is strongly linked to structure, the structural network does not remain 
static, but rather undergoes changes with disease progression (Seeley et al., 
2009). Such hypotheses illustrate dynamics of structural networks.   
 Changes to the white matter network in neurodegeneration are studied 
significantly less than gray matter network changes such as atrophy, resting 
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and task-based fMRI and electrophysiological measures. Current hypotheses 
of white matter network neurodegeneration have been developed and 
perpetuated using tract-based spatial statistics (TBSS), which include 
fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity (AD) and 
radial diffusivity (RD). While diseases such as Amyotrophic Lateral Sclerosis, 
Alzheimer’s Disease and Schizophrenia have a moderate amount of data 
suggesting degeneration of the structural network, findings in Huntington’s 
Disease and Parkinson’s Disease are relatively rare (Abrahams et al., 2005; 
Damoiseaux et al., 2009; Mori et al., 2007).  
 While these findings are important to understand measures of tract 
integrity, they do little to elucidate changes in network organization. As such, 
graph theory represents a useful tool to help elucidate topological dynamics of 
neurodegeneration. Unfortunately, topological changes associated with 
neurodegeneration remain understudied. Most neurodegenerative studies of 
white matter organization are limited to specific patient cohorts compared to 
healthy controls (Lo et al., 2010; McColgan et al., 2015; van den Heuvel et al., 
2010).  Few studies evaluate models of structural degeneration after disease 
onset utilizing graph theoretic approaches, neither cross-sectionally nor 
longitudinally. In hopes of providing new data to this space, the current thesis 
seeks to model and elucidate changing brain architecture after disease onset 
using schizophrenia (Chapter 4).    
 
Alzheimer’s Disease 
 Alzheimer’s disease (AD) is the most prevalent neurodegenerative 
disorder and is characterized by progressive memory loss in old age. It affects 
1 in 100 patients and 6% of individuals over age 70 (Bird et al., 2003). Though 
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the disease is largely sporadic, various alleles of the APOE gene have been 
linked to sporadic and the rare familial AD incidence (Saunders et al., 1993). 
Dynamics on structural networks in AD 
 The earliest histopathological human studies by Braak and Braak 
illustrate characteristic patterns of disease progression in AD (Braak and 
Braak, 1991). Briefly, it is believed pathology begins in the locus coerlus (LC) 
before spreading to the entorhinal cortex, the broader hippocampus, 
throughout the medial temporal lobe and frontal and parietal regions (68 – 
Brett) (Brettschneider et al., 2015). This patterning has been supported and 
expanded by additional post mortem, animal model and human neuroimaging 
evidence (Braak and Braak, 1996; de Calignon et al., 2012; Fischer et al., 
2016).  
 Though several models of neurodegeneration exist, the current thesis 
will be limited to exploring the prion hypothesis. Specifically, the prion 
hypothesis in AD postulates that toxic tau protein misfold and aggregate first in 
the LC before spreading throughout the brain, transynaptically. Unknown 
cellular mechanisms ultimately cause tau to trigger amyloid beta pathology, 
which also spreads throughout the cortex to the brainstem (Thal et al., 2002).  
The recent advent of non-invasive PET tracers allow visualization of amyloid 
beta and tau in vivo recapitulate AD patterning, which recapitulate these 
patterns of disease in vivo (Schöll et al., 2016; Schwarz et al., 2016). 
Particularly, animal injection studies provide strong evidence for trans-synaptic 
spread, illustrating that exogenous injection of human mutant tau into the 
LC/EC spreads to connecting regions in a stereotypical manner (Clavaguera 
et al., 2009; Iba et al., 2015, 2013). 
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 As a result of the robust converging evidence supporting the prion 
hypothesis, the NDM, explained above, was developed to model tau dynamics 
on a static healthy structural network. This model will be used in the 
subsequent thesis as a tool to elucidate mechanisms of disease spread in AD. 
Dynamics of structural networks in AD 
 Tract-level differences in white matter integrity is a well-established 
biomarker of AD. A proliferation of studies, both in public and private datasets, 
show diffuse, global alterations in white matter tracts, especially in tracts 
connecting frontal and temporal regions (Uncinate Fasciculus) as well as 
tracts in the temporal region (Inferior Longitudinal Fasciculus) and tracts 
connecting the front and back of the brain (Superior Longitudinal Fasciculus) 
(Hasan et al., 2012; Lee et al., 2015; Nir et al., 2013; Rowley et al., 2013).  
 Despite significant changes in tract integrity, studies of structural 
topology in AD are inconclusive. For example, some studies report aberrant 
global topology across all metrics in AD, while others report disturbance of just 
a few topological metrics (Bai et al., 2012; Daianu et al., 2013; Lo et al., 2010). 
Incidentally, other studies report structural organization of the backbone is 
intact (Daianu et al., 2015). 
 Still, the extent to which disease spread is affected by well-established 
changes in structural integrity and inconclusive changes in topology remains 
poorly understood. Furthermore, it remains unknown if AD is primarily a 
disorder of the gray matter network (dynamics on structural networks) or the 
white matter network (dynamics of structural networks). To answer this 
question, the current study uses the Network Diffusion Model, which is 
independent of traditional graph summary metrics, as a mechanistic tool. By 
testing the Network Diffusion Model on differing static networks, results can be 
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synthesized to form conclusions that evaluate dimensions of both dynamics 
on structural networks as well as dynamics of structural networks.  
 
Huntington’s Disease 
 Huntington’s Disease (HD) is the most common form of inherited 
neurodegenerative disease. The incurable disorder is caused by an autosomal 
dominant mutation causing CAG repeat expansion and is characterized by 
abnormal motor movements and personality changes. Like all 
neurodegenerative diseases, the age of onset begins in adulthood, with the 
age of onset being inversely related to the length of mutated CAG repeats. 
Death usually occurs 10-15 years after onset (Arrasate and Finkbeiner, 2012). 
Dynamics of structural networks in HD   
 Relatively little whole brain preliminary evidence exists supporting 
dynamics of structural networks in HD. However, there is compelling work 
done in pre-HD suggesting that white matter network alterations do occur early 
in the disease, showing loss of white matter integrity of certain tracks, which is 
related to symptomatology (Rosas et al., 2006). Similarly, DTI-based studies 
focusing on regions of interest linked to the basal ganglia show decreased 
structural connectivity in HD compared to healthy controls (Kloppel et al., 
2008; Marrakchi-Kacem et al., 2013; Novak et al., 2015). However, few 
studies illustrate whether changes to structural organization correspond to 
changes in structural integrity. One such study, utilizing human neuroimaging 
included in the current thesis, investigates global topology of HD. Vulnerability 
of rich club regions and loss of topological metrics reflective of network 
integration is reported (McColgan et al., 2015). Because dynamics of 
structural networks in HD have already been modeled in our subject cohort, 
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the present thesis examines dynamics on structural networks. Present models 
in the context of HD will be described below.  
Dynamics on structural networks in HD   
 It is suggested that while structural changes in the white matter network 
of HD exist, substantially more evidence exists to make a case for modeling 
dynamics on structural networks in HD. For example, neuroimaging data of 
657 subjects show gray matter changes are detectable in pre-HD subjects 
significantly sooner than white matter changes (Paulsen et al., 2010).  
 Unlike other neurodegenerative diseases, which are not characterized 
by a clear cause-and-effect mutation, CAG nucleotide repeats are linked to 
pathogenic expansion of glutamines on the huntingtin protein (HTT) in HD 
(Arrasate and Finkbeiner, 2012). 
 It is hypothesized that pathogenic HTT is the cause of degeneration in 
HD. Immunostaining of post mortem HD brains shows HTT inclusions in the 
nucleus as well as the cytoplasm and in neuronal processes (Becher et al., 
1998; Gutekunst et al., 1999; Kim et al., 2001). Furthermore, pathogenic HTT 
correlates with HD symptoms in transgenic mouse models and found in 
neurons before the onset of behavioral symptoms (Davies et al., 1997; 
Ordway et al., 1997). A multitude of studies suggest mutant HTT misfolds and 
aggregates. For example, cell culture models show that mutant HTT is 
capable of oligomerizing and causing cell death (Herrera et al., 2011). Mutated 
HTT has been reported to diffuse into extracellular space and inside adjacent 
cells to act as seeds for further aggregation and neurotoxicity (Ren et al., 
2009). Similarly, transgenic mouse models illustrate formation of HTT 
aggregations that spread throughout the brain (Ordway et al., 1997). 
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  The striatum is believed to be the origin of pathology in HD. This is 
supported by converging post mortem, animal model and human 
neuroimaging data. For example, several post mortem studies show global 
atrophy of the brain, with the striatum experiencing the most drastic reductions 
(de la Monte et al., 1988; Vonsattel et al., 1985). Similarly, animal models 
utilizing genetic knock-ins report the striatum as the region of the first and 
most significant degeneration (Hodgson et al., 1999; Zhang et al., 2010). 
Classic human neuroimaging studies also illustrate extreme atrophy in striatal 
regions compared to the rest of the brain, which is associated with clinical 
phenotypes (Aylward et al., 2000; Harris et al., 1992; Starkstein et al., 1992).
 The previously introduced prion hypothesis is one popular hypothesis of 
pathology spread in HD. In the case of HD, it proposed that mutant HD 
pathology begins in the striatum before diffusing before spreading both 
rostrally and caudally throughout the cortex (Brundin et al., 2010). Though 
prion hypotheses seem logical in the context of mutant HTT findings, contrary 
work shows mutant HTT is more actually common the cerebral cortex than the 
striatum (Gutekunst et al., 1999). Moreover, HTT aggregates occur in the 
interneurons, instead of the medium spiny projection neurons known to die 
first in HD (Kuemmerle et al., 1999). While it is obvious that pathology indeed 
spreads in HD, whether it is caused by HTT itself, or downstream inclusion 
bodies or deficits in cell signaling remains unclear.   
 Nonetheless, similar to other neurodegenerative disorders, 
degenerative phenomena follow stereotypical patterns in HD (Tabrizi et al., 
2013, 2012, 2009). Hypotheses of HD spread have been developed in human 
post mortem, mouse model and cell culture work. Due to the rarity of the 
disorder, which affects 3 in 100,000 million people, large neuroimaging 
 17 
datasets of HD are rare (Harper, 1992). Correspondingly, predictive whole 
brain models evaluating disease spread remain absent. The Network Diffusion 
Model represents an excellent tool to test neurodegenerative dynamics on 
structural networks in HD. Specifically, Chapter four of the current thesis is the 
first work to empirically evaluate several models of toxicity spread rooted in 
prion hypotheses in HD using an unprecedented human neuroimaging 
dataset.  
 
Schizophrenia  
 Schizophrenia affects 1% of the population worldwide and is 
characterized by extreme heterogeneity of symptomatology both between 
subjects and also within a single subject (Fornito et al., 2012). Unlike other 
neural disorders with well characterized symptoms, clinical heterogeneity 
makes it increasingly difficult to pinpoint where abnormalities in neural circuitry 
lie and how they arise. Originally proposed by Wernicke due to the nature of 
symptoms, it is postulated that network disorganization in focal areas of the 
brain leads to global aberrant information integration (Rubinov and Bullmore, 
2013b).  
 Similar to other neurodegenerative diseases, age of onset can be early 
adulthood. However, some subjects have onset beginning in the late teens 
and a small percentage of subjects even experience childhood onset (DeLisi, 
1992). Due to several factors, including age discrepancies, human 
neuroimaging researchers are divided on how to classify schizophrenia 
(Kochunov and Hong, 2014). There is compelling evidence to suggest primary 
disturbance most likely from a genetic abnormality leads to a predisposition of 
schizophrenia, which results in a prolonged brain developmental period. Such 
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findings lead some researchers consider schizophrenia a neurodevelopmental 
disorder (Benes et al., 1994; Rapoport et al., 2012; Walsh et al., 2008).  
Conversely, changes in white matter integrity and gene expression cause 
some groups classify the disease as purely neurodegenerative (Pasternak et 
al., 2012; Rao et al., 2015). Still, others call it a neurodegenerative disorder 
with neurodevelopmental antecedents (Ashe et al., 2001). This debate is of 
particular relevance because determining whether a particular hallmark is a 
pathogenic mechanism (neurodegenerative) or a coping response 
(neurodevelopmental) has important therapeutic consequences (Arrasate and 
Finkbeiner, 2012) 
 As such, the current thesis seeks to shed light on progressive, possibly 
neurodegenerative, processes implicated in schizophrenia by modeling on-
going structural brain changes. Because no pathogenic proteins have been 
strongly linked to schizophrenia in a manner similar to other 
neurodegenerative disorders, dynamics of network models will be 
emphasized. Due to strong evidence of abnormal gene expression in 
schizophrenia, the relationship between structural changes and gene 
expression will also be explored.  
Dynamics of structural networks in SZ 
 Current models suggest SZ is a disorder of global brain dysconnectivity 
in the white matter network (Pettersson-Yeo et al., 2011). White matter 
changes as it relates to TBSS, which are metrics reflective of white matter 
integrity, are widespread. Though prevalent, TBSS findings are diffuse and 
inconsistent. Inconsistency both within and between subject cohorts in imaging 
protocols exacerbates inconsistency. For example, Fujino and colleagues 
show reduced FA in frontal, temporal, parietal and occipital lobes, a large 
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portion of the corpus callosum and also the corona radiata. A subset of 
psychosis symptoms correlate with FA in the IFOF and the anterior thalamic 
radiation (Fujino et al., 2014). In medication-naïve subjects, reduced FA in the 
the ILF and left IFOF in subjects all subjects is observed compared to controls. 
However, patients with audio-visual hallucinations show higher connectivity in 
the forceps major and IFOF than subjects with auditory hallucinations (Amad 
et al., 2014; Liu et al., 2014). While such work is integral in understanding 
changes to integrity, it does not provide significant context to dysconnectivity 
theories, as whole-brain organization is not probed.  
 A handful of studies apply graph theory to DTI networks in 
schizophrenia to assess a variety of global and local metrics (Fornito et al., 
2012; van den Heuvel et al., 2013, 2010; Wang et al., 2012). Among these 
topological studies, more consistent findings emerge. Less central hubs in 
frontal regions and to some degree, subcortical/limbic areas is observed. 
Differences in metrics reflective of network integration in these same regions is 
also observed. These studies lend tremendous support to abnormal structural 
network organization, reflecting dysconnectivity. 
 However, such studies generally compare patients and controls at 
baseline. Models of how structural networks in SZ change after disease onset 
are lacking. Furthermore, topological abnormalities have yet to be integrated 
into a clinically validated model of schizophrenia; such a model would for 
instance allow a rational approach to the search for treatment and prevention 
of the disorder (Rubinov and Bullmore, 2013b). Hence, Chapter 5 of the 
current work seeks to understand changes dynamics of structural networks 
after SZ onset.  
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The current thesis  
 This thesis utilizes complex graph theoretic methodology and 
multimodal human neuroimaging data to construct and evaluate structural 
dynamic network models of neurodegeneration in several debilitating 
disorders, including Alzheimer’s Disease, Huntington’s Disease and 
Schizophrenia. Chapter 1, “An Introduction to Structural Network 
Dynamics and its Application to Neurodegeneration,” presents the field of 
network neuroscience and reviews literature of the current state of knowledge 
of neurodegenerative models in relevant disorders. The advent of non-invasive 
neuroimaging techniques and the application of graph theory has led to 
neuroscientists conceptualizing the complete brain as a network graph of 
nodes and edges in a field called network neuroscience. Within network 
neuroscience, we introduce that brain changes can be modeled according to 
two dimensions, which include a 1) dynamics on networks as well as a 2) 
dynamics of networks approach. Prior work shows that all neurodegenerative 
disease, show a stereotypical pattern of disease progression throughout the 
brain, but mechanisms underlying network spread remain unknown. Though 
there is much evidence supporting several different hypotheses of spread, 
most of these models have been developed as a result of converging post 
mortem, mouse model and cell culture studies. Few have been evaluated in 
vivo. The subsequent set of original studies seeks to test and create new 
models of prion-based disease spread implicating the structural connectome.  
 Alzheimer’s Disease is perhaps the most well-studied 
neurodegenerative disease and represents an excellent disorder to test 
hypotheses of both dynamics on structural networks and dynamics of 
structural networks. Chapter 2, “Preserved Overall Network Organization 
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in AD Spectrum Despite Loss of White Matter Tract Integrity,” examines 
whether the structural network is simply a conduit of pathology or also 
undergoes degeneration itself. Particularly, predictive performance of the 
Network Diffusion Model is examined on both healthy and diseased 
connectomes to give insight into mechanisms mediating disease spread and 
probe network structural topology. It is illustrated that despite measurable 
losses in white matter tract integrity, organization of the brain in Alzheimer’s 
disease is preserved.  Chapter 3, “A New Network-Constrained Technique 
to Characterize Neurodegenerative Progression Rate in Alzheimer’s 
Disease” extends work conducted in Chapter 2 by presenting a new method 
to detect the rate of speed of pathology spread in AD using the NDM and 
establishing a relationship between baseline CSF biomarkers and a subject’s 
range of speed of neurodegeneration. 
 After confirming the white matter network serves as a conduit for 
degeneration in AD, a disease that mirrors AD in many ways, but is 
fundamentally understudied in the context of human neuroimaging due to its 
extremely rare incidence, is examined. Chapter 4, “Structural Network 
Model of Pathology Spread Best Predicts Neurodegeneration in 
Huntington’s Disease,” empirically tests several mechanisms rooted in the 
prion hypothesis that may mediate trans-synaptic pathology spread in HD, 
including genetic hypotheses, distance hypotheses, activity-dependent 
hypotheses and structural hypotheses. The first work to model hypotheses of 
pathology spread in HD, it is illustrated that a directional structural network 
model of neurodegeneration best predicts end state HD pathology. It is also 
shown that intrinsic structural architecture is important in mediating disease 
spread.   
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 Having fully examined dynamics on networks, further elucidation 
involving dynamic of networks is required, using schizophrenia as a model 
disorder. Unlike AD and HD, Schizophrenia is not linked to a clear pathogenic 
protein species. However, hallmark patterns of neurodegeneration are still 
present. Chapter 5, “Age-Related Changes in Topological Degradation of 
White Matter Networks and its Relationship to Gene Expression in 
Chronic Schizophrenia,” probes changes in brain organization and 
corresponding relationships to gene expression with age in chronic 
schizophrenia. Age-related changes in the white matter network that are 
driven by younger subjects is observed, which suggest schizophrenia could be 
best viewed as a neurodevelopmental disorder and perhaps not 
neurodegenerative. Together, these findings point to the importance of 
structural network organization and feasibility of constructing topological 
models to capture the dynamic nature of neurodegeneration. Chapter 6 
“Toward an Umbrella Approach to Modeling Neurodegeneration: Clinical 
Implications, Future Studies and Conclusions,” integrates findings from 
the original studies presented in this thesis into the context or prior work on 
neurodegeneration. The feasibility of constructing a single umbrella model 
applicable to all neurodegeneration is discussed. Lastly, clinical implications of 
such an umbrella approach, methodological limitations of the current work and 
propose future advances in future research are considered.
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Chapter 2: 
Preserved Overall Network Organization in AD Spectrum 
Despite Loss of White Matter Tract Integrity 
Introduction 
 Presence of amyloid-β plaques and tau protein-related 
neurodegeneration are widely accepted biomarkers of Alzheimer’s Disease 
(AD) (Braak and Braak, 1991; Jack and Holtzman, 2013; Pearson et al., 
1985). Several proposed models of AD exist, including the amyloid-cascade 
hypothesis, cascading network failure hypothesis and the prion hypothesis 
(Jones et al., 2016). The current work investigates “prion-like” transmission 
AD, whereby specific proteins misfold, aggregate and propagate, causing toxic 
gain of function and loss of function (Jucker and Walker, 2013). It is 
hypothesized these proteins spread trans-synaptically along neuronal 
pathways in specific patterns, as observed by classic clinical and anatomical 
progression in patients (Braak and Braak, 1991; Pearson et al., 1985; Saper et 
al., 1987). Converging human neuroimaging data showing stereotyped gray 
matter atrophy and functional connectivity impairments support this view 
(Apostolova et al., 2007; Pievani et al., 2011; Thompson et al., 2003). 
Recently published human neuroimaging of tau protein in AD recapitulate 
classic disease spread in vivo, which further supports trans-synaptic spread 
hypotheses (Schöll et al., 2016; Schwarz et al., 2016).  
 The brain’s anatomic connectivity, given by white matter (WM) fiber 
pathways, is thought to play a key role in mediating regional relationships 
between various imaging biomarkers (Pandya et al., 2016). Anatomic 
connectivity appears to be impaired in AD and conversely, might serve as 
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conduit for progressing pathologies (Damoiseaux et al., 2009; Liu et al., 2011; 
Raj et al., 2012; Xie et al., 2006). Recently, our group proposed a graph 
theoretic model of tau pathology spread enacted on DTI-based WM 
connectivity networks. This model, called the network diffusion model (NDM), 
predicted that observed spatial patterns of degenerative diseases might be 
explained simply as a consequence of network spread. Subsequently, the 
NDM successfully predicted future atrophy patterns of AD subjects using their 
baseline regional atrophy (Raj et al., 2015). Thus, the NDM is based on the 
transmission of tau, but successfully predicts progression of regional atrophy, 
owing to the strong association between the two (Attems et al., 2012; Forman 
et al., 2002). In these models, connectivity networks were obtained from 
healthy subjects only, under the assumption that anatomic connectivity serves 
merely as a conduit for the transmission and ramification of pathologic entities, 
rather than itself being the primary target of those pathologies.  
 It is therefore emerging that both pathology and connectivity affect each 
other. While highly connected hub-like regions appear to have impaired 
connectivity in AD, they are also facilitators of pathology, and anchor 
epicenters or attractors into which pathology accumulates, as given by the 
network diffusion theory (Lo et al., 2010; Raj et al., 2012; Zhou et al., 2012). 
Intuitively, these hubs receive more exposition to pathogens due to their 
central roles in the network. Hence it is of interest to determine the causality of 
these processes, i.e. whether network organization governs disease 
transmission, or vice versa. Would lower connectivity or deteriorated 
microstructure impede synaptic spread or would higher pathology burden 
cause greater impairment of fiber tracts to pathogens and thus augment 
pathology propagation? 
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 The current study uses network modeling in a multimodal dataset of 
124 subjects from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) to 
investigate the impact of AD pathology on WM network organization, and the 
impact of WM network organization on pathology spread in the AD spectrum. 
We hypothesize that if WM network topology is altered prominently in AD, then 
it would lead to measurable change in the pattern of atrophy spread predicted 
by the NDM (Raj et al., 2012). To test this, we investigate 1) Global and local 
WM network organization changes in AD 2) The impact of thresholding on 
network metrics and 3) NDM performance on both canonical healthy 
connectomes as well as subject-specific connectomes against empirical 
regional longitudinal patterns.  
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Methods  
Participants 
 All subject data were obtained from the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) database (http://adni.loni.usc.edu/). ADNI is a 
public-private private, large multisite longitudinal study with the goal of tracking 
AD biomarkers and accelerate prevention and treatment of the disease. 
Subjects were diagnosed and grouped to Alzheimer’s Disease (AD), Late Mild 
Cognitive Impairment (LMCI), Early Mild Cognitive Impairment (EMCI) and 
Control (CON) according to ADNI data description. All subjects have 
volumetric MRI and Diffusion MRI data. All subjects had at least one follow-up 
scan and there were no converters between scans. Subject demographic 
information is listed in Table 2.1.    
 
Table 2.1. Demographic information of study participants. 
+ Denotes average time elapsed from baseline to the final longitudinal scan on 
which the NDM model is tested. 
*** p<.001     ** p<.01  
Group  N  Age 
 (std)  
Age 
vs. 
CON  
Male / 
Female  
Gender 
 vs. 
CON 
Amyloid 
Burden 
 (std) 
Amyloid 
vs. CON  
Time 
Elapsed 
From 
Baseline+ 
AD 19  73.5 
 (9.9) 
p=0.64 11 M / 
8 F 
p=0.22 1.54  
(.21) 
p=5.08e-
05 *** 
131.3 
days 
EMCI  42 70.5 
 (7.7) 
p=0.23 24 M / 
18 F 
p=0.03 1.35  
(.23) 
p=0.11 454.7 
days  
LMCI 26 72.6  
(6.3) 
p=0.86  18 M / 
8 F 
p=0.50 1.44  
(.22) 
p=0.002 
** 
532.8 
days 
CON  37 72.4  
(6.1) 
-- 19 M / 
18 M 
-- 1.28 
 (.15) 
-- -- 
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MR image acquisition 
 DTI and inversion-recovery spoiled gradient recalled (IR-SPGR) T1-
weighted imaging data were acquired on several General Electric 3T scanners 
using scanner specific protocols. Briefly, DTI data were acquired with a voxel 
size of 1.372 × 2.70 mm3, 41 diffusion gradients and a b-value of 1000 s/mm2. 
IR-SPGR data were acquired with a voxel size of 1.022 × 1.20 mm3. All 
imaging protocols and preprocessing procedures are available on the ADNI 
website. (http://adni.loni.usc.edu/methods/). 
T1-weighted image processing 
 Automated cortical and subcortical volume measures were performed 
with FreeSurfer software package, version 5.3 
(http://surfer.nmr.mgh.harvard.edu/fswiki)   (Fischl et al., 2004, 2002). 
Automated cortical and subcortical volume measures were performed with 
FreeSurfer software. To reduce the confounding effect of intra-participant 
morphological variability, each participant’s longitudinal data series was 
processed by FreeSurfer longitudinal workflow 
(http://surfer.nmr.mgh.harvard.edu/fswiki/LongitudinalProcessing). A previous 
test-retest study validated that the longitudinal processing provides consistent 
regions of interest (ROI) segmentation (Reuter et al., 2012). All images 
underwent standardized quality control. Participants with complete 
segmentation failure or gross errors throughout all brain regions were rated as 
complete failure. Participants with gross errors in one or more specific brain 
regions (i.e., temporal lobe regions, superior regions, occipital regions, and 
insula) were given partial pass rating. Participants with partial pass rating were 
included in analyses. 
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 Raw DWIs were corrected for image artifacts including Eddy current, 
motion, and EPI distortions using FSL toolbox (https://fsl.fmrib.ox.ac.uk/fsl).  
Diffusion tensors were modeled at each voxel in the brain from the corrected 
DWI scans using CAMINO toolbox (http://www.camino.org.uk). Afterward, the 
deterministic simple whole WM streamlining has been applied on the diffusion 
tensor images (DTI) using CAMINO software. The tissue masks from T1 
image was rigidly registered to the first frame of the DWI and used in the WM 
tractography. Subject-specific FreeSurfer (Desikan-Killarney) cortical and 
subcortical parcellations mapped in the DTI subject space is used to calculate 
the 86x86 ROI-ROI connectivity matrix. 
Network construction and analysis 
 The number of resulting streamlines connecting any two gray matter 
regions, including from both cortical and subcortical regions were considered 
as edge weights in the resulting graphs. To control for inter-subject variance in 
total streamline count, the number of connections between each tract was 
divided by the total number of tracts computed on each subject’s tractography 
data, to yield a connectivity density metric.     
 Characteristic graph metrics to examine differences in network topology 
were calculated from undirected, weighted structural connectivity matrices. 
Matrices were not thresholded unless otherwise noted. Network metrics 
including density, global efficiency, clustering coefficient, local connection 
strength, local efficiency and local modularity were computed in MATLAB 
using the Brain Connectivity Toolbox (BCT) (Rubinov and Sporns, 2010).  
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Network Diffusion Model 
 The network diffusion model (NDM) is used as described in Raj et al. 
2012. The NDM was constructed and illustrated as described in Figure 2.1. 
Briefly, AD-related disease pattern, given by the vector x(t), is modeled as a 
diffusive process:  
    (Eq 1) 
where x0 is the initial regional pattern of the disease, on which the term e−βHt 
acts as a spatial and temporal blurring operator. We therefore call e−βHt, “the 
diffusion kernel.” The computation of the above equation is accomplished via 
the eigenvalue decomposition H  = UΛU† , where U  = [u1  … uN ], giving: 
 
    (Eq 2) 
 In other words, the NDM is evaluated via the eigen-decomposition of 
the Laplacian matrix, such that the pattern of disease at any point of time is 
given as a linear superposition of the eigenmodes ui’s of the Laplacian. 
Eigenmodes are calculated, using spectral graph theory on the WM 86x86 
ROI Laplacian matrix based on spectral graph theory. These eigenmodes, in 
turn, represent fundamental substrates upon which network spread of 
pathological entities is enacted. Hence, we investigated whether the prominent 
eigenmodes are conserved between patients’ individual subject-specific 
connectomes and a canonical healthy connectome obtained by averaging a 
large number of healthy subject connectomes. 
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Statistical analysis 
 A cross-sectional design is used to evaluate topology differences in 
connectomes, because most subjects had a single DTI scan. Independent, 
two-sided t-tests were used to test for differences in characteristic graph 
metrics between each patient group (AD, LMCI, EMCI) compared to controls. 
Patient groups were not evaluated in relation to each other. Glass brains 
depicting magnitude of t-statistic using a previously reported method are used 
for visualization (LoCastro et al., 2014; Pandya et al., 2016; Raj et al., 2012). 
All reported significant p-values survived FDR correction for multiple 
comparisons and are FDR adjusted unless otherwise noted (Benjamini and 
Hochberg, 1995). In the case of non-Gaussian variables (measured with 
Anderson-Darling tests), global graph metrics were successfully replicated 
with non-parametric permutation testing (10,000 permutations) (Table 2.3) 
(Razali and Wah, 2011).  
 To evaluate changes in connectivity strength in the graph, the Network 
Based Statistic (NBS) was used. The NBS is a validated, nonparametric 
statistical method for performing statistical analysis on large networks, which 
deals with the issue of multiple comparisons by controlling for the family-wise 
error rate (FWER) (Bai et al., 2012; Cocchi et al., 2012; Zalesky et al., 2010). 
FWER-corrected p-values are calculated for each component using 
permutation testing (5,000 permutations). The NBS was used on weighted, 
non-thresholded networks, with the primary threshold for each link-based t-
statistic set to 2.5, significantly more conservative than prior studies (Zalesky 
et al., 2011).  
 Figure 2.1 illustrates workflow of the NDM. The output of the NDM, x(t), 
is a vector of positive values at any post-baseline time t, representing 
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predicted pathology burden spreading from the baseline regional pattern. 
Results of the NDM were normalized to a Gaussian distribution via a Box-Cox 
transformation (Osborne, 1964). Since the NDM by itself is defined in terms of 
model time and not real time in years, the NDM was executed over a range of 
100 arbitrary “model time” time points, until the model hit steady state.  
 Observed pathology, as measured by regional atrophy differences in a 
subject’s longitudinal scan, was logistic rescaled to a value between 0 – 1 for 
each subject. To evaluate predictive power of the NDM, we performed whole 
brain Pearson correlation analysis between predicted pathology vs. observed 
pathology. This analysis carried out for each of the 100 model time points. 
Since the model is specified in terms of model time, its relationship to a 
patient’s disease duration is not a priori known. Hence we compared empirical 
subject data with NDM output at all model times, and the model time point that 
yielded the best correlation was selected. For each subject, correlation 
analysis was performed to evaluate prediction accuracy of the NDM 
implemented on the template healthy connectome. Prediction accuracy was 
also evaluated on the subject-specific connectome. Fisher r-to-z 
transformations were used to compare if NDM prediction accuracy changed 
with connectome choice (Fisher, 1921). All analysis was performed in 
MATLAB. 
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Figure 2.1. Workflow of the NDM. A subject’s baseline gray matter atrophy 
pattern and WM connectome are used as inputs to the NDM. (1) The model 
predicts a subject’s future atrophy at a single time point on a 0 - 1 scale. (2) 
Model accuracy at a single time point is determined by correlation analysis of 
predicted end atrophy vs. measured end atrophy. Measured end atrophy is 
determined by a subject’s longitudinal scan. (3) The NDM model is modeled 
over a wide range of time units, until the model hits steady steady. The 
resulting curve is the model’s prediction accuracy over a range of model time 
units. The highest correlation at any time, which represents the model’s best 
prediction accuracy, is selected as Rmax. (4) This analysis is carried out for 
each subject. Each subject’s Rmax is depicted. 
 33 
Results 
Cortical volume 
 First, it is confirmed that results from the current study’s imaging 
pipeline reproduce numerous previously published data on this same ADNI 
cohort. Baseline regional cortical volume from the 86 Freesurfer ROIs are 
compared between patients on the AD spectrum and controls. Atrophy is 
corrected for intracranial volume. Figure 2.2 shows t-statistics resulting from a 
two-tailed student’s t-test, which were obtained at each brain region. All 
reported regional significance in glass brains survive FDR correction for 
multiple comparisons. Table 2.2 depicts the full list of p-values.  
 Universally, patients show significantly decreased regional cortical 
volumes (Figure 2.2). These data showing prominent atrophy in subcortical 
and temporal cortices demonstrate that our imaging pipeline reproduces well-
known previously reported classic features of AD topography.  
 
Figure 2.2. Volumetric glass brains. Glass brains displaying cortical volume 
in CON vs. AD. Blue denotes atrophy in AD vs. CON. Figure thresholded for 
significance at p<0.05 and all illustrated results survived FDR multiple 
corrections. For a full-list of p-values see Table 2.2. 
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Table 2.2. List of volumetric statistics.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
p-value (FDR Corrected) Region 
2.02E-08 Right Inferior Temporal 
2.78E-06 Left Hippocampus 
3.84E-06 Right Fusiform 
4.17E-06 Right Entorhinal 
4.17E-06 Left Amygdala 
5.97E-06 Left Superior Temporal 
6.84E-06 Left Entorhinal 
9.84E-06 Left Accumbens 
1.64E-05 Left Inferior Temporal 
1.84E-05 Right Inferior Parietal 
1.84E-05 Right Hippocampus 
2.03E-05 Left Middle Temporal 
5.46E-05 Right Precuneus 
5.73E-05 Left Fusiform 
7.78E-05 Right Rostral Middle Frontal 
8.29E-05 Right Parsorbitalis 
8.29E-05 Left Parahippocampal 
8.29E-05 Left Superior Frontal 
9.30E-05 Right Middle Temporal 
1.10E-04 Right Superior Frontal 
1.66E-04 Right Amygdala 
2.80E-04 Left Insula 
3.13E-04 Left Lateral Orbitofrontal 
3.86E-04 Right Isthmus Cingulate 
0.001 Left Rostral Middle Frontal 
0.002 Right Lateral Orbitofrontal 
0.002 Right Superior Parietal 
0.002 Right Temporal Pole 
0.003 Right Superior Temporal 
0.004 Left Inferior Parietal 
0.004 Left Bankssts  
0.005 Left Precuneus 
0.005 Left Supramarginal 
0.006 Right Precentral 
0.006 Left Parstriangularis 
0.009 Left Superior Parietal 
0.009 Right Accumbens 
0.011 Right Medial Orbitofrontal 
0.011 Right Bankssts   
0.011 Left Parsorbitalis 
0.014 Right Posterior Cingulate 
0.014 Right Frontal Pole 
0.017 Right Insula 
0.019 Left Frontal Pole 
0.019 Left Temporal Pole 
0.024 Left Putamen 
0.034 Right Supramarginal 
0.035 Left Precentral 
0.037 Left Posterior Cingulate 
0.040 Right Putamen 
0.044 Left Parsopercularis 
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Global network analysis 
 Next, graph theory analysis is used to determine if commonly used 
metrics of global WM network organization and topology are disrupted in the 
AD spectrum. Specifically, we assess density, a measure of the overall 
number and strength of fiber connections, pathlength, a measure of network 
integration and efficiency, which is reflective of the ability of the network to 
sustain information flows (Rubinov and Sporns, 2010). Subcortical and 
subcortical regions constitute the graph. Connectivity matrices are not 
binarized, but kept as weighted values. Matrices are not thresholded.  
 Global metrics of density, path length and efficiency are compared 
between each patient group and controls. Remarkably, no global metrics are 
significantly different between patients and controls (Figure 2.3). Across all 
three groups in the AD spectrum, patients show no significant difference in 
density compared to control subjects (AD: p=0.65, LMCI: p=0.65, EMCI: 
p=0.89). Similarly, no significant difference is observed in pathlength in 
patients vs. controls (AD: p=0.85, LMCI: p=0.65, EMCI: p=0.65) nor global 
efficiency (AD: p=0.97, LMCI: p=0.82, EMCI: p=0.65). All reported p-values 
are FDR corrected for multiple corrections.  
 Due to limited sample sizes and the possibility of the summary network 
metrics being non-Gaussian, we performed additional analysis. First, we used 
the Anderson-Darling test to test for Gaussianity of each metric. Then we 
performed non-parametric permutation testing (10,000 permutations) for the 
few variables with non-Gaussian distributions (Table 2.3). In confirmation of 
above findings, no significant differences are found. In sum, we observe 
disease groups do not show significantly altered global topological properties 
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compared to healthy controls when weighted, non-thresholded connectivity 
matrices consisting of both cortical and subcortical regions are used.    
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Figure 2.3. Global network measures. Global network measures in the AD 
spectrum vs. controls. All reported p-values are FDR corrected for multiple 
comparisons. Boxplots depict the standard t-test.  
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Table 2.3. Global metric permutation testing. 
 
 
Metric 
Normal 
Distribution 
Normality 
test 
p-value  
T-test vs. 
CON 
(no FDR) 
Permutation 
Test vs CON 
(No FDR) 
Density     
AD Yes p=0.66 p=0.3612 p=0.3679 
LMCI No p < 0.001 p=0.2531 p=0.2763 
EMCI Yes p=0.04 p=0.7958 p=0.7961 
CON Yes p=0.27 -- -- 
Efficiency     
AD No p < 0.001 p=0.2827 p=0.3547 
LMCI Yes p=0.30 p=0.4974 p=0.4987 
EMCI Yes p=0.10 p=0.4828 p=0.4889 
CON No p < 0.001   -- -- 
Pathlength       
AD Yes p < 0.03 p=0.6574 p=0.6611 
LMCI No p=0.01 p=0.1773 p=0.1824 
EMCI Yes p=0.15 p=0.1073 p=0.1094 
CON  Yes p=0.40 -- -- 
 
Note: The core assumption of the independent samples t-test is that variables 
are distributed somewhat normally. All tests of normality were carried out with 
the Anderson-Darling test, whose null hypothesis is that variables come from a 
normal distribution. A p-value of < .01 indicates that the Anderson-Darling test 
fails to reject the null hypothesis at the 1% significance level. Because t-tests 
have to be approximately normal, a cutoff of p<.01 is used. 10,000 
permutations were carried out unless otherwise noted.  
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Local network analysis 
 Next, local network analysis is performed to probe distributed 
topological changes among specific brain regions. We examine local 
betweenness centrality, a measure of hub-ness, local strength, the sum of a 
region’s connections, and local efficiency, which is a measure of local 
information flow (Rubinov and Sporns, 2010).  
 Only a handful of nodal differences, concentrated in frontal and 
temporal regions of all local graph metrics, are observed. However, virtually 
none of the differences survive FDR correction for multiple comparisons 
(Figure 2.4). In the AD vs. CON group, only nodal strength of the left 
precuneus (p=6.66e-05) survives FDR correction for multiple comparisons 
(Figure 2.4B). No local metrics in the LMCI vs. CON nor EMCI vs. CON group 
survive FDR correction. (LMCI and EMCI glass brains data not shown.)  
 To further probe topological differences independent of nodal summary 
graph metrics, we assess whether nodal strength distributions are different in 
AD vs. CON. For each group, we plot a distribution of the strength all nodes 
and fit the distribution with power law alpha. A Kolmogorov–
Smirnov test reveals no significant difference between the strength 
distributions (p=0.98) and power law alpha values of the fitted strength 
distributions are virtually identical (CON: Alpha = 5.81, AD: Alpha = 5.92).  
  Taken together, Figure 2.4 and Figure 2.5 show local graph topology is 
not significantly altered between disease groups and healthy controls using 
weighted, non-thresholded connectivity matrices.   
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Figure 2.4. Local network metrics. Glass brains of local network measures 
in AD vs. CON. Images are thresholded at p<.05 significance and no reported 
p-values survived FDR corrections except regional strength in the left 
precuneus. Blue denotes decreased in AD compared to CON. Green denotes 
increased in AD compared to CON.  
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Figure 2.5. Nodal strength distributions. Histograms of the nodal strength 
distribution across all subjects in addition to nodal strength distribution fitted 
with a power law alpha function.  
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Tract level results 
 Due to prior reports of significant alterations of graph theory metrics in 
AD compared to control subjects, we next evaluate the possibility that our 
tractography and network extraction pipeline is uniquely insensitive to changes 
in connectivity compared to previous tract-level analyses. Thus, we assess 
whether the connectivity changes detected by the present methodology 
agreed with specific tracts reported to be disrupted in AD. To evaluate tract-
level changes in fiber strength, we examine strength between every pair of GM 
regions in the brain (as opposed to previously, a node’s sum of strengths), 
using the Network-Based Statistic (NBS) as detailed in Methods. 
   Significant alterations in a number of WM connections in ROIs along 
the uncinate fasciculus (UF), superior longitudinal fasciculus (SLF) and 
cingulum bundle (CB) (Figure 2.6, Table 2.4). Thus, in agreement with 
previous literature, connectivity values returned by our pipeline show 
significant impairment in tract-level WM changes in WM fiber count of AD 
compared to controls. These results confirm that the non-significant topology 
findings described above are not due to lack of sensitivity caused by the 
present study’s connectivity and tractography pipelines.  
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Figure 2.6. Tract-level differences. Glass brains of tract-level differences in 
AD vs. CON as measured by ROI-ROI connectivity strength using the NBS. 
Blue denotes tract decreased in AD relative to CON.   
 
  
 44 
Table 2.4. List of tract-level differences. Region pairs with decreased ROI-
ROI connectivity strength in AD relative to CON as measured using the NBS. 
Alterations depicted above in Figure 2.6. 
  
Regions  Tract Hemisphere 
Subnetwork 1, p=.01   
Isthmus Cingulate / Post Central  CB Right  
Isthmus Cingulate / Precentral   CB Right  
Paracentral / Precentral  SLF Right 
Post Central / Putamen   -- Right 
Transverse Temporal / Putamen  UF Right  
   
Subnetwork 2, p=.01    
Caudal Anterior Cingulate / Parsopercularis  CB Left 
Paracentral / Parsopercularis   SLF Left 
Caudal Anterior Cingulate / Parstriangularis CB Left 
Parsopercularis / Posterior Cingulate  CB Left 
Caudal Anterior Cingulate / Rostral Middle Frontal  CB Left 
Caudal Middle Frontal / Rostral Middle Frontal  SLF  Left 
Caudal Middle Frontal / Superior Temporal -- Left 
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Effect of thresholding 
Next, we explore whether our graph metrics appear different from previous 
reports due to the effect of stringent thresholding and/or binarization. To test 
whether these effects are responsible for observed discrepancies, we replicate 
previous findings by thresholding and binarizing our connectomes. 
Thresholding percentages are defined against raw non-zero connections.  
 Figure 2.7 shows thresholding in combination with binarization at a wide 
range of thresholds k, yields significant results across global metrics density, 
path length and global efficiency in AD vs. CON. Specifically, density of 
thresholded and binarized networks yields significance in the range of k = 5% - 
65% (Figure 2.7A1), pathlength in the range 15% - 60% (Figure 2.7A2) and 
global efficiency in the range 5 - 65% (Figure 2.7A3).  
 Thresholding-only of weighted matrices (with no binarization) yields 
significant differences in topology for a narrow range of threshold K, which 
include 5%, 30% and 35% (Figure 2.7B2). Similarly, global efficiency is 
significantly lower in AD than controls at k=5% and k=10% (Figure 2.7B3). See 
Table 2.6 for a full list of p-values. 
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Figure 2.7. Sparsity graphs. A) Weighted matrices are binarized and 
thresholded at various percentages of non-zero connections, as represented 
by k. B) Weighted matrices are thresholded with no binarization, at various 
percentages of non-zero connections, as represented by k. * indicates 
significance between AD and CON. The blue line represents controls and the 
red line represents AD. 
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Table 2.5. Thresholding statistics. Global metric differences in AD vs. CON 
over a range of thresholds in both binarized and weighted networks.   
 
 
 
 
 
 
 
% Threshold 
of Non-0 
Connections 
Density of 
Binarized 
Network 
Global 
Efficiency  
of 
Binarized 
Network 
 
Global 
Efficiency  
Of 
Network 
Pathlength 
of 
Binarized 
Network  
Pathlength 
of 
Weighted 
Network 
 
 
5% p<0.001*** p<0.001*** p<.01 ** p=0.07 p<.05 * 
10% p<0.001*** p<0.001*** p<.01 ** p=0.36 p=.49 
15% p<0.001*** p<0.001*** p=.14 p<0.001*** p=.90 
20% p<0.001*** p<0.001*** p=.27 p<0.001*** p=.37 
25% p<0.001*** p<0.001*** p=.39 p<0.001*** p=.08 
30% p<0.001*** p<0.001*** p=.50 p<0.001*** p<.01 ** 
35% p<0.001*** p<0.001*** p=.75 p<0.001*** p<.01 ** 
40% p<0.001*** p<0.001*** p=.92 p<0.001*** p=.15 
45% p<0.001*** p<0.001*** p=.97 p<0.001*** p=.68 
50% p<0.001*** p<0.001*** p=.97 p<0.001*** p=.68 
55% p<0.001*** p<0.001*** p=.97 p<0.001*** p=.68 
60% p<0.001*** p<0.001*** p=.97 p<0.001*** p=.68 
65% p<0.01** p<.05 * p=.97 p=0.09 p=.68 
70% p=0.30 p=0.27 p=.97 p=0.37 p=.68 
75% p=0.30 p=0.27 p=.97 p=0.37 p=.68 
80% p=0.30 p=0.27 p=.97 p=0.37 p=.68 
85% p=0.30 p=0.27 p=.97 p=0.37 p=.68 
90% p=0.30 p=0.27 p=.97 p=0.37 p=.68 
95% p=0.30 p=0.27 p=.97 p=0.37 p=.68 
100% p=0.30 p=0.27 p=.97 p=0.37 p=.68 
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Eigenmodes 
 Our prior work presents the concept of, eigenmodes, “persistent 
modes”, which is a topological (and linear) metric of the WM connectome 
governing disease spread. Eigenmodes were shown to form an effect basis on 
which baseline atrophy data can be projected for prediction of a subject’s 
future atrophy (Raj et al., 2015, 2012). We hypothesize that if the network 
architecture is significantly impacted by AD, as differences in tract-level 
changes might suggest, then the resulting eigenmodes of the diseased 
network will be significantly different than those in controls.  
 To compare eigenmodes between groups, the dot product of 
eigenmode from the average AD connectome is calculated in respect to that of 
healthy controls. Since eigenmodes are unchanged by overall sign, the 
absolute value of the dot product is taken. A value of 1 denotes perfect match 
between the eigenmodes from the two groups, and a value of zero denotes 
that the eigenmodes are orthogonal, hence fully dissimilar. The first three 
eigenmodes are presented as previous studies show the first three 
eigenmodes are the most stable (Raj et al., 2012; Wang et al., 2017). 
 We show all eigenmodes dot products are very close to 1, illustrating 
nearly identical eigenmodes in dementia compared to age-controlled healthy 
brains. (Table 2.5). Figure 2.8 presents a depiction of AD and CON network 
eigenmodes. Thus, despite widespread atrophy and impaired tract-level 
connectivity, we observe overall architecture of the diseased network does not 
result in measurable changes to its characteristic eigenmodes.  
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Table 2.6. Comparison of characteristic eigenmodes. Absolute value of dot 
products of group-wise comparisons of characteristic eigenmodes. A dot 
product of 1 denotes eigenmode equivalence.    
 
 
 
 
 
 
 
 
 
Figure 2.8. Glass brains of eigenmodes. Topology of nearly identical 
eigenmode 1, eigenmode 2 and eigenmode 3 of AD and CON connectomes. 
Blue denotes positive and yellow denotes negative; note however that 
eigenmodes are invariant under a global sign change.   
Eigenmode AD • CON LMCI • CON EMCI • CON 
1 1 1 1 
2 0.9986 0.9995 0.9996 
3 0.9983 0.9991 0.9986 
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Performance of diseased connectomes in the NDM 
 Given no observable AD-related differences in network organization, we 
examine whether models of AD progression based on WM graph topology is 
altered in disease. To test this, we use a network diffusion model (NDM) of 
pathology spread shown to provide a strong prediction of regional patterns of 
disease progression (Raj et al., 2015, 2012). Previously, the NDM was 
implemented using a healthy template connectome. The current work directly 
compares performance of the NDM on an age-matched connectome from 
ADNI controls vs. a patient’s own disease-impaired connectome. We 
hypothesize that if overall network architecture is significantly altered in AD, 
then the model will give dissimilar outcomes of pathology spread.  
 The NDM obtains predictions of future regional patterns of atrophy (x(t)) 
from a patient’s baseline volumetric scan (x0) (see Equation 1 in Methods). To 
test model performance, we correlate the subject’s observed end atrophy from 
a longitudinal scan vs. predicted atrophy as modeled by the NDM (See 
Methods). This procedure was carried out independently on both the healthy 
template connectome in addition to the subject-specific connectome. The 
furthest time point with the highest proportion of patients within each patient 
group was selected to allow for measurement of maximum disease 
progression.    
 Figure 2.9 shows that use of the diseased connectome in the NDM 
does not significantly increase nor decrease the high correlation between 
predicted future atrophy and observed end state atrophy. Specifically, Figure 
2.9A1 shows overall NDM performance on the control connectome, which is 
obtained by correlation analysis of each subject’s predicted future atrophy vs. 
observed end state atrophy.  
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 Because baseline regional atrophy has been shown to highly correlate 
to future atrophy patterns, the degree to which the NDM improves over 
baseline is examined. NDM improvement is represented by the change in 
correlation coefficient (∆ r) between modeled-predicted atrophy vs. end state 
atrophy and baseline vs. end state atrophy (Eq 3).  
 
NDM Improvement = Model Correlation to End State - Baseline Correlation to End State  (Eq 3)  
 
 For example, in AD patients, on average, the NDM yields a model 
accuracy of r = 0.80 between predicted atrophy vs. observed end state 
atrophy. The correlation between baseline regional atrophy vs. observed end 
state atrophy is r = 0.70. Thus, the NDM offers improvement of ∆ r = 0.10, on 
average, compared to solely using baseline atrophy as a predictor of future 
atrophy.  
 Figures 2.9B1-2 show each subject’s NDM improvement from baseline 
on both the ADNI control connectome vs. a patient’s own disease-impaired 
connectome. Choice of connectome does not appear to significantly impact 
model improvement. This confirmed by intra-subject Fisher r-to-z 
transformations comparing the correlation coefficients (Table 2.7). 
Furthermore, paired t-tests reveal no significant difference in the time it takes 
for model to achieve optimal diffusion on control vs. individual connectomes 
(AD: p=0.27, LMCI: p=0.22, EMCI p=0.42) (Figure 2.10). Thus, our results 
suggest that even if certain elements of the WM connectivity network are 
impaired by disease, they do not impair the overall network organization and 
topology to the extent necessary to alter the network mediation of AD 
pathology progression in the AD spectrum.    
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Figure 2.9. NDM performance. NDM performance on individual patient 
connectomes vs. age-matched control connectomes. (A) NDM on the control 
connectome, by correlating predicted future atrophy vs. measured atrophy. 
(B). Model improvement from baseline on the control connectome (C). Model 
improvement from baseline on the individual connectome.  
 53 
Table 2.7. Model performance on various connectomes. Each subject’s 
correlation coefficient of the template connectome, Subject-Specific 
connectome and an independent template connectome. Blue denotes AD, 
green denotes LMCI and purple denotes EMCI subjects. 
 
 + As dictated in the methods section, NDM prediction accuracy was evaluated 
with Pearson’s correlation. There was no difference in model accuracy unless 
otherwise noted.  
ADNI  
Template  
Connectome  
ADNI 
Subject 
Connectome 
Independent 
Template 
Connectome 
 Template  
Connectome 
Subject 
Connectome 
Independent 
Template 
Connectome 
r = 0.8207 r = 0.8194 r = 0.8189  r = 0.7299 r = 0.7304 r  = 0.7320 
r = 0.8158 r = 0.8120 r = 0.8006  r = 0.8870 r = 0.8867 r  = 0.8866 
r = 0.8128 r = 0.8150 r  = 0.8177  r = 0.6468 r = 0.6276 r  = 0.7172 
r = 0.7050 r = 0.6989 r  = 0.6881  r = 0.7760 r = 0.7701 r  = 0.7669 
r = 0.7604 r = 0.7585 r  = 0.7523  r = 0.7504 r = 0.7511 r  = 0.7439 
r = 0.7232 r = 0.7036 r  = 0.7347  r = 0.7196 r = 0.7163 r  = 0.7033 
r = 0.7078 r = 0.7066 r = 0.7116  r = 0.6231 r = 0.6047 r  = 0.6330 
r = 0.8587 r = 0.8574 r = 0.8611  r = 0.6557 r = 0.6434 r  = 0.6562 
r = 0.6463 r = 0.6253 r = 0.7058  r = 0.5491 r = 0.5430 r  = 0.5300 
r = 0.8133 r = 0.8123 r = 0.8212  r = 0.5271 r = 0.5103 r  = 0.5492 
r = 0.7272 r = 0.7208 r = 0.7371  r = 0.7542 r = 0.7460 r  = 0.7626 
r = 0.7866 r = 0.7864 r = 0.7838  r = 0.5606 r = 0.5610 r  = 0.5565 
r = 0.7936 r = 0.7936 r = 0.7935  r = 0.9115 r = 0.9108 r  = 0.8942 
    r = 0.5459 r = 0.5414 r  = 0.5422 
r = 0.6326 r = 0.6219 r  = 0.6428  r = 0.6108 r = 0.6106 r  = 0.6125 
r = 0.2919 r = 0.2897 r  = 0.3058  r = 0.8190 r = 0.8148 r  = 0.8154 
r = 0.7259 r = 0.7247 r  = 0.7374  r = 0.6369 r = 0.6013 r  = 0.5948 
r = 0.6677 r = 0.6602 r  = 0.6710  r = 0.4381 r = 0.4357 r  = 0.4162 
r = 0.7464 r = 0.7468 r  = 0.7467  r = 0.5723 r = 0.5585 r  = 0.5816 
r = 0.7504 r = 0.7058 r  = 0.7538  r = 0.5623 r = 0.5545 r  = 0.6120 
r = 0.7439 r = 0.7353 r  = 0.7453  r = 0.8115 r = 0.8114 r  = 0.8137 
r = 0.6562 r = 0.5913 r  = 0.6362  r = 0.8045 r = 0.8004 r  = 0.7792 
r = 0.8019 r = 0.7973 r  = 0.8086  r = 0.6076 r = 0.6051 r  = 0.5969 
r = 0.8776 r = 0.8782 r  = 0.8772  r = 0.6591 r = 0.6443 r  = 0.6209 
r = 0.6372 r = 0.6277 r  = 0.6228  r = 0.6463 r = 0.6341 r  = 0.6482 
r = 0.5339 r = 0.5235 r  = 0.5471  r = 0.7447 r = 0.7368 r  = 0.7287 
r = 0.8560 r = 0.8563 r  = 0.8554  r = 0.7876 r = 0.7704 r  = 0.7622 
r = 0.3634 r = 0.3552 r  = 0.3844  r = 0.7774 r = 0.7757 r  = 0.7803 
r = 0.8339 r = 0.8293 r  = 0.8210  r = 0.4842 r = 0.4712 r  = 0.5058 
r = 0.9026 r = 0.9041 r  = 0.9029  r = 0.7704 r = 0.7699 r  = 0.7645 
r = 0.7326 r = 0.7302  r  = 0.7485  r = 0.6705 r = 0.6629 r  = 0.6821 
r = 0.8433 r = 0.8414 r  = 0.8354  r = 0.5652 r = 0.5633 r  = 0.5491 
r = 0.8228 r = 0.8057 r  = 0.8043  r = 0.6277 r = 0.5888 r  = 0.5843 
r = 0.7459 r = 0.7468 r  = 0.7469  r = 0.6994 r = 0.6979 r  = 0.7095 
r = 0.6098 r = 0.6089 r  = 0.6014  r = 0.5507 r = 0.5141 r  = 0.5489 
r = 0.7404 r = 0.7404 r  = 0.7403  r = 0.7269 r = 0.7258 r  = 0.7363 
r = 0.7013 r = 0.6974 r  = 0.7092  r = 0.2520 r = 0.2504 r  = 0.2498 
r = 0.5245 r = 0.5152 r  = 0.5309  r = 0.6489 r = 0.6127 r  = 0.6891 
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Figure 2.10. Tmax distributions. Histogram of each subject’s Tmax 
distribution when the NDM is tested on an individual patient connectome vs. 
an age-matched healthy connectome. Tmax is the arbitrary model time it takes 
for optimal diffusion on the network.   
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 To address potential concerns of ADNI tractography quality, which is an 
issue common in large multi-site, publicly available datasets, we assess NDM 
performance in AD subjects on an independent control connectome (mean 
age = 36.5 + 11.8 years). Data were collected and processed as detailed in 
(Kuceyeski et al., 2011). Figure 2.11 illustrates NDM prediction accuracy 
results are unchanged when using an independent control connectome. 
Furthermore, Figure 2.11 shows thresholding minimally affects model 
performance. Weighted matrices are non-binarized and thresholded at various 
percentages of non-zero connections, as represented by k (Table 2.5). Fisher 
r-to-z transformations show no significant difference in model prediction 
accuracy as a result of thresholding (Table 2.7). Taken together, these data 
confirm previously presented results and also mitigate concerns of ADNI 
tractography quality. 
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Figure 2.11. Independent template connectome. NDM performance on 
independent control template connectomes at various thresholds in AD. 
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Table 2.8. Thresholding independent connectome. Performance of the 
NDM on an independent control template connectome at various weighted 
thresholds, as represented by correlation coefficients between model 
predicted atrophy vs. end state measured atrophy. 
 
Subject  K = 100% 
(No 
Threshold) 
K = 80% K = 60% K = 40% K = 30% K = 20% 
AD#1  0.8189 0.8189  0.8186 0.8175 0.8059 0.7690 
AD #2  0.8006 0.8005 0.8003 0.7927 0.7671 0.7420 
AD #3  0.8177 0.8177 0.8176 0.8173 0.8133 0.8054 
AD #4 0.6881 0.6880 0.6878 0.6774 0.6718 0.6366 
AD #5 0.7523 0.7523 0.7522 0.7519 0.7492 0.7486 
AD #6 0.7347 0.7344 0.7266 0.7186 0.7020 0.6630 
AD #7 0.7116 0.7115 0.7114 0.7104 0.7072 0.6939 
AD #8 0.8611 0.8611 0.8611 0.8608 0.8567 0.8444 
AD #9  0.7058 0.7048 0.7039 0.6689 0.6533 0.6217 
AD #10 0.8212 0.8212 0.8211 0.8210 0.8206 0.8071 
AD #11 0.7371 0.7371 0.7364 0.7194 0.7094 0.6704 
AD #12 0.7838 0.7838 0.7837 0.7829 0.7813 0.7688 
AD #13 0.7935 0.7935 0.7935 0.7935 0.7935 0.7932 
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Discussion 
 The present study uses network modeling to show that, despite 
measurable changes in integrity of specific fiber tracts, the overall topological 
organization of the WM network is not appreciably impaired. Most 
interestingly, AD does not appear to alter the ability of the network to mediate 
pathology spread in AD. This conclusion is supported by three main findings 1) 
WM network organization, as reflected by graph analysis weighted, non-
thresholded graphs, is largely unchanged between patients and controls, 2) 
Eigenmode analysis confirms no measurable effect of disease on overall 
network topology and 3) Use of a patient’s diseased connectome in place of a 
healthy connectome does not improve performance of a previously published 
network diffusion model (NDM).  
Atrophy in the AD spectrum 
 First, we confirm the current imaging pipeline reproduces previously 
reported classic features of AD topography, specifically, gray matter volume is 
decreased in AD, globally and especially in subcortical and temporal regions 
(Figure 2.2). This finding is in agreement with published literature (Apostolova 
et al., 2007; Baron et al., 2001; Fischer et al., 2016; Peter et al., 2014; 
Thompson et al., 2003).  
Global and local topology 
 WM disruptions are analyzed using global and local graph metrics. We 
show topology is not significantly different in all 3 patient groups compared to 
controls (Figure 2.3). Nodal results converge with global findings. Upon first 
survey, there are a few nodal differences between patients and controls 
predominately in frontal and temporal regions. These differences do not 
survive FDR correction (Figure 2.4). However, prior publications report 
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significant changes in network topology in AD vs. CON (Daianu et al., 2015a, 
2015b, 2013; Lo et al., 2010; Prescott et al., 2014).  
 Thus, we next explore the potential causes underlying the discrepancy. 
We consider two possibilities: 1) Our pipelines for image processing, 
tractography and network extraction algorithms are different from previous 
work, and might be uniquely insensitive to measure changes in connectivity 
that are known to be present from well-established tract-level analyses or 2) 
The discrepancy is caused by lack of binarization or thresholding to our 
connectomes, dissimilar to methodology in previous reports.  
Tract-level results 
 First, we consider the possibility that our connectivity pipelines are 
insensitive to changes in tract integrity. We assess whether connectivity 
changes detected by the present methodology comports with specific tracts 
known to be disrupted in AD. In agreement with previous literature, tract-level 
changes are detected in WM fiber count of AD compared to controls. We show 
significant alterations in a number of WM connections in ROIs along the 
uncinate fasciculus (UF), superior longitudinal fasciculus (SLF) and cingulum 
bundle (CB) (Figure 2.6, Table 2.4). These tract-level results of fiber count in 
AD converge with prior diffusion MRI studies reflective of tract-integrity within 
the ADNI dataset (Lee et al., 2015; Nir et al., 2013; Rowley et al., 2013). 
Taken together, our results and published findings from the ADNI dataset 
replicate other FA alterations reported in AD as a whole (Hasan et al., 2012; 
Liu et al., 2011; Mielke et al., 2009; Stricker et al., 2009). 
 These results confirm preserved global topology findings described 
above are not due to lack of sensitivity caused by the present study’s 
connectivity and tractography pipelines. Hence, the current work suggests that 
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tract-level alterations in AD do not lead to significant changes in global 
measures of WM network organization.     
Effect of thresholding 
 Prior work relies on binarization and/or thresholding of connectivity 
matrices prior to computing graph metrics (Table 2.9). Hence, we consider the 
possibility that discrepancy in our graph theory findings are caused by lack of 
binarization or thresholding being initially applied to connectomes. As 
previously reported, thresholding these connections can therefore lead to 
induced topology, an aspect of current graph theoretic approaches that we 
wished to avoid (Drakesmith et al., 2015; Langer et al., 2013). 
 When graph analyses are repeated under varying thresholds, followed 
by binarization, we demonstrate significant results across all three of our 
global graph metrics at a wide range of thresholds from 5% to 65% of all non-
zero connections in the original weighted matrix (Figure 2.7A, Table 2.5). 
Thresholding of weighted matrices with no binarization also yields significant 
results across all three of our global graph metrics, but at much narrower 
range of thresholds (Figure 2.7B, Table 2.5). These results suggest that 
thresholding and binarization introduce topological constraints that may be 
most likely responsible for the apparent contradiction between our data and 
prior reports of significant topological differences in AD.  
  For instance, many recent reports of topological differences using graph 
theory within the ADNI dataset found significance after thresholding 
connectivity matrices based on the k-core “structural backbone” of network 
hubs (Daianu et al., 2015a, 2015b, 2013). Even this k-core analysis concludes 
that overall organization of the high-cost and high-capacity networks are 
relatively preserved in the AD spectrum, a finding which is in line with our 
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results (Daianu et al., 2015b). These results are supported by results in Figure 
2.5, which showing no significant difference between hub distributions, as 
reflected by power alpha, in AD vs. CON. 
 The final methodological difference between the current study and prior 
work is the use of both cortical and subcortical regions in the construction of 
the network graph. Previous work recognizes that the addition of subcortical 
regions refines network organization (Daianu et al., 2015b). Few prior studies 
use graphs consisting of both cortical and subcortical regions (Table 2.9). 
Interestingly, prior work using subcortical and subcortical regions in addition to 
no binarization nor thresholding successfully replicate our results of no 
significant findings of global efficiency or path length in AD (Bai et al., 2012; 
Reijmer et al., 2013). Density is not assessed. Importantly, concerns of 
diffusion MRI quality or other study-specific bias are mitigated because these 
studies were replicated in AD cohorts independent of ADNI.  
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Table 2.9. Summary of prior work. Summary of prior studies involving AD-
related topological characteristics. Highlighted studies indicate results 
replicated by the current study. 
 
* D denotes density, Eglob denotes global efficiency and Lp denotes pathlength. 
▲ denotes increased in AD vs. CON, ▼ denotes decreased in AD vs. CON, 
NS denotes nonsignificant . + Preclinical AD vs. Control subjects defined in 
cognitively healthy older adults on basis of global amyloid beta burden only, 
with preclinical converter status unconfirmed.  
Study &  
Patient Group 
ADNI Network 
Construction 
 
Include 
Sub 
cortical 
D Eglob Lp Comments 
Current Study 
MCI & AD 
✓ Weighted, 
Unthresholded 
✓ NS NS NS  
Lo et al. 2010  
AD 
 Weighted, 
Thresholded 
 --  ▼ 
 
▲ 
 
 
Bai et al. 2012  
MCI 
 Weighted, 
Varying Thresholds 
✓ -- NS 
 
NS Metrics 
reported at 0 
thresholding  
Reijmer et al. 2013  
MCI & AD 
 Weighted, 
Unthresholded 
✓ 
 
-- NS NS  
Daianu et al. 2013  
MCI & AD 
✓ Binarized, 
Varying k-core 
thresholds 
 -- ▼ ▼ Created 
graphs by 
hemisphere 
Prescott et al. 2014  
MCI & AD 
✓ Weighted, 
Unthresholded 
 
 
 
 
-- -- -- Grouped 
metrics by 
cortical lobe   
Daianu et al. 2015b  
MCI & AD 
✓ Binarized, 
Varying k-core 
thresholds  
 -- ▼ ▲ 
 
 
Daianu et al. 2015a 
Early-Onset AD 
 Binarized, 
1 K-Core threshold  
 -- -- -- Evaluated 
location of 
hubs only 
Fischer et al. 2015  
Preclinical AD 
✓ 
 
Weighted, 
Thresholded 
✓ 
 
N/A N/A N/A Subjects not 
comparable+ 
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Characteristic eigenmodes 
 Thus far, the present study had explored global and local graph metrics, 
which are usually non-linear and sensitive to edge thresholding and 
binarization, as demonstrated above. Given this strong dependence on 
somewhat arbitrary parameters, we sought to determine if characteristic 
eigenmode, a topological (and linear) metric governing disease spread, is 
altered in dementia. We have previously shown that any network spread 
process implies a prominent role for the so-called network “eigenmodes”, 
which were shown to form an effective basis on which atrophy data can be 
projected for potential differential diagnosis. These eigenmodes are useful 
predictors of dementia, the spread of epilepsy and of normal brain activity 
(Abdelnour et al., 2015; Raj et al., 2012).  
 Furthermore, eigenmodes represent distinct spatial patterns that bear a 
strong resemblance to known patterns of various dementias and recapitulate 
recent findings of dissociated brain networks in dementia (Buckner et al., 
2005; Du et al., 2007; Seeley et al., 2009; Zhou et al., 2010). Our prior work 
shows evidence that there is a one-to-one correspondence between the 
healthy network’s eigenmodes and atrophy patterns of normal aging and 
dementia (Raj et al., 2012). The first 2-3 principal network eigenmodes appear 
to be reproducible between healthy subjects, and the first two eigenmodes 
appear to be largely conserved even in patients with congenital agenesis of 
corpus callosum (Wang et al., 2017). 
 Interestingly, the current work shows eigenmodes, which are important 
predictors of degenerative progression, are virtually identical in AD vs. CON 
(Table 2.6) (Figure 2.8). This suggests that despite widespread atrophy and 
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clear evidence of impaired tract-level connectivity, characteristic eigenmodes, 
global network architecture is preserved.  
 
Performance of the Network Diffusion Model 
 Given no observed significant differences in network architecture in AD 
vs. CON, we examine whether models of disease progression based on WM 
network topology is altered by disease. To do this, we utilize the NDM, a 
recent graph model of pathology spread that successfully predicts regional 
patterns of disease progression (Raj et al., 2015, 2012) (Figure 2.1). The 
previously published model is based on a template healthy connectome, under 
the assumption that the structural network serves merely as a conduit for 
transmitting proteinopathies, rather than being the first to be impaired itself. 
  In the present study, we asked whether the model would give similar 
outcomes if a patient’s own disease-impaired connectome was used in place 
of a healthy connectome. Thus, by exploring the effect of individualized patient 
connectomes on the network diffusion model, we sought to determine 
indirectly whether the overall network architecture is significantly altered by 
disease, to the extent of causing measurable differences in how pathology 
might travel on the network.  
 Use of patient-specific connectomes in place of an age-matched, 
control connectome does not improve prediction of a patient’s future gray 
matter atrophy (Figure 2.9). Personalized individual connectomes perform just 
as well, but not better, than healthy connectomes in capturing the longitudinal 
evolution of regional atrophy in AD. This finding is true across all three 
dementia groups of AD, LMCI and EMCI. Performance similarity between 
connectomes does not reflect poor predictive ability of the NDM, which gave 
typically high correlations (R > 0.8 in most cases). Furthermore, there is no 
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significant difference in the time it takes to achieve optimal diffusion across 
both connectomes (Figure 2.10). To mitigate possible concerns of DTI quality 
in ADNI, these results were replicated using an average connectome obtained 
from an independent high resolution DTI dataset of younger control subjects 
(Figure 2.11) (Table 2.8).  Equal performance of the NDM between subject-
specific diseased and healthy connectomes supports our conclusion that 
overall WM network organization is preserved in AD, and tract level 
impairments do not lead to altered mediation of pathology spread in AD.  
 The finding that the overall network architecture is preserved in 
dementia points to the possibility that neurodegenerative pathology primarily 
targets gray matter rather than WM network architecture, a finding widely 
replicated in topological studies of the GM network (Liu et al., 2012; Wang et 
al., 2013). Hence, either WM connectivity alteration is minor in the global brain 
context, or our measurement techniques are insensitive to it. There is one 
other possible explanation specific to the NDM results. Connectivity 
alterations, even if significant, might happen in a manner that does not change 
the topographic spread patterns the network will sustain. This is supported by 
the finding that thresholding weighted networks, which induces changes in 
graph metrics, does not result in significant changes to NDM performance 
(Figure 2.11, Table 2.7). 
  Such a finding points to an inherent strength of near-linear models like 
the NDM: Small changes in network connectivity will only elicit a 
correspondingly small change in the output of the model. This stands in stark 
contrast with most current graph theoretic summary metrics like path length 
and efficiency, which are inherently non-linear. Note that these non-linearities 
persist even if the metrics are redefined to utilize weighted rather than binary 
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connections, because these metrics are defined with respect to implied 
neighbors, which is essentially a binary decision. This point is helpful in 
interpreting the threshold dependence widely seen in graph theoretic 
concepts, and also replicated here in Figure 2.7. 
 We have already noted that overall network topology measured by 
graph theoretic metrics appears resistant to local changes in fiber integrity. 
Connectivity loss will, of course, change the speed of network spread 
according to the NDM model, but appears not to change the latter’s predictive 
ability (maximized over all model times). The speed of network spread, 
encapsulated in the model parameters 𝛽 and 𝑡𝑚𝑎𝑥, is a key feature of the 
NDM, but was not considered here because our focus is on predictive power 
of future atrophy patterns rather than their timeline. Fitting rate parameter of 
the ND model, and its neural/genetic correlates, will be the subject of our 
future work.  
Limitations 
 Technical limitations of volumetric and tractography processing 
pipelines include HARDI spatial and angular resolution, coregistration errors, 
low test-retest reliability of volumetric data, and distance bias inherent in 
tractography. Therefore, it must be acknowledged that atrophy and 
connectivity results in this paper share the same sensitivity and accuracy 
issues common to all computational neuroanatomic data currently in public 
domain. However, our connectome technique successfully detected changes 
in tract-level connectivity, hence methodological limitations and insensitivity 
may not be the primary driver of our key results. To mitigate concerns of 
tractography quality, we illustrated reproducibility on tractography gathered 
and processed in an independent control dataset (Figure 2.11) (Table 2.8).  
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 The NDM is a first-order, linear, parsimonious model of diffusive spread 
that assumes the structural connectivity network remains static over the 
duration of the longitudinal analysis. This is reasonable because the 
observation window (2 - 4 years) is short compared to the course of the 
disease. Although the model enables long-term projections of future atrophy, 
model validation in the current work is limited to public (ADNI) data sets of 
narrow time span (2 - 4 years), preventing long-term longitudinal follow-up. 
This is a future point of work that will be addressed as the ADNI study 
continues to collect additional longitudinal data. 
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Chapter 3: 
 A New Network-Constrained Technique to 
Characterize Neurodegenerative Progression Rate in 
Alzheimer’s Disease  
 
Introduction 
 Pathological processes in the brains of Alzheimer’s Disease (AD) 
patients start more than a decade before the first symptoms are noticed (Jack 
et al., 2013; Price and Morris, 1999). The long, inexorable course of 
progression of AD gives rise to a stereotyped pattern of regional pathology, 
atrophy and dysfunction. These features have led to intensive recent interest 
in the prognostic ability of molecular and imaging biomarkers to predict 
longitudinal decline and clinical outcomes for practical purposes such as 
differential diagnosis, therapeutic treatment and clinical trial inclusion (Ewers 
et al., 2015; Mattsson et al., 2014; Shaw et al., 2011; Tosun et al., 2016).  
 Current measures of decline rely on changes in cognitive metrics like 
MMSE, as well as imaging-derived measures of atrophy rates defined as 
changes in global brain volume of an individual (Karas et al., 2004; Schindler 
et al., 2017). There are two limitations with reliance on global brain volumes as 
measures of longitudinal changes. First, a global rate ignores the highly 
spatially varying patterns of AD-related atrophy. Second, the global atrophy 
rate measure ignores the process by which progression proceeds in the brain, 
which is now thought to involve network-level spread. Network spread is, in 
turn, undergirded by a well-studied process of “prion-like” transsynaptic 
transmission of misfolded pathologic proteins amyloid beta and tau (Frost and 
 106 
Diamond, 2010; Jucker and Walker, 2013; Prusiner, 1998). It is possible to 
overcome these limitations by obtaining separate rate values for each brain 
region. However, such a method has limited utility for clinical applications 
where a single rate metric is needed for the purpose of prognosis or as a 
primary endpoint of clinical trials. 
 In order to overcome these limitations, this paper presents a new 
measure of disease progression rate in AD. Our previously published Network 
Diffusion Model (NDM) recapitulates spatial and temporal patterns of AD-
related pathology spread along the brain’s white matter (WM) fiber architecture 
(Raj et al., 2012). It also calculates longitudinal AD progression of a subject’s 
atrophy patterns staring from their baseline MRI data (Raj et al., 2015). The 
strength of this approach is that it connects a biophysically realistic model of 
microscopic processes involving protein transmission to the macroscopically 
realized behavior at the whole brain regional level. Therefore, we reasoned 
that the NDM would serve as a robust model from which a pathology 
progression rate metric can be derived.  
 The current work makes three main contributions: First, we propose an 
algorithm to compute the speed of pathology spread parameter from 
longitudinal MRI of a subject. The NDM contains a single (a priori unknown) 
rate parameter called the diffusivity rate 𝛽, which we propose is a primary 
metric of disease progression rate. It gives a single number that encapsulates 
the entire spatiotemporal evolution of the disease and serves as a more 
mechanistically relevant measure of rate of progression in AD. Second, we 
thoroughly characterize this rate parameter on a large cohort of 810 subjects 
across the AD disease spectrum available in the ADNI study (Mueller et al., 
2005). We describe how the rate depends on various natural stratifications of 
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the AD cohorts, such as diagnostic group or APOE4 allele status. Third, we 
explore whether it is possible to predict a subject’s speed of 
neurodegeneration from baseline CSF and MRI biomarkers, with the ultimate 
goal of one-day circumventing costly and time consuming scanning 
procedures for prognostic application.  
 
Methods  
Participants 
 All subject data were obtained from the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) database, a public-private multisite longitudinal 
study (http://adni.loni.usc.edu/). Subjects were diagnosed as Alzheimer’s 
Disease (AD), Late Mild Cognitive Impairment (LMCI), Early Mild Cognitive 
Impairment (EMCI) or Control (CON) according to ADNI data description. All 
subjects have at least 2 longitudinal time points of volumetric MRI and 92% of 
subjects have baseline CSF, which includes Amyloid Beta, Tau and 
phosphorylated tau. 92% of subjects also had measures of the Mini-Mental 
State Exam (MMSE) and Functional Activities Questionnaire (FAQ) to assess 
cognitive impairment. MMSE and FAQ measurements are considered baseline 
as 99% of cognitive measurements were collected within 1.25 years of the 
baseline MRI scan (mean = .59 years, median = 0.55 years. 4 EMCI subjects 
had baseline cognitive metrics measured ~2 years post baseline scan).   
 Patients are age-matched to healthy controls (AD: p = 0.65, LMCI: 
p=0.77, EMCI: p=0.10). 40 subjects from the CON group were eliminated to 
age-match for LMCI and EMCI subjects. Subjects are also gender matched 
(AD, p=0.06, LMCI: p=0.76, EMCI: p=0.77). There was a moderate trend 
toward significant difference in age between AD and CON, but the decision to 
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not eliminate any subjects was made in order to include in an order to maintain 
the largest sample size for later machine learning techniques. There were no 
converters between scans. Subject demographic information is listed in Table 
1.   
 
Table 3.1. Subject demographics.  
Dx N =  Age 
(std) 
Sex 
(% 
F) 
APOE4 
Status 
(0/1/2) 
MMSE 
(std) 
 
 
FAQ 
(std) 
CSF 
AB 
(pg/mL) 
(std) 
CSF 
Tau 
(pg/mL) 
(std) 
CSF 
pTau 
(pg/mL) 
(std) 
AD 
 
117 74.9 
(8.1) 
38% 24/51/22 
83%+ 
21.6 
(3.9) 
85%+ 
15.5 
(6.9) 
84%+ 
134.6 
(37.2) 
94%+ 
 
131.2 
(64.8) 
89%+ 
58.9 
(32.9) 
94%+ 
LMCI 
 
172 72.5 
(7.7) 
45% 74/69/27 
99%+ 
26.7 
(2.4) 
97%+ 
4.8 
(5.7) 
97%+ 
159.4 
(49) 
94%+ 
99.8 
(54.5) 
89%+ 
47.6 
(27.4) 
94%+ 
EMCI 
 
289 71.3 
(7.2) 
44% 161/103/20 
98%+ 
28 
(1.8) 
95%+ 
2.3 
(3.5) 
95%+ 
183.8 
(51.2) 
94%+ 
77.2 
(47.6) 
89%+ 
36.8 
(21.1) 
94%+ 
CON 
 
232 74.5 
(6.9) 
53% 153/56/6 
93%+ 
28.9 
(1.3) 
91%+ 
0.44 
(2) 
90%+ 
198.1 
(51.2) 
94%+ 
68 
(33.7) 
89%+ 
33.1 
(17.9) 
89%+ 
  + Denotes percentage of data available in diagnostic cohort   
 
MR image acquisition and processing 
 DTI and inversion-recovery spoiled gradient recalled (IR-SPGR) T1-
weighted imaging data were acquired on several General Electric 3T scanners 
using scanner specific protocols. Briefly, DTI data were acquired with a voxel 
size of 1.372 × 2.70 mm3, 41 diffusion gradients and a b-value of 1000 
s/mm2. IR-SPGR data were acquired with a voxel size of 1.022 × 1.20 mm3. 
All imaging protocols and preprocessing procedures are available on the ADNI 
website. (http://adni.loni.usc.edu/methods/). Automated cortical and 
subcortical volume measures were performed with FreeSurfer software 
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package, version 5.3 (http://surfer.nmr.mgh.harvard.edu/fswiki) For details on 
T1-weighted data preprocessing, please see Supplementary Methods.   
DTI acquisition and processing 
 The WM connectome was constructed by taking the mean of diffusion 
MRI data of normal, healthy subjects. Normal subject data were collected 
jointly by Weill Cornell Medical College and the Brain Trauma Foundation. 
Seventy-three healthy subjects (40 men, 33 women, 30.2±6.7 years) were 
used to create the normative connectivity information in the form of 
tractograms. T1-weighted structural and diffusion-weighted MR images were 
collected on a 3 T GE Sigma EXCITE scanner (GE Healthcare, Waukesha, 
WI). The High Angular Resolution Diffusion Images data were acquired with 
55 isotropically distributed diffusion-encoding directions 
at b=1000 sec/mm2 and one at b=0 sec/mm2, from 72 1.8-mm thick interleaved 
slices (no slice gap) and 128×128 matrix size, zero-filled during reconstruction 
to 256×256, with a field of view (FOV) of 230 mm2. The structural scan was an 
axial three dimensional inversion-recovery fast spoiled gradient-recalled echo 
sequence ((echo time [ET]=1.5 msec, repetition time [TR]=6.3 msec, inversion 
time [TI]=400 msec) flip angle of 15°) with a 256×256 matrix over a 
230 mm2 FOV and 156 1.0-mm contiguous partitions. The diffusion images 
were corrected for eddy current and motion artifacts using FMRIB Software 
Library (FSL) (Smith et al., 2004). 
 T1 images were processed by first segmenting the tissue into 
cerebrospinal fluid, WM and GM. The GM segment was subsequently 
parcellated into 86 different ROIs using cortical and subcortical structures from 
the FreeSurfer (Desikan-Killarney) gray matter parcellation. The parcellated 
GM was then linearly transformed and resampled to diffusion image space for 
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use in tractography. Briefly, the surface voxels of the parcellated cortical and 
subcortical structures were used to seed the tracts. Proposed and validated in 
Iturria-Medina and colleagues (2005), the tractography algorithm implemented 
here incorporates tissue classification probability and orientation distribution 
information in a Bayesian manner. A tract terminated when the algorithm 
reached the boundary of an image volume, the edge of a GM region, a voxel 
not in the gray or WM masks, or when the angle between subsequent steps 
exceeded π/3. This analysis was done using the eighth version of Statistical 
Parametric Mapping (SPM), (Friston et al., 2007), a software package within 
Matlab R2009a (The Mathworks, Inc., Natick, MA), and the Individual-Based 
Atlas toolbox (Aleman-Gomez, 2006) within SPM.  
 Further details of the image processing and tractography method are 
given in a previous publication (Kuceyeski et al., 2013, 2011). To control for 
inter-subject variance in total fiber count, a density metric was computed by 
dividing by the total number of tracts based on each subject’s tractography 
data. The subsequent undirected connectomes were not thresholded and kept 
as weighted.  
The Network Diffusion Model 
 Our group’s previously published NDM has been shown to accurately 
recapitulate spread of Alzheimer’s Disease pathology throughout the brain 
(Raj et al., 2015, 2012). Briefly, pathology transmission is modeled as a 
network diffusion process: 
𝐱(𝑡) =  𝑒−𝛽𝐻𝑡𝐱𝟎                        (1) 
where 𝐱𝟎 and 𝐱(𝑡) are the initial and evolved patterns of the regional pathology 
respectively, expressed as 86x1 vectors, corresponding to the 86-region brain 
atlas. The matrix exponential exp (−𝛽𝐻𝑡) acts as a spatial and temporal 
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blurring operator, called the diffusion kernel. Matrix 𝐻, called the network 
Laplacian, is a derivative of the connectivity matrix obtained from the WM 
structural organization. The parameter 𝛽 represents the diffusion speed 
coefficient, which is considered the rate of disease progression/speed of 
neurodegeneration in the current study.  
Relationship to atrophy. The measurable phenotype (regional MRI-derived 
atrophy) in region 𝑘 is assumed to be the consequence of and thus 
proportional to the accumulation of pathology. Hence, it is modeled as the 
integral: 
𝜙𝑘(𝑡) = ∫ 𝑥𝑘(𝜏)
𝑡
0
 𝑑𝜏   (2) 
On the whole brain this gives: 
𝚽(𝑡) =  ∫ 𝐱(𝜏)
𝑡
0
 𝑑𝜏   (3) 
Relationship between baseline atrophy and its rate of change. It was 
shown in (Raj et al., 2015a) that the relationship at baseline scan between 
atrophy and its rate of change (as modeled by NDM) under the integral 
relationship above is given by 
𝑑𝚽
𝑑𝑡
|𝑡=𝑡𝑏𝑎𝑠𝑒  =  𝛽?̃?(𝛽𝑡𝑏𝑎𝑠𝑒)𝚽𝐛𝐚𝐬𝐞            (4) where we define a new variant of the 
Laplacian ?̃?(𝛽, 𝑡) = 𝑑𝑖𝑎𝑔 ({
1
𝛽𝑡
,         𝑖 = 1
𝜆𝑖𝑒
−λi𝛽𝑡
1− 𝑒−λi𝛽𝑡
 , 𝑖 > 1
} ) 𝑈† involving the 
eigendecomposition 𝐻 = 𝑈𝛬𝑈†, with eigenvalues 𝜆𝑖. Please see Raj et al., 
2015 for details. Thus, the network diffusion model deterministically predicts 
that the atrophy at baseline and its rate of change are related via the matrix 
?̃?(𝛽, 𝑡). Note the relationship involves an unknown time between onset and 
baseline scan 𝑡𝑏𝑎𝑠𝑒.  
where we define a new variant of the Laplacian 
?̃?(𝛽, 𝑡) = 𝑑𝑖𝑎𝑔 ({
1
𝛽𝑡
,         𝑖 = 1
𝜆𝑖𝑒
−λi𝛽𝑡
1− 𝑒−λi𝛽𝑡
 , 𝑖 > 1
} ) 𝑈†           (5) 
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involving the eigendecomposition 𝐻 = 𝑈𝛬𝑈†, with eigenvalues 𝜆𝑖. Please see 
Raj et al. 2015 for details. Thus, the NDM deterministically predicts that the 
atrophy at baseline and its rate of change are related via the matrix ?̃?(𝛽, 𝑡). 
Note the relationship involves an unknown time between onset and baseline 
scan 𝑡𝑏𝑎𝑠𝑒. 
Algorithm for fitting 𝜷 to individual subjects’ longitudinal scans 
 For each subject, the beta parameter is computed using the subject’s 
longitudinal atrophy patterns.  The algorithm has the following steps: 
1. First, the atrophy slope of each region is calculated independently, using the 
time elapsed between each scan. Let 𝑡𝑙𝑜𝑛𝑔 be a vector of timestamps (length 
nt) of a patient’s longitudinal visits, in years and their volumetric-processed 
regional atrophy patterns be contained in the (nt x 1) vector for any given 
region, 𝛟. A fitted estimate of slope of atrophy for that region is calculated 
from this longitudinal data, as per: 
𝛟 =  (𝟏 𝑡𝑙𝑜𝑛𝑔) (
𝑎
𝑏
) ;      𝛥𝜙 = 𝑏                         (6) 
In our implementation, the above fitting was performed using MATLAB’s 
pseudoinverse function. Regions with negative atrophy slopes are set to 0, as 
thickening of the cortex is a rare and unlikely event in AD, and most likely is a 
result of measurement or analysis noise.  
 Since the rate relationship Eq (4) involves two unknowns, 𝛽 and 𝑡𝑏𝑎𝑠𝑒, 
we need to achieve joint fitting to measured regional slope data. However, 
given that the two parameters appear together in the matrix relationship, 
instead of a joint fitting approach we conduct a two-step process detailed in 
steps 2 and steps 3:  
2. Set 𝛽 =  𝛽0. Then minimize over 𝑡𝑏𝑎𝑠𝑒: 
𝑡𝑏𝑎𝑠?̂? =  𝑎𝑟𝑔𝑚𝑎𝑥𝑡𝑏𝑎𝑠𝑒  {𝑐𝑜𝑟𝑟(𝛽0?̃?(𝛽0𝑡𝑏𝑎𝑠𝑒)𝚽𝐛𝐚𝐬𝐞,
𝛥𝚽
𝛥𝑡
)} 
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where 𝑐𝑜𝑟𝑟(⋅,⋅) refers to the Pearson correlation coefficient between two 
vectors, and recall that 
𝛥𝚽
𝛥𝑡
 is the measured slope from step 1.  
3. Then the optimal rate ?̂? is given by least squares fitting of 𝛽 in the linear 
system: 
1
𝛽0
𝛥𝚽
𝛥𝑡
= 𝛽?̃?(𝛽0𝑡𝑏𝑎𝑠?̂?)𝚽𝐛𝐚𝐬𝐞 
 
Statistical analysis 
 Following calculation of each subject’s beta parameter from baseline 
and subsequent longitudinal volumetric scans, beta outliers were removed. 
Outliers are defined as 1.5 times greater or less than the inter-quartile range 
separately for each diagnostic group.  
 Differences in subject characteristics across diagnostic groups, APOE 
status categories and clusters were assessed with the Kruskal Wallis H-test, a 
non-parametric one-way ANOVA on ranks (Kruskal and Wallis, 1952). 
Wilcoxon rank sum tests were used in the case of comparing 2 groups directly 
(Wilcoxon, 1950). Differences in frequencies were assessed with classic chi 
square analysis.  Due to the non-parametric nature of the data, correlations 
were assessed with the Kendall rank correlation coefficient (Bolboaca and 
Jäntschi, 2006). Independent, two-sided t-tests were used to test for 
differences in local brain volume. Glass brains depicting magnitude and t-
statistic are used for visualization (LoCastro et al. 2014). Multivariate linear 
regression analysis was used to examine the relationship between multiple 
CSF biomarkers, cortical/subcortical volumes and beta. The coefficient of 
determination, R2 was used to evaluate model fit.  
 Z-scores of CSF metrics were computed relative to age-matched 
controls to normalize features for hierarchical clustering analysis and K 
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nearest neighbors (KNN) classification. Hierarchical clustering analysis was 
used to delineate clusters of subjects in a 6 dimensional space defined by 
baseline CSF biomarkers of AB, Tau, pTau and their respective ratios. 3 was 
selected as the cluster size because the variance ratio criterion (Calinski-
Harabasz index), defined as the ratio of between-cluster variance to within-
cluster variance, is maximized at 3 clusters (Maulik and Bandyopadhyay, 
2002). 
 With cluster labels obtained from hierarchical clustering, a KNN 
classifier assigned subjects to clusters based on the Euclidean distance from k 
nearest neighbors. Classifier performance was tested over a wide range of k 
nearest neighbors. Classification performance was evaluated by calculating 
classification error by 5-fold cross validation. 490 patients on the AD spectrum 
of 578 patients (excluding outliers) had complete data on all 6 CSF biomarkers 
of interest in the current study and were used in clustering analysis and KNN 
classification. All analysis was carried out in MATLAB.   
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Results 
 We propose the beta parameter modeled in the current study is 
reflective of pathology spread.  We hypothesize there will be a strong 
relationship between beta and global atrophy as well as a strong relationship 
between beta and slope of cognitive decline. First, we show a high correlation 
between the modeled beta parameter and global rate of atrophy (r=0.42, 
p=3.7e-48) (Figure 3.1A). We also show a moderate correlation between the 
modeled beta parameter and slope of cognitive decline as measured by 
MMSE (r=0.22, p=0.0003) (Figure 3.1B).  
 
 
Figure 3.1. Beta vs. global atrophy and MMSE. A) Correlation between 
each subject’s modeled speed of pathology spread (beta) and global atrophy 
rate. B) Correlation between each subject’s beta and slope of cognitive decline 
as measured by MMSE. Blue represents AD, teal represents LMCI and yellow 
represents EMCI.   
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 Prion AD hypotheses suggest the disease spreads in an exponential, 
viral-like manner, with the disease spreading faster with increased disease 
severity (Prusiner, 1998). Thus, we hypothesized subjects later in clinical 
progression have a higher rate of disease spread than subjects early in the 
disease. To test this hypothesis, each subject’s beta parameter (speed of 
disease spread) was calculated and the effect of beta across each of the 3 
diagnostic groups was assessed using a non-parametric Kruskal Wallis H test. 
We observe a significant effect of beta across diagnoses on the AD spectrum 
(p=6.67e-18). Furthermore, when directly comparing the earliest stage EMCI 
group to the AD group, we show a significant difference in beta between EMCI 
and AD patients (p=5.72e-18) (Figure 3.2A).  
 A wide body of literature implicates the role amyloid beta in clinical 
deterioration, suggesting clinical trajectories of subjects with higher amyloid 
burden worsen faster than subjects without high amyloid beta burden (Okello 
et al., 2009; Tosun et al., 2016). Because amyloid positivity is highly 
associated with the number of putative APOE4 alleles, we examined the 
relationship between beta and APOE4 allele status (Morris et al., 2010; 
Sunderland et al., 2004). 266 patients have 0 APOE4 alleles, 195 patients 
have 1 allele and 66 have 2 APOE4 alleles. Thus, we hypothesized beta is 
higher in subjects with the pathogenic APOE4 allele compared to subjects 
without the APOE4 allele. A one way Kruskal-Wallis test confirms this, 
illustrating a significant effect of beta across subjects with 0 , 1 and 2 APOE4 
alleles (p=0.0006) Specifically, we observe beta in subjects with the E4/E4 
allele is significantly higher than subjects without the E4 allele (p= 7.50e-04) 
(Figure 3.2B). 
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Figure 3.2. Beta by diagnostic group and APOE allele. A) Significant effect 
of beta by diagnostic group across the AD spectrum. B) Significant effect of 
beta by APOE4 allele status across the AD spectrum. 
 
 
 Next, we conduct an exploratory correlation analysis to examine the 
relationship between each subject’s baseline CSF biomarker and rate of 
pathology progression. We individually probe baseline CSF amyloid beta, tau, 
ptau, ratio of AB/tau, AB/pTau and pTau/tau. We hypothesize a significant 
relationship between at least one of baseline CSF biomarkers and speed of 
pathology spread, both within all subjects and within individually diagnostic 
groups.  
 Contrary to our hypothesis, correlation analysis reveals weak 
relationships between beta and baseline CSF measurements (Figure 3.3A). 
Though baseline CSF values are highly correlated with one another, 
correlation to speed of disease diffusion is overall poor (Figure 3.3B). 
Additional linear, quadratic and power models did not reveal significant 
relationships between CSF biomarkers and beta (data not shown). Multivariate 
linear regression using multiple CSF biomarkers as predictor variables for beta 
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also yielded poor predictive ability as assessed by the coefficient of 
determination (data not shown). 
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Figure 3.3. Beta vs. CSF biomarkers. A) Scatterplots depicting lack of strong 
correlations between baseline CSF AB, Tau, pTau and their ratios vs. beta in 
all subjects, AD-subjects only and EMCI-subjects only. B) Heat map 
illustrating correlations of baseline CSF measurements with one another and 
beta.  
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 At this point in the investigation, we hypothesized efforts to predict a 
patient’s precise beta from baseline CSF metrics were unsuccessful due to 
potential subject heterogeneity in CSF profile. There is precedent for this 
hypothesis, as prior work shows CSF biomarker profile across the AD 
spectrum is variable, with clusters of subjects present (Iqbal et al., 2005). 
Hierarchical clustering analysis was utilized to understand potential subject 
heterogeneity in baseline CSF biomarker profile. We show subjects are clearly 
delineated into 3 clusters, which are defined by the z-scores of 6 baseline CSF 
biomarkers (Figure 3.4A). There is no significant effect of age across cluster 
(p=0.20, Cluster 1: 71.3 years, Cluster 2: 72.9 years, Cluster 3: 72.7 years).     
 Because subjects fall into clearly delineated clusters based on baseline 
CSF biomarker profile, we hypothesized we could predict a subject’s cluster 
based on baseline CSF characteristics. To test this hypothesis, a K nearest 
neighbor (KNN) classifier sorted the 490 subjects with complete data into 
clusters based on Euclidean distance from k nearest neighbors. Cluster 1 
consists of 108 subjects, cluster 2 is comprised of 207 subjects and 175 
subjects are in cluster 3. The KNN classifier predicts cluster identity at a rate 
of more than 90% of the time in a 5 k-fold cross validated model over a wide 
range of 1 – 90 nearest neighbors. As expected, classifier performance drops 
below chance as more than 350 neighbors are added, an action which adds 
significant variance to the model (Figure 3.4B).   
 Next, we examine CSF biomarker signatures that define each of the 3 
identified clusters. First, we plot z-scores of the 6 CSF biomarkers computed 
relative to age-matched, healthy controls, as a function of cluster identity. 
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Then, we examine concentration of the three CSF biomarkers, amyloid beta, 
tau and ptau, of each of the clusters in relation to each other.   
 We observe cluster 1 is characterized by the least pathogenic 
biomarker profile as it shows very little difference relative to controls across all 
6 biomarkers. Conversely, cluster 3 appears to be the most pathogenic 
cluster, as it shows the most remarkable differences in CSF biomarkers 
compared to controls. Specifically, cluster 3 mirrors the pathogenic biomarker 
signature of typical of AD, which includes decreased CSF AB and increased 
Tau and pTau compared to controls. Cluster 2 falls between cluster 1 and 2 in 
terms of pathogenic profile. (Figure 3.4C)  
 When compared directly to each other, we observe Cluster 3 appears 
significantly more pathogenic than Cluster 1. Specifically, Cluster 3 exhibits 
significantly less baseline CSF AB compared to cluster 1 as well as 
significantly higher pTau and Tau (AB: p=1.93e-43, pTau: p= 5.63e-45, Tau: 
p=1.79e-44) (Figure 3.4D).  
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Figure 3.4. CSF biomarker clustering and classification. A) Dendrogram 
depicting 3 clusters defined by z-scores of baseline CSF biomarkers. B) KNN 
classifier accuracy over a wide range of nearest neighbors in a 5 k-fold cross 
validation model. C) Average z-score of CSF metrics vs. age-matched controls 
D) CSF metrics across clusters. Error bars represent one standard deviation.   
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 Following successful identification, prediction and characterization of 
baseline CSF profile, which define the disparate clusters, we examine baseline 
volume differences and the speed of disease spread across clusters. 
Volumetric differences in each cluster was calculated with respect to the same 
group of age-matched controls. We observe that baseline atrophy patterns 
correspond to baseline CSF profiles. Specifically, cluster 3 is characterized by 
the most pathogenic atrophy, while cluster 1 is the least. Cluster 2 falls 
squarely in the middle (Figure 3.5A).   
 Evaluation of beta across clusters shows a significant effect of beta 
across clusters (p=3.89e-6). Specifically, the cluster defined by the most AD-
related CSF biomarkers, cluster 3, shows the highest speed of disease 
progression (Figure 3.5B). Conversely, cluster 1, which is characterized by the 
least pathogenic biomarkers, has the lowest speed of disease progression. As 
depicted in the boxplots of Figure 3.5B, the 25th and 75th percentile range of 
cluster 1 is 0.0349 - 0.1044, the equivalent range for cluster 2 is 0.0509 - 
0.1380 and lastly, 0.0598 - 0.1542 for cluster 3.  
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Figure 3.5. Baseline volumetric and degeneration speed by cluster. A) 
Glass brains depict t-statistics of differences in baseline volumetric by cluster 
compared to age-matched controls Gold represents hyperatrophy, all other 
colors represent atrophy. B) Boxplot of beta by cluster.   
 
 We also observe a significant effect of baseline FAQ and baseline 
MMSE cognitive scores across clusters, with cognitive score as the subject’s 
earliest cognitive time point (FAQ: p=9.01e-7) (MMSE: 7.23e-5) (Figure 3.6A-
B). Clinical measures are most compromised in cluster 3 vs. cluster 1 (FAQ: 
p=7.98e-07, MMSE: p=1.69e-05), a finding that converges with each cluster’s 
biomarker profile and speed of disease spread. Correspondingly, we observe 
the more pathogenic cluster 3 has a higher, but non-significant, percentage of 
APOE4 allele carriers compared to the least pathogenic cluster (Figure 3.6C).  
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Figure 3.6. Cognitive scores and APOE by cluster. A-B) Differences in 
baseline cognitive score FAQ and MMSE across cluster. C) Frequencies in 
APOE4 across clusters. Pink represents cluster 1, green represents cluster 2 
and blue represents cluster 3. 
 
  
 Lastly, we show significant correlations between a subject’s speed of 
disease spread and baseline cognitive score, which differ across clusters. 
Examining baseline MMSE, we observe cluster 2 has the strongest 
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relationship between beta and the cognitive metric (r=-0.28, p=2.5e-8), 
followed by cluster 1 (r=0.20, p=0.004) and a relatively weak cluster 3 (r=-
0.14, p=0.02) (Figure 3.7A). Interestingly, the FAQ survey shows the strong 
relationship with beta in cluster 1 (r=0.28, p=8.7e-05), followed by cluster 3 
(r=0.20, p=.0003) and is the weakest in cluster 2 (r=0.15, p=0.002) (Figure 
3.7B).  
  
 127 
 
Figure 3.7. Cluster-specific beta vs. cognitive score. A) Correlation 
between rate of disease progression and baseline MMSE cognitive score 
across each of the three clusters. B) Correlation between beta and baseline 
FAQ cognitive score across each of the three clusters. Blue represents AD, 
turquoise represents LMCI and yellow represents EMCI.  
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 Though we were able to predict a narrow range of beta based on 
cluster assignment from CSF biomarker profiles, we strived to obtain a more 
accurate prediction of beta. To do this, we integrated neuroimaging with our 
cluster analysis. Though the initial goal of the study was to circumvent 
neuroimaging all together, the use of one neuroimaging biomarker as opposed 
to several longitudinal ones still represents an improvement in regards to 
clinical efficiency. We hypothesized the regression model of cluster 3, the 
cluster exhibiting the most pathogenic characteristics, would yield the highest 
prediction as reflected by R2.   
 To test this hypothesis, we created a regression model using the top 10 
most atrophied regions characteristic of AD pathology. ROIs were obtained by 
independent t-tests in the AD group vs. age-matched controls. ROIs were all in 
the middle temporal lobe and include: Left hippocampus, right hippocampus, 
left amygdala, left entorhinal, right amygdala, left middle temporal gyrus, left 
inferior temporal gyrus, right entorhinal cortex, right inferior temporal and right 
middle temporal gyrus. These top 10 most atrophied ROIs were used in 
conjunction with the three baseline CSF biomarkers, AB, tau and pTau to form 
a 13 variable multivariate linear regression for beta prediction. We observe 
that the least pathologically severe cluster, cluster 1, gives a relatively weak 
R2 of 0.15, the middle cluster yields a moderately strong R2 of 0.26 and the 
most pathologically severe cluster 3 yields a relatively week R2 of 0.12. In 
cluster 2’s linear regression, which yielded the highest coefficient of 
determination, CSF Amyloid Beta was the most significant predictor (p=.0006) 
followed by volume of the right amygdala (p=.005), right hippocampus volume 
(p=.002) and left hippocampus volume (p=.01). 
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 Next, we conducted the same regression analysis using global atrophy 
rate as the respone variable in order to directly compare the performance of 
our modeled beta parameter to global atrophy rate. Dissimilar to beta 
regression results, we observe that prediction of global atrophy rate using the 
same regressors yields the strongest R2 in the least pathologically severe 
cluster 1 (Figure 3.8D). Cluster 2 and cluster 3 yield relatively poor predictive 
ability of global atrophy rate with R2=0.12 and R2=0.06, respectively (Figure 
3.8E-F).  
 
 
Figure 3.8. Linear regressions predicting beta by cluster. Regressions 
include the top 10 most atrophied regions characteristic of AD pathology and 3 
CSF metrics. A) To predict beta in Cluster 1 B) To predict beta in Cluster 2 C) 
To predict beta in Cluster 3 D) To predict global atrophy rate in Cluster 1 E) To 
predict global atrophy rate in Cluster 2 F) To predict global atrophy rate in 
Cluster 3.   
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Discussion 
 The present study applies graph theoretic approaches and machine 
learning in a multimodal dataset of 810 subjects to obtain a new measure of 
rate of progression. Using our group’s previously published Network Diffusion 
Model of AD spread (Raj et al., 2015, 2012), we derive a single 
neurodegeneration rate, given by the model’s diffusivity parameter 𝛽, from 
each subject’s longitudinal MRI data. This rate measure depends on various 
natural stratifications of the AD cohorts. At the group level it is highest for AD 
patients, lower for LMCI and lowest for EMCI, indicating that the degenerative 
process speeds up over time. The rate is higher for subjects with 2 putative 
APOE4 alleles compared to subjects with no putative APOE4 alleles. 
 However, these group differences mask substantial individual 
variability, which is shown in cluster analysis based on baseline CSF metrics. 
We demonstrate that 3 separate clustered emerge, which are characterized by 
differing degrees of AD-related pathology as reflected by cognitive scores, 
APOE allele status, beta parameter and baseline atrophy patterns. We then 
focused on the clinically relevant problem of predicting the rate parameter from 
a subject’s baseline data only. We found that baseline CSF biomarkers, even 
within clusters, were not able to predict individual rate parameters. However, a 
combination of CSF and MRI biomarkers at baseline can predict a narrow 
range of rate values, and this prediction is most accurate in those subjects 
who happen to be in the middle of their degenerative course. This is the first 
study to propose a rate metric derived from the known mechanism of 
progression in AD, and the first to successfully model a narrow range of a 
subject’s rate of brain degeneration from baseline CSF and MRI biomarkers.  
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Characterizing the rate parameter 
 We observed a highly significant correlation between our proposed rate 
of pathology spread and global rate of atrophy, suggesting that the former can 
serve as a mechanistically realistic surrogate of the latter (Figure 3.1A). We 
also show a moderately significant correlation between rate of pathology 
spread and cognitive decline as measured by the MMSE (Figure 3.1B). 
Although it is not expected that the proposed rate measure will completely 
track the established global atrophy rate measure, it is comforting that the two 
are closely associated. To confirm that proposed beta measure converges 
with current hypotheses of neurological decline, we tested the effect of 
modeled beta parameters across diagnostic groups and APOE allele status. 
AD subjects had the highest speed of pathology spread compared to LMCI 
and EMCI subjects (Figure 3.2A). 
  Because AD is reported to spread faster in a prion-like manner with 
disease progression, it is expected that AD subjects have higher rates of 
disease spread compared to LMCI and EMCI (Brundin et al., 2010; Jucker and 
Walker, 2013; Prusiner, 1998). Similarly, the highest speed of pathology 
spread was present in APOE E4/E4 subjects compared to E4/E3 and E3/E3 
(Figure 3.2B). This result is in accordance with prior work, as the effect of 
APOE and amyloid beta burden on accelerated cognitive and clinical decline 
in both AD and cognitively normal subjects is well-established (Doraiswamy et 
al., 2014; Lim et al., 2014; Tosun et al., 2016). These results robustly 
characterize the proposed rate measure, and demonstrate that it agrees with 
current literature and hypotheses.  
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Predicting rate parameter from baseline CSF biomarkers 
 The ability to predict a subject’s speed of neurodegeneration from 
baseline CSF and MRI biomarkers will be critical to approach the ultimate goal 
of one-day circumventing costly and time consuming scanning procedures for 
prognostic application. Simple correlation analysis reveals no significant, 
straightforward relationship between baseline CSF biomarker and speed of 
neurodegeneration (Figure 3.3). Though this result is contrary to our original 
hypothesis, it is not entirely surprising, as current molecular biomarker models 
posit the relationship between disease spread and CSF biomarker is dynamic 
and changes with stage of disease, suggesting more sophisticated modeling is 
necessary (Jack et al., 2013; Jack and Holtzman, 2013).  
 Therefore, we employed machine learning, specifically hierarchical 
clustering and K nearest neighbors (KNN) classification of 490 patients on 6 
baseline CSF profiles, to establish a relationship between a subject’s baseline 
CSF biomarkers and rate of AD progression. The 6 baseline CSF metrics 
include AB, pTau, Tau, AB/tau, AB/pTau, pTau/Tau. Hierarchical clustering 
revealed 3 distinct clusters (Figure 3.4A). CSF profiles across clusters are 
roughly arranged in order of pathological severity, going from cluster 1 
(highest Ab42, lowest tau) to cluster 3 (lowest Ab42, highest tau), see Figure 
3.4C-D. Although there is no one-to-one mapping between CSF clusters and 
AD stage, we found that cluster 1 was most enriched with EMCI and cluster 3 
by AD, suggesting a clear order of severity, both pathologically and clinically. 
KNN classification successfully assigned subjects to clusters with >90% in a 5 
k-fold validation approach (Figure 3.4B). These results are consistent with 
previous work, particularly (Iqbal et al., 2005) (Wallin et al., 2010), which 
demonstrated existence of similar clusters from non-ADNI AD patients. The 3 
 133 
clusters are also arranged in order of increasing atrophy burden (Figure 3.5A). 
Mirroring the variability in CSF biomarkers and atrophy between clusters, we 
found that each cluster also displays a distinct range of the beta rate 
parameter (Figure 3.5B). Notably, the more pathogenic clusters also show 
higher rates of disease spread, cognitive impairments and frequency of 
putative APOE alleles (Figure 3.4-6). Within clusters, patients have differing 
relationships to cognitive metrics (Figure 3.7).  
 However, it is clear that CSF biomarkers alone are insufficient to 
correctly estimate an individual patient’s rate parameter. Partly this reflects the 
well-known heterogeneity amongst AD cohorts (Iqbal et al., 2005) (Wallin et 
al., 2010). Visual inspection of our 3 CSF-based clusters reveals a mix of AD, 
LMCI and EMCI (Figure 3.7). Prior classification work in large datasets, in 
particular a CSF classification study in 675 subjects showed that while CSF 
profile was able to discriminate between neural disorders such as depression 
and AD, it performed poorly at classifying across different dementias, 
suggested dementias have intertwined pathophysiology (Ewers et al., 2015). 
Therefore we reasoned that MRI-derived biomarkers might be necessary to 
further improve predictive ability. 
MRI-derived atrophy and CSF biomarkers predict rate of progression 
 When baseline neuroimaging biomarkers were introduced along with 
CSF biomarkers into a linear regression model, a subject’s beta parameter 
could be predicted with a relatively high coefficient of determination in cluster 2 
(R2 = 0.26), and moderately predictive in clusters 1 and 3 (R2 ~0.15) (Figure 
3.8A-C). At first, it would appear more plausible that cluster 3, the most 
pathologically severe cluster, would yield the best linear regression results. A 
closer inspection revealed that cluster 3 is highly enriched with mature AD 
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patients, and cluster 1 for early or mild cases (Figure 3.7). In contrast, cluster 
2 may be considered a middle phase that is most active pathologically. 
Previous studies have frequently observed this behavior, which has been 
accommodated by considering a non-linear model of progression (Jack et al., 
2010).  
 This model expects that progression rates increase initially until an 
inflection point is reached. Thereafter a plateau effect becomes operational, 
such that further rate increases are constrained by resource challenged 
environments corresponding to mature disease (Jack et al., 2010, 2013; Jack 
and Holtzman, 2013). In this respect, our result showing the highest rate of 
progression in middle pathological stages (cluster 2) is consistent with the 
literature. In contrast, Figures 3.8D-F show the highest predictive ability using 
these same regressors to predict global atrophy rate is highest in the least 
pathogenic cluster 1. Predictive ability is poor for subjects in the middle and 
end of their degenerative courses, which provides further support for the use 
of modeled beta parameter, as global atrophy is shown not to be sensitive 
enough to detect network constrained AD-pathology spread. 
Clinical implications 
 There has been recent interest and remarkable progress in prognostic 
neuroimaging and molecular biomarkers (Ba et al., 2017; Tosun et al., 2016). 
Notwithstanding, the relationship between baseline and longitudinal 
progression is inconsistently described (Mattsson et al., 2009; Schindler et al., 
2017). Moreover, overall accuracy of clinical diagnosis based on cognitive 
metric is shown to be low (Beach et al., 2012). Dependence on cognitive score 
as a metric of disease spread is problematic, because some individuals 
clinically diagnosed with MCI and AD dementia later are discovered to have 
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non-AD etiologies and cognitively normal controls may have preclinical AD 
(Hassenstab et al., 2016). Prior work shows baseline biomarker profiles can 
distinguish AD from other neurological diseases, assess risk for progression 
from Mild Cognitive Impairment (MCI) to AD as well as predict progressors 
from non progressors in clinical trial environments (Ewers et al., 2015; 
Mattsson et al., 2014; Shaw et al., 2011; Tosun et al., 2016). However, the 
majority of this work has been done by neuroimaging protein biomarkers in 
vivo. Unfortunately, neuroimaging equipment and analysis are expensive, time 
consuming and not readily available in all clinical settings. A practical, 
inexpensive tool to predict speed of neurodegeneration has not yet been 
developed. Brain imaging with MRI, FDG-PET, and amyloid PET often require 
advanced imaging analyses, which may not be easily accessible in all clinical 
environments.  
 A lumbar puncture, in contrast, may be done in many different clinical 
settings and CSF samples can easily be shipped to a central laboratory for 
analysis (Herukka et al., 2017). Over the past 6 years, diagnostic criteria for 
Alzheimer’s Disease (AD) has evolved to include molecular biomarkers 
(McKhann et al., 2011). A wide body of literature corroborates that AD 
pathology is accompanied by a stereotypical decrease in CSF Amyloid-beta 
(AB) in addition to increased CSF tau and phosphorylated tau (pTau) 
(Andreasen et al., 2003, 2001; Hulstaert et al., 1999; Rosén et al., 2013; 
Tapiola et al., 2009). CSF biomarkers influence decision making depending on 
the extent to which biomarkers reflect AD pathology, consistency between 
clinical–pathologic information, and the ambiguity of protein values (Gooblar et 
al., 2015).  
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 Hence, we focused on predicting a subject’s progression rate from CSF 
biomarkers from a single lumbar puncture. It was found necessary to include 
MRI regional atrophy, which we feel is clinically acceptable, as most patients 
will have had at least a standard-of-care MRI exam. We demonstrated that the 
rate of progression can be reasonably predicted from baseline CSF and MRI 
in a large class of subjects falling within an intermediate pathological cluster. 
In clinical terms, this is perhaps also the group that can most benefit from a 
prognostic indicator of longitudinal progression. To our knowledge, this is the 
first study to propose a network-based measure of progression rate and to 
predict it from baseline CSF and MRI biomarkers, see, e.g. (Herukka et al., 
2017). It is our hope that the proposed rate measure will be used in a 
prognostic manner as a screening tool for differential diagnosis, clinical trial 
inclusion and therapeutic treatments. In order to facilitate adoption we are 
making the computer code available freely on our website (www.ideal-
cornell.com ).  
Limitations 
 There exists concern that lack of standardization of CSF protocols to 
detect AB42 and tau is common across sites, with different commercial kits 
utilizing their own standards, anti-bodies, ranges and cut-offs (Lehmann et al., 
2015). However, the University of Pennsylvania (UPenn) ADNI Biomarker 
Core laboratory has thoroughly studied and published methodology regarding 
measurement of Aβ1–42, t-tau and p-tau181 in highly clinically annotated ADNI 
CSF samples to identify and attempt to control key sources of analytical 
variability (Shaw et al., 2011). Furthermore, it has been suggested that 
longitudinal CSF data is necessary for prognostic application as biomarkers 
can change linearly with time, exponetially, sigmoidally, etc (Fagan et al., 
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2014; Jack and Holtzman, 2013). The current study mitigates that issue as 
90% of the CSF data included was collected within a year of each subject’s 
baseline scan, reducing the need for extensive modeling of biomarker 
dynamics. An additional limitation is that the NDM is a first-order, linear, 
parsimonious model of diffusive spread that assumes that the structural 
connectivity network remains static and unchanged over the duration of the 
longitudinal analysis. This is reasonable because the observation window (2-4 
years) is short compared to the course of the disease. Additionally, although 
the model enables long-term projections of future atrophy, model validation in 
the current work is limited to public (ADNI) data sets of rather narrow time 
span (2–4 years), precluding long-term longitudinal follow-up.  
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Chapter 4: 
Structural Network Model of Pathology Spread Predicts 
Neurodegeneration in Huntington’s Disease 
Introduction 
 Huntington’s Disease (HD) is an autosomal dominant genetic disorder 
caused by a mutation (CAG repeat expansion) in the Huntingtin gene (HTT). 
The topography of HD in the human brain displays a well characterized and 
stereotyped regional pattern and progression. Disease pathology initially 
appears in the striatum, followed by striatal neighbors and connected cortical 
areas (Brettschneider et al., 2015) 
 The mechanisms underlying stereotyped patterning and progression 
are not fully understood. It is suggested that both cell-cell communications 
governed by anatomical and functional connections, and cell autonomous 
molecular factors characterized by gene expression signatures, play a role in 
vulnerability to disease spread (Brettschneider et al., 2015; Frost and 
Diamond, 2010; Jucker and Walker, 2013; Lee et al., 2010; Prusiner, 1984; 
Seeley, 2017). It is less clear whether cell type and molecular factors are the 
main source of regional vulnerability in HD, or whether non-cell autonomous 
factors, of which network connectivity is a canonical example, are the key 
driver of vulnerability. It is possible that both sets of factors play a role, 
however their relative contribution and interactions remain unknown.  
 Previous studies of selective regional vulnerability in HD have generally 
focused on cellular toxic effects involving cell autonomous mechanisms, such 
as proteolytic and post translational modifications (Ross and Tabrizi, 2011). 
Recently, it is emerging that non-autonomous mechanisms, likely involving the 
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brain’s anatomic or functional connectivity patterns, might also be responsible 
for selective vulnerability in HD. Indeed, mutant HTT is pathogenic, has a 
tendency to aggregate and potentially diffuse to extracellular space and 
thence to neighboring cells to act as a seed for further aggregation (Lee et al., 
2001; Tan et al., 2015). This process is reminiscent of the well-studied prion 
model of neurodegeneration, which hypothesize that misfolded proteins 
spread trans-synaptically along neuronal pathways in specific patterns. 
Several neurodegenerative disorders including Alzheimer’s Disease (AD), 
Frontotemporal Dementia (FTD), Parkinson’s Disease (PD), Amyotrophic 
Lateral Sclerosis (ALS) and Huntington’s Disease (HD) report aggregation and 
transmission of pathogenic proteins between cells in addition to stereotypical 
patterns of disease progression (Hansen et al., 2011; Herrera et al., 2011; 
Jack and Holtzman, 2013; Lee et al., 2001; Neumann et al., 2006; Spillantini et 
al., 1998). 
 Given that trans-synaptic transmission must proceed along axonal 
projections, the spatiotemporal dynamics of pathology spread can be 
quantitatively and deterministically captured once the inter-regional anatomic 
connectivity patterns are known. Recently, our group proved tested this 
hypothesis with a mathematical model of prion-like spread on diffusion MRI-
based structural networks. We proposed a mathematical model of prion-like 
trans-synaptic spread of neurodegenerative pathology called the network 
diffusion model (NDM). This model demonstrated that observed spatial 
patterns of neurodegeneration in common degenerative diseases like 
Alzheimer’s and frontotemporal dementia can be explained simply as a 
consequence of network spread (Raj et al., 2012). This model also gives an 
explanation of selective regional vulnerability in terms of disease epicenters, 
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called eigenmodes, associated with pathology. The model was successfully 
validated to predict future atrophy patterns of AD subjects from baseline 
atrophy patterns on a single template connectome (Raj et al., 2015).  
 The current study explores two of the potential mechanisms underlying 
selective regional vulnerability in HD: 1) Molecular factors characterized by 
innate regional gene expression patterns of HD-related genes; and 2) Prion-
like spread of HTT and downstream protein products along connectivity. In 
addition to structural connectivity, the current study also assesses a distanced-
model connectivity model as well as a functional connectivity model. To 
assess regional gene expression models of HD, regional gene expression is 
used from of 6 healthy brains published by the Allen Institute, with a set of 
genes selected on the basis of their relevance to HD. For connectivity-based 
model, a previously published NDM to a variety of connectomes quantitatively 
assesses whether trans-synaptic transmission of HD pathology can 
recapitulate observed HD topography. Empirical data to test various models 
comes from an unprecedented dataset of 231 subjects with HD from the 
Track-HD study, a multinational prospective observation study of HD that 
examines clinical and biological findings of disease progression in individuals 
with pre-manifest HD and early-stage HD (Tabrizi et al., 2012, 2011, 2009). 
This is the first published study to systematically test multiple hypotheses of 
pathology spread in living human subjects with HD.  
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Methods  
Participants 
 Track-HD is a multinational prospective observational study of 
Huntington’s disease (HD) that examines clinical and biological findings of 
disease progression in individuals with pre-manifest HD and early-stage HD. 
Inclusion criteria, procedures, data collection and data storage have been 
described previously (Tabrizi et al., 2012, 2011, 2009). Subjects were 
assessed at four study sites in the Netherlands, the UK, France, and Canada. 
The study was approved by local ethics committees and written informed 
consent was obtained from each participant before enrollment.   
 Individuals without HD but carrying the mutant huntingtin gene (classed 
as preHD-A if ≥10.8 years and preHD-B if <10.8 years from predicted onset), 
participants with early HD (classed as HD1 if they had a total functional 
capacity score of 11–13 and HD2 if they had a score of 7–10), and healthy 
controls. Controls were selected from the spouses or partners of individuals 
with premanifest or early Huntington’s disease or were gene-negative siblings, 
to ensure consistency of environments. All control groups were age-matched 
and gender matched with patient group (Table 4.1).  
 
Table 4.1. Study participants.   
Patient 
Group  
Patient 
N  
Patient 
Age 
(std)  
Patient 
Gender  
Control 
 N  
Control 
Age 
(std) 
Control 
Gender 
Age 
p-
value  
Gender 
p- 
value 
preHD-
A 
62   41.05 
(8.63) 
33 (F)  
29 (M) 
100 43.34  
(8.77) 
57 (F) 
43 (M) 
p=.11 p=.28 
preHD-
B 
54  40.65  
(8.73) 
33 (F) 
21 (M) 
93 42.27 
(8.11) 
53 (F) 
40 (M) 
p=.26 p=.39 
HD1 72 46.69  
(10.37) 
42 (F) 
30 (M) 
119 46.20 
(10.42) 
68 (F) 
51 (M) 
p=.75 p=.73 
HD2 43 51.98  
(8.55) 
19 (F) 
24 (M) 
92  50.23 
(7.94) 
54 (F) 
38 (M) 
p=.25 p=.63 
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MR image processing 
 MRI was collected and processed as described in (Tabrizi et al., 2013). 
The brain was parcellated into 86 different ROIs using cortical and subcortical 
structures from the FreeSurfer (Desikan-Killarney) gray matter parcellation.  
White matter connectome 
 The white matter (WM) connectome was constructed by taking the 
mean of diffusion MRI data of normal, healthy subjects. Normal subject data 
were collected jointly by Weill Cornell Medical College and the Brain Trauma 
Foundation. Seventy-three healthy subjects (40 men, 33 women, 30.2 ± 6.7 
years) were used to create the normative connectivity information in the form 
of tractograms. T1-weighted structural and diffusion-weighted MR images 
were collected on a 3 T GE Sigma EXCITE scanner (GE Healthcare, 
Waukesha, WI). The High Angular Resolution Diffusion Images data were 
acquired with 55 isotropically distributed diffusion-encoding directions 
at b=1000 sec/mm2 and one at b=0 sec/mm2, from 72 1.8-mm thick interleaved 
slices (no slice gap) and 128×128 matrix size, zero-filled during reconstruction 
to 256×256, with a field of view (FOV) of 230 mm2. The structural scan was an 
axial three dimensional inversion-recovery fast spoiled gradient-recalled echo 
sequence ((echo time [ET]=1.5 msec, repetition time [TR]=6.3 msec, inversion 
time [TI]=400 msec) flip angle of 15°) with a 256×256 matrix over a 
230 mm2 FOV and 156 1.0-mm contiguous partitions. The diffusion images 
were corrected for eddy current and motion artifacts using FMRIB Software 
Library (FSL) (Smith et al., 2004). 
 T1 images were processed by first segmenting the tissue into 
cerebrospinal fluid, WM and GM. The GM segment was subsequently 
parcellated into 86 different ROIs using cortical and subcortical structures from 
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the FreeSurfer (Desikan-Killarney) gray matter parcellation. The parcellated 
GM was then linearly transformed and resampled to diffusion image space for 
use in tractography. Briefly, the surface voxels of the parcellated cortical and 
subcortical structures were used to seed the tracts. Proposed and validated in 
Iturria-Medina and colleagues (2005), the tractography algorithm implemented 
here incorporates tissue classification probability and orientation distribution 
information in a Bayesian manner. A tract terminated when the algorithm 
reached the boundary of an image volume, the edge of a GM region, a voxel 
not in the gray or WM masks, or when the angle between subsequent steps 
exceeded π/3. This analysis was done using the eighth version of Statistical 
Parametric Mapping (SPM), (Friston et al., 2007), a software package within 
Matlab R2009a (The Mathworks, Inc., Natick, MA), and the Individual-Based 
Atlas toolbox (Aleman-Gomez, 2006) within SPM.  
 Further details of the image processing and tractography method are 
given in a previous publication (Kuceyeski et al., 2013; Kuceyeski et al., 2011). 
To control for inter-subject variance in total fiber count, the number of 
connections between each tract was divided by the total number of tracts 
based on each subject’s tractography data. Because DTI cannot provide 
directionality, the connectome was symmetric. The subsequent undirected 
connectomes were not thresholded and kept as weighted. Functional 
connectivity acquisition and preprocessing are also available in (Kuceyeski et 
al., 2013). Similarly, functional connectivity matrices were kept as weighted, 
non-thresholded and directionality was maintained.  
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Directional connectivity networks 
 Mesoscale mouse connectome data was used from the Allen Brain 
Institute (Oh et al., 2014). Total projection volume between regions was 
generated by multiplying element-wise by the rows the connectivity matrix 
times the number of voxels in each seeding region. As the MBCA connectivity 
matrix, retrieved from Oh et al. 2014, gave per-voxel normalized connectivity 
strength, our adjustment of connectivity to the size of each region 
approximates total connectivity. This procedure for approximating total axon 
volume or connectivity between regions is laid out in detail in SI.5 in Oh, et.al., 
2014. Following this, we applied a thresholding criteria of getting rid of all 
values that were less than 0.05 the standard deviation of the nonzero entries 
of the mouse connectivity matrix, resulting in a network density < 0.14. The 
network derived from the Allen Institute is directed and the matrix representing 
the mouse connectivity network is therefore not symmetric over its diagonal. 
The above generated network is arranged such that per-region outgoing 
connectivity is given by each row and per-region incoming connectivity is given 
by each column. 
Genetic data 
 Microarray gene expression data from post-mortem healthy human 
brains were downloaded from the Allen Brain Atlas Institute and obtained as 
described in (Hawrylycz et al., 2012). Microarray data were composed of 926 
regions of the brain, each one belonging to a set of 58,692 probes that 
correspond to 29,181 distinct genes. Unique probe ID’s often represented the 
same gene and were all used for analysis of the gene, as done by (Freer et 
al., 2016). For analysis, the 926 regions in the microarray data were mapped 
to 86 regions of the Desikan Atlas. Data points that were unable to be mapped 
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to the Desikan Atlas included WM tracks and were excluded from analysis. 
The exclusion of WM tracks should have little impact on analysis due to its 
large composition of myelinated axons and its expendable role in research that 
successfully links expression signature to vulnerability in neurodegeneration 
(Freer et al., 2016). If multiple probes existed for a single gene, expression 
was averaged together for each ROI. Genes of interest were selected from a 
DisGeNET database, which generates integrates human gene-disease 
associations from curated databases and text mining (Piñero et al., 2015). 
 
Network Diffusion Model (NDM) 
The network diffusion model is used as described in Raj et al. 2012. Briefly, 
HD-related disease pattern, given by the vector x(t), is modeled as a diffusive 
process:  
(Eq 1) 
where x0 is the initial regional pattern of the disease, on which the term e−βHt 
acts as a spatial and temporal blurring operator. We therefore call e−βHt, “the 
diffusion kernel.” The computation of the above equation is accomplished via 
the eigenvalue decomposition H  = UΛU† , where U  = [u1  … uN ], giving: 
 
(Eq 2) 
 
In other words, the network diffusion model is evaluated via the eigen-
decomposition of the Laplacian matrix, such that the pattern of disease at any 
point of time is given as a linear superposition of the eigenmodes ui’s of the 
Laplacian. Eigenmodes are calculated, using spectral graph theory on the WM 
86x86 ROI Laplacian matrix based on spectral graph theory. See Raj et al. 
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2012 for a full description of the network diffusion model. These eigenmodes, 
in turn, represent fundamental substrates upon which network spread of 
pathological entities is enacted. Hence, we investigated whether the prominent 
eigenmodes are conserved between patients and healthy subjects.   
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Figure 4.1. NDM construction. Using our established neuroimaging pipeline 
the regional atrophy vector for a patient is obtained; a “glass brain” rendering 
of regional atrophy is shown in panel 1.) For each model time t, the vector x(t) 
is correlated against empirical atrophy vector; an example scatter plot is 
shown in panel 2.) The Pearson’s R statistic is plotted over all model times t, 
giving what we call the “R-t curve” shown in panel 3.) This process is repeated 
for all possible single regional seed locations, and the maximum R, denoted as 
Rmax here, for each is recorded. 4) A histogram of Rmax for all 86 brain regions 
serving as seed. 
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 The steps leading up to NDM model construction are illustrated in 
Figure 4.1. To evaluate predictive power of the NDM, the correlation between 
simulated and observed atrophy was plotted over a wide array of model time 
units, giving what we call the R(t) curve (Figure 4.1.3,). The time unit with the 
highest correlation coefficient was selected as reflective of model 
performance. All analysis was performed in MATLAB. 
 
Results 
Atrophy patterns by disease stage 
 First, we illustrate that the regional atrophy patterns of the Track-HD 
subjects measured by our pipeline across the four disease severity (preHD-A, 
preHD-B, HD-1, HD-2) in a cross-sectional design reflects classic patterning of 
HD (Figure 4.2). Specifically, the earliest pre-disease subjects (preHD-A) show 
significant striatal atrophy in relation to the rest of the brain. Atrophy worsens 
with disease severity, ultimately reaching a state of global brain degeneration 
in HD-2 subjects. Throughout all stages, the striatum remains the region with 
the most atrophy. Other significant areas exhibiting atrophy are in the occipital 
cortex, but only in advanced subjects (HD-1 and HD-2). Regional atrophy 
remains bilateral in all groups. 
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Figure 4.2. HD volumetrics. Glass brains displaying differences in cortical 
thickness and subcortical volumes in HD vs. CON. Red denotes atrophy in HD 
patients compared to age-matched, gender-matched controls. Nodes across 
all four stages are drawn to the same proportion.   
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Bivariate associations between regional atrophy and healthy gene 
expression 
 To test the hypothesis that innate molecular factors are responsible for 
the observed regional patterns of HD atrophy, we utilize post mortem 
microarray data from 6 healthy subjects published by the Allen Brain Institute 
(Oh et al., 2014). We examine correlations between regional expression of 
selected genes and regional group-level atrophy. We observe no correlation 
between HTT expression and atrophy at any stage of HD (Figure 4.3A1-2). 
Hence, we examine the relationship between atrophy and gene expression of 
12 additional highly implicated genes in HD. We observed that PPAR has a 
significant positive correlation with pathology at the latest stage of HD (r=0.37, 
p=4.51e-04) (Figure 4.3B1-2). This correlation appears to be related to 
disease severity, as there is no correlation in the earliest stage of pre-HD 
(r=0.01, p=NS). Similarly, we observe a correlation in DRD2 expression that 
appears to be severity-related. DRD2 has a significant correlation with pre-
HDA atrophy (r=0.37, p=5.45e-04), that increases at HD-2 (r=0.54, p=8.31e-
08) (Figure 4.3C1-2). For a full list of observed genes and p-values, see Table 
4.2.     
 To probe the collective effect of the most highly implicated genes in HD, 
we perform principal components analysis (PCA) on gene expression of all 12 
genes of interest. Similar to PPAR and DRD2, the first principal component of 
gene expression appears to be pathology related, as the relationship 
increases in the later stages of the disease (preHD-A: r=0.42, p=5.30e-05 and 
HD-2: r=0.65, p=1.24e-11) (Figure 4.3D).  
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HTT production followed by network spread does not predict HD atrophy 
 Subsequently, we test the hypothesis that a network spread model 
initiated by HTT gene expression, will successfully recapitulate HD 
topography. Our group’s previously published NDM is used to model network 
spread from baseline HTT gene expression patterns. Atrophy data from 
subjects in HD-2 was utilized as the model’s observed end state to allow for 
maximal disease-related effect size. The NDM was evaluated on a healthy 
structural network, under the assumption that the WM network serves as a 
conduit for pathology and does not undergo significant degeneration itself.  
 With HTT expression pattern as the vector x0 in the NDM equation, we 
correlated the NDM model prediction vector x(t) at all model times t against 
HD-2 atrophy vector. The model appears to give negative Pearson’s R, 
implying that a network spread process seeded with HTT expression would 
not explain HD atrophy at any model time t. This suggests that baseline HTT 
patterns do not significantly mediate network-based spread in HD (Figure 
4.3A3).  
 Although PPAR, DRD2 and PCA #1 had moderately high correlation 
with atrophy as described above, we saw virtually no evidence that 
subsequent NDM-based network spread would give better fit with HD-2 
atrophy. Diffusing PPAR from its baseline state does not offer any 
improvement over the baseline correlation (Figure 4.3B3), with correlation 
curve being strictly monotonically decreasing from a high value at t=0.  
Similarly, DRD2 and PCA #1 have high correlation values at t=0, and further 
network diffusion gives only a miniscule improvement (<0.007) (Figure 4.3C3, 
Figure 4.3D3). These results suggest that while regional gene expression may 
be related to pathology production associated with regional atrophy, network 
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models of trans-synaptic spread rooted in gene expression do not recapitulate 
HD topography.  
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Figure 4.3. Gene diffusion. A, B, C, D1-2) Glass brains showing gene 
expression of post mortem healthy human brains from the Allen Brain Institute. 
Correlation coefficients and p-values depict the association between healthy 
gene expression and HD atrophy at HD-2. A-D3) Graphs of NDM accuracy 
over time, using healthy gene expression as the baseline state on a healthy 
structural network. 
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Table 4.2. Genetic correlations to atrophy. Correlations between nodal 
atrophy and gene expression in the latest (HD-2) and earliest (preHD-A) stage 
of HD.   
 
 
Connectivity-based network spread from a single seed region 
 Distance hypotheses of neurodegeneration postulate that distance 
between infected nodes mediates pathology spread. Similarly, activity-
dependent models hypothesize neurons that fire together in distinct regions 
are integral to trans-synaptic disease spread. Other models premise structural 
connectivity mediates the travel of toxic proteins across the brain 
(Brettschneider et al., 2015). Thus, we sought to empirically test if distance, 
functional or structural connectivity-based network models best recapitulate 
pathology spread in human subjects living with HD. This did not require us to 
develop different NDM models; the same NDM equation was applied to 
different adjacency matrices. A DTI-based connectivity matrix was used to test 
structural connectivity hypotheses, a Euclidean distance between all region-
pairs to test distance hypotheses, and a resting state functional connectivity 
matrix to test activity-dependent hypotheses. 
Supplementary Table 1. Genetic Correlations 
Correlation to HD-2 
Atrophy 
Correlation to 
 preHD-A Atrophy 
Gene r value p value r value p value 
HTT -0.07 0.48 0.07 0.52 
PPAR 0.37 4.51E-04 * 0.01 0.32 
BDNF -0.42 4.91E-05 * -0.10 0.35 
DRD2 0.54 8.31E-08 * 0.37 5.45E-04 * 
GRIN2A -0.18 0.10 -0.19 0.09 
GRIN2B -0.04 0.69 0.13 0.23 
GRIN3A -0.47 5.26E-06 * -0.16 0.12 
HAP1 0.10 0.38 0.09 0.39 
PARK7 -0.27 0.01 * -0.11 0.28 
SLC6A4 0.10 0.34 0.05 0.64 
SLC18A2 0.11 0.30 0.12 0.28 
TBP -0.28 0.008 * -0.28 0.10 
PCA #1 .65 1.24E-11 * .42 5.30E-05 * 
* denotes significance 
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 Since the initial seed configuration of the baseline patterns of HD 
pathology (x0) is unknown, we empirically tested all seeds, separately, for all 
possible seed locations. For each model run, we simulated pathology spread 
from a single brain region, and recorded the maximum correlation coefficient 
(Pearson’s R) between the simulated NDM vector and the empirical HD 
atrophy vector over a wide range of model time. We hypothesized that the 
best seed location will give the highest Pearson’s R.  
 Results from empirically testing all three models from all seeds in the 
brain are illustrated in Figure 4.3. The R(t) curves corresponding to NDM 
model accuracy over time are shown in the top row (Figure 4.4A1-3).  Each 
curve corresponds to a single site acting as a seed for NDM. Across all three 
models, the highest correlations are seen in striatal seeds (shown in bold red) 
for all thee adjacency models. Histograms of the maximum R for all seed 
locations are shown in Figure 4.4B1-3. Across all three models, we observe 
striatum is the most likely place of pathology origin, as it is the seed yielding 
the highest correlation to observed state atrophy. Specifically, we identify three 
regions of the striatum: Caudate, Putamen and Nucleus Accumbens. 
Moreover, these data show that both structural and functional connectivity 
serve as equally good substrates for network diffusion, whereas Euclidean 
distance does not. There is no evidence of network diffusion in the distance-
based model, as maximum correlation achieved by model stimulation is less 
than a .01 improvement from baseline.  
 Figure 4.4C1-3 lends further support to NDM results, as we observe 
there is no relationship between regional distance from the striatum and 
atrophy (r=-0.09, p=NS) nor between functional connectivity to the striatum 
and atrophy (r=0.11, p=NS). However, we observe a significant relationship 
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between a region’s structural connectivity to the striatum and its HD atrophy 
(r=0.24 p=0.03). Taken together, these data show striatal-seeding on a 
structural connectivity-based network model best recapitulates HD spread in 
vivo and suggest structural connectivity to the striatum may be implicated in 
trans-synaptic pathology spread in HD.  
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Figure 4.4. Distance, functional and structural NDM. Evaluating distance, 
activity-dependent and structural connectivity models of disease spread in HD. 
A1-3) Model accuracy over time of the model being simulated separately from 
each seed in the brain. B1-3) Histograms of the highest accuracy achieved by 
each seed. C1-3) Association between the model characteristic and regional 
pathology. 
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Directional network diffusion 
 A limitation of the NDM approach is that it is based on bidirectional DTI 
connectivity networks, which assumes connections are the same in both 
direction. This could limit NDM predictive ability, because trans-synaptic 
transmission may have a distinct directional bias, such that misfolded protein 
species may follow anterograde transport or signaling pathways. This is 
especially true in subcortical and striatal connections, which are known to be 
highly directional in comparison to corticocortical connections.  
 Thus, we hypothesized a directional (anterograde) process of spread 
along a structural connectivity network will further improve model performance. 
We use a directional human connectome obtained from blending non-
directional human DTI and directional viral tracing connectomes of the mouse 
(see Methods).  
 We observe the directional structural connectome greatly improves 
model performance compared to the original, non-directional structural 
connectome. Similar to Figure 4.4, the striatum is again the most likely source 
of pathology origin (Figure 4.5A). Unlike the non-directional case, network 
diffusion does not dissipate into non-predictive patterns with low R. Instead, 
they seem to settle into highly predictive patterns with high R at large model 
times t, suggesting presence of a stable network attractor, a hypothesis that 
this will be interrogated in more detail below.  
 Figure 4.5B-C illustrate model accuracy over time and improvement 
over the baseline state when anterograde pathology diffusion is simulated 
from striatal seeds. The Nucleus Accumbens is suggested as the most likely 
origin of pathology. Further supporting the NDM results, Figure 4.5D shows a 
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significant relationship between anterograde connectivity to the Nucleus 
Accumbens and nodal degeneration (r=0.66, p=7.38e-12).  
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Figure 4.5. Striatal directional NDM. Accuracy of the directional, structural 
NDM in predicting HD disease spread when pathology is simulated from each 
of the striatal seeds. A) Model accuracy over time of all seeds. B) Zooming in 
on diffusion of striatal seeds over time. C) Ultimate model accuracy achieved 
(highest correlation) in blue and in teal, the improvement the model offers 
compared to just using the baseline atrophy to predict. D) Correlation between 
local degeneration and striatal connectivity.  
 
 167 
  Having established the striatum as the best seed from which to simulate 
pathology spread in all the models, we compiled model performance from the 
striatum across select models (Figure 4.6.) However, it remains unclear if the 
striatum performs as the best seed due to high baseline regional atrophy or 
characteristics of the tested models such as distance, functional connectivity 
or structural connectivity. To elucidate a possible confounding effect of striatal 
atrophy, we seed the NDM at the striatum, but randomly scramble the 
directional structural connectome as a negative control. We show that when 
the directional structural connectome is scrambled, the model does not 
perform. No diffusion occurs as the model simply falls to steady state (Figure 
4.6A-B).  
 
 
Figure 4.6. Scrambled directional NDM. Performance across several models 
including the striatal seeded directional structural connectome, original 
structural connectome, scrambled directional connectome. A) Accuracy as 
various models diffuse over time. B) Highest accuracy attained for each model 
and its improvement from baseline.  
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Seeded directional NDM of individual subjects 
 All results so far were obtained by correlating NDM prediction against 
group atrophy patterns. In order to assess inter-subject variability and 
consistency of our results, we examined NDM model performance at individual 
subjects basis. The maximum correlation of each subject against the 
anterograde NDM model, for all possible seed regions, was obtained, and the 
seed that gave the highest R value was recorded. The distribution of best 
seeds in all individuals is shown in the histograms of Figure 4.7, stratified by 
lobe. The striatum is again the most frequent origin of pathology in individual 
subjects. The parietal lobe was second highest, third was subcortical regions 
and we also observed 2 occipital regions. No frontal regions were identified as 
pathology seeds in any subjects (Figure 4.7). A majority of subjects show a 
maximum model accuracy of r = 0.50 or more, and the highest correlation we 
observed was r = 0.84. For a full list of individual subject data, see Table 4.3.  
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Figure 4.7. Individual directional NDM. Histograms illustrating the most 
likely place of disease origin and the models best predictive accuracy when 
the directional structural NDM is simulated on subject-specific atrophy patterns 
in HD-2.  
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Table 4.3. Individual subject seeds. Best seeds for individual subjects using 
the directional anterograde structural connectivity NDM.  
 
  Supplementary Table 2. Individual subject best seeds using directional anterograde connectivity model. 
R max T max Best Seed R max T max Best Seed 
0.86 30.30 NaC 0.52 65.66 Amygdala 
0.80 32.83 NaC 0.50 250.00 Supramarginal 
0.78 32.83 NaC 0.47 143.94 Superior Parietal 
0.76 40.40 NaC 0.47 27.78 NaC 
0.76 85.86 Thalamus 0.46 22.73 Caudate 
0.67 30.30 NaC 0.46 30.30 Thalamus 
0.65 22.73 Superior Parietal 0.44 121.21 Ventral DC 
0.64 35.35 NaC 0.42 78.28 Entorhinal 
0.63 250.00 Postcentral 0.42 35.35 Superior Parietal 
0.61 88.38 Amygdala 0.41 179.29 Temporal Pole 
0.60 90.91 Thalamus 0.40 15.15 Inferior Temporal 
0.59 98.48 Ventral DC 0.38 55.56 Post Central 
0.58 25.25 NaC 0.37 27.78 Inferior Parietal 
0.57 27.78 NaC 0.36 103.54 Transv. Temporal 
0.57 90.91 Supramarginal 0.34 35.35 Cuneus 
0.57 106.06 Amygdala 0.34 20.20 Inferior Temporal 
0.55 32.83 Inferior Parietal 0.33 15.15 NaC 
0.54 73.23 Supramarginal 0.32 20.20 Insula 
0.54 27.78 NaC 0.31 20.20 Inf. Parietal 
0.54 50.51 Postcentral 0.30 25.25 Superior Parietal 
0.53 78.28 Postcentral 0.27 20.20 NaC 
0.53 136.36 Precuneus 
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Non-seeded anterograde NDM 
 Although results thus far support a key role for anterograde network 
transmission in HD patterning, they require the extraneous assumption of a 
originating or seeding site. There is little evidence in the literature indicating 
that the striatum and specifically the nucleus accumbens has an etiologically 
or mechanistically privileged place in HD pathophysiology. In comparison, our 
non-network analyses involving the role of gene expression do not require 
such extraneous assumptions.  
 Therefore, we sought to address whether focal seeding was a 
necessary condition for anterograde transmission in HD, or whether diffuse or 
random seeding would perform just as well. An indication that this might be so 
was already observed in Figure 4.5A, where almost all seed locations 
produced R(t) curves that eventually settled into a steady state with a high R 
value. As mentioned, this is indicative of a potential network attractor. Using 
graph theory, we had previously demonstrated that any network diffusion 
process will eventually be dominated by the most persistent eigenmodes of 
the network, specifically the smallest eigenmodes of the graph Laplacian (Raj 
et al. 2012). 
 Our group’s prior work with the NDM shows eigenmodes are epicenters 
from which disease vulnerability can be predicted and future pathology 
patterns can be projected. Therefore, we hypothesized that the anterograde 
network Laplacian’s primary eigenmode (whose eigenvalue is zero) would 
resemble the topography of regional HD atrophy. The resulting glass brain 
rendering of the eigenmode is shown in Figure 4.8A1. Intriguingly, the 
eigenmode’s spatial pattern is highly suggestive of HD topography, with high 
values in the striatum and cuneus. There is a significant relationship between 
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HD atrophy pattern and the first eigenmode that appears to be related to 
disease severity. In pre-HD-A this relationship is significant (r=0.53 p=1.96e-
07) and the relationship strengthens as the highest disease severity group, 
HD-2 (r=0.64 p=1.98e-11) (Figure 4.8A1-2). This pattern is echoed, but to a 
much weaker extent in functional networks (Figure 4.8B1-3).  
 Mathematically, the first eigenmode is a linear network attractor, a state 
into which any anterogradely diffusing pathology will increasingly accumulate, 
even if pathology seeding was random, diffuse or uniform. The above result 
therefore supports the idea that the prominent sites of HD atrophy may not be 
imitating sites, but rather the sites at which early pathology first accumulates 
beyond some threshold. Subsequent network transmission will continue to  
exhibit similar topography, as shown earlier in Figure 4.5A on anterograde 
NDM from striatal seeding.  
 To confirm accumulation of anterogradely diffusing pathology from non-
focal seeding predicts HD regional atrophy, we perform simulations of 
anterograde NDM from three diffuse seeding processes on the directional 
structural connectome: 1) Seeding in proportion to HTT regional expression; 2) 
uniform seeding in every location; 3) Seeding in proportion to the 12- gene 
PCA regional gene expression. In each case, the NDM model was evaluated 
at a range of model times t>0, and the corresponding R(t) curve was plotted. 
 These results, contained in Figure 4.9, show that although there are 
subtle differences in the intermediate time behavior of each seeding strategy, 
the eventual, steady state R value was very similar (r = 0.59, p < 1e-10). This 
result supports the notion that a focal or specific regional seed is not required 
for HD pathology, and that most kinds of diffuse seeding patterns will 
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eventually result in observed HD atrophy pattern, purely as a result of 
anterograde network diffusion.   
 
 
 
 
Figure 4.8. Structural and functional eigenmodes. A1, B1) Structural and 
functional eigenmodes, respectively. A2, B2) Relationship between local 
degeneration and eigenmode of the earliest pre Huntington’s stage. A3, B3) 
Relationship between local degeneration and eigenmode at the latest stage of 
the disease.  
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Figure 4.9. Anterograde NDM glass brains. Anterograde network diffusion 
starting from HTT (left) and gene PCA (right) seeding. Both seeding strategies 
give similar results, each undergoing anterograde transmission and 
accumulating increasingly in a striatal-dominant pattern governed by the first 
network Laplacian eigenmode. Increasing model time t is depicted from top to 
bottom. The bottom row shows the corresponding R(t) curves, indicating that 
each seeded pattern settles into a steady state pattern around r = 0.59.  
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Discussion  
 The current study applies network modeling to a rare disease as the 
first to systematically test hypotheses of disease spread in human subjects 
living with HD. Other neurodegenerative diseases like FTD, AD and ALS 
syndromes have been well-studied from a human brain network perspective, 
and have received more attention than equally important and related disorders 
such as HD (Seeley, 2017), due to a lack of available human data on this rare 
disorder, which affects approximately 3 to 7 in 100,000 individuals in western 
populations (Harper, 1992). The present analysis takes advantage of an 
unprecedented dataset of 231 subjects with HD from Track-HD, a 
multinational prospective observation study of HD. Our key results are 
described below.   
Observed Pathology Across HD Stages 
 Across 4 stages of HD severity, the striatum suffers the most atrophy, 
followed by generally diffuse moderate atrophy everywhere – even in subjects 
who are more than 10.8 years before disease onset. These are well 
established findings (Tabrizi et al., 2013, 2011, 2009). The occipital cortex is 
the only other area showing enhanced atrophy, but only in advanced subjects. 
As the disease progresses, the brain ultimately reaches a state of global 
degeneration, with the striatum the most significant  (Figure 4.2). Our 
replication of this result converges with characteristic features of HD as classic 
Human neuroimaging and post-mortem report significant global brain atrophy, 
with the striatum as the region of most atrophy (de la Monte et al., 1988; Kuhl 
et al., 1982; Vonsattel et al., 1985). These data point to the lack of regional 
discrimination in HD, except for the striatum. 
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Regional gene expression is a moderate to weak predictor of HD 
topography 
 We sought to understand whether innate regional expression of HD-
implicated genes can predict above described HD topography. WT HTT has 
been illustrated to generate oligomers by itself and oligomerize with mutant 
HTT, causing additional aggregation and apoptosis (Herrera et al., 2011). 
Surprisingly, we found that HTT expression in the healthy human brain has 
almost no association with the regional pattern of atrophy seen in HD patients 
at any stage (Figure 4.2A1-2). This finding is at odds with the overwhelming 
support of the key role of mutant HTT in HD pathogenesis (Bradford et al., 
2009; Chou et al., 2008; Herrera et al., 2011; Lee et al., 2001; Ren et al., 
2009; Tan et al., 2015). 
 Next, we hypothesized that while there may not be direct relationship 
between HTT expression and local degeneration, perhaps mutant HTT had 
downstream effects on other genes. To test this hypothesis, we evaluated the 
relationship between HD atrophy and gene expression of 12 additional highly 
implicated genes in HD. PPAR had a significant positive correlation atrophy at 
the latest stage of HD (r = 0.37, p=4.51e-04) (Figure 4.3B1-2). This correlation 
appears to be related to disease severity, as there is no correlation in the 
earliest stage of pre-HD (r = 0.01 p=NS). We observed a correlation in DRD2 
expression that appears to be disease-severity-related. DRD2 has a significant 
correlation with pre-HDA atrophy (r = 0.37, p=5.45e-04), that increases at HD-
2 (r = 0.54, p=8.31e-08) (Figure 4.3C1-2). Disease-severity-related 
correlations of PPAR, DRD2, BDNF and GRIN3A support prior evidence 
implicating abnormality of these genes in metabolism, dopamine vulnerability, 
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neuronal growth, and excitatory synapse signaling and their roles in HD (Duan 
et al., 2003; Marco et al., 2013; Quintanilla et al., 2008; Zuccato et al., 2005). 
 To probe the collective effect of the most highly implicated genes in HD, 
we performed principal components analysis (PCA) on gene expression of all 
12 genes. Similar to PPAR and DRD2, the first principal component of gene 
expression appears to be pathology related, as the relationship increases in 
more severe disease (preHD-A: r=0.42, p=5.30e-05 and HD-2: r=0.65, 
p=1.24e-11) (Figure 4.3D). Interestingly, associated genes reflect a 
predominantly striatum pattern. 
  A visual inspection shows that all significant genes and their 
combinations described above in fact reflect a strong dominance of the 
striatum (Figure 4.3). DRD2 codes for dopamine receptors which are 
predominantly found in striatal structures, and PPAR and BDNF are also 
highly expressed there, and this pattern also continues in PCA of these genes. 
Therefore, we considered whether the above gene results are simply a 
reflection of the fact that the striatum is selectively vulnerable to HD atrophy, 
and that the implicated genes simply reflect that, with no other mechanistic 
basis. This notion is strengthened by the fact that HTT, which is known to be 
the etiological culprit, does not in fact show any resemblance to HD atrophy 
patterns.   
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HTT aggregation and propagation in HD does not recapitulate HD 
atrophy 
 Mutated HTT is a pathogenic protein linked to network degeneration via 
trans-synaptic spread in a manner similar to pathogenic proteins implicated in 
other neurodegenerative disorders, such as tau (AD), amyloid beta (AD), 
alpha-synuclein (PD) and SOD1 (ALS) (Nagai et al., 2007; Schwarz et al., 
2016; Spillantini et al., 1998). Current hypotheses of pathology spread in 
neurodegeneration are centered on the prion hypothesis, which posits that 
toxic proteins spread trans-synaptically along neuronal pathways in specific 
patterns. This hypothesis has been particularly well-studied in tauopathies 
such as AD (Jucker and Walker, 2013). Converging neuroimaging, post-
mortem and mouse injection site studies all point to mutated tau aggregating 
and spreading stereotypically throughout the neural network in AD (Braak and 
Braak, 1996; Clavaguera et al., 2009; Schwarz et al., 2016). 
 There is mounting evidence that mutant aggregated HTT is capable of 
prion-like spread between cells. Wildtype HTT can generate oligomers by itself 
and oligomerize with mutant HTT, causing additional aggregation and 
apoptosis (Herrera et al., 2011). Mutated HTT has been reported to diffuse 
into extracellular space and inside adjacent cells to act as seeds for further 
aggregation and neurotoxicity (Ren et al., 2009). Glial cells are another 
purported mechanism of mutant HTT spread in HD, as glial cells can transport 
mutant HTT without undergoing apoptosis themselves, but still cause neuronal 
death (Bradford et al., 2009; Chou et al., 2008). A non-cell anonymous, 
synaptic vesicle mediated transport of pathology in ex vivo and in vivo models 
of HD was demonstrated in (Pecho-Vrieseling et al., 2014). 
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 Hence, we hypothesized that network spread would recapitulate HD 
topography when seeded with the baseline pattern of regional HTT gene 
expression. To our knowledge, such a network model of disease propagation 
has not been reported before. To achieve this, we utilized a computational 
Network Diffusion model (NDM) which we had previously proposed as a 
means of modeling tau propagation in the AD brain (Raj et al., 2012a). As in 
previous work, the NDM used here was evaluated on a healthy structural 
network, under the assumption that the WM network serves as a conduit for 
pathology and does not undergo significant degeneration itself.  
 We found that disease spread simulated from baseline HTT patterns 
does not successfully recapitulate HD progression (Figure 4.3A3). It is of 
course possible that HTT aggregation may not necessarily mimic baseline wild 
type HTT expression. Prior work shows that medium spiny neurons in the 
striatum contain few HTT nuclear aggregates, but nonetheless undergo the 
most extensive damage, experiencing significant apoptosis (Gutekunst et al., 
1999). However, in our analysis, we expect that over the whole brain, wild type 
HTT expression should have regional association with atrophy. Our results 
suggest that neither HTT regional expression by itself, nor its subsequent 
network transmission, is capable of recapitulating HD topography. This is 
surprising in view of the key role of mutant HTT in HD pathogenesis. 
 180 
Evaluating associated genes as a starting point for network transmission 
 We also simulated the NDM initiated from 12 of the implicated gene’s 
expression patterns, but found no evidence that post-production network 
spread via NDM contributes to HD atrophy patterns. Neither PPAR nor DRD2, 
nor PCA exhibited evidence of diffusion through the structural network, as 
model performance improvement is less than .01 from baseline (Figure 4.3). 
BDNF and GRIN3A were also significantly correlated with atrophy, but did not 
demonstrate diffusion. Collectively these data suggest that while certain genes 
may play a role in mediating tissue vulnerability to disease spread, network 
models of trans-synaptic spread rooted in gene expression do not recapitulate 
HD topography. 
Focal seeding followed by network spread recapitulates HD atrophy 
 Since network spread following baseline gene expression did not 
recapitulate HD atrophy, we tested whether network spread from focal seed 
sites would perform better. Although trans-synaptic transmission appears the 
most likely candidate, the exact mode of transmission is unknown. Hence to 
minimize model bias we simulated spread between regions in a number of 
ways: spread mediated by inter-regional distance; spread mediated by 
functional connectivity between brain regions; and spread mediated by WM 
fiber connectivity. We found that for each model, striatal seeding, specifically 
Caudate, Putamen and Nucleus Accumbens, gave the best results (Figure 
4.4). Converging post mortem and neuroimaging studies showing the striatum 
is the most likely region of pathology origin in HD (de la Monte et al., 1988; 
Kuhl et al., 1982; Vonsattel et al., 1985).  
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No evidence of distance-based spread 
  Interestingly, the Euclidean distance-based model does not give any 
evidence of spreading (since its R(t) curve in Figure 4.4 is monotonically 
decreasing). There was also no relationship between regional distance from 
the striatum and regional atrophy (r=-0.09, p=NS). These results appear to 
rule out a primarily distance-based model of spread – an important finding 
since conventional understanding of cell-cell transmission involves the uptake 
of pathological proteins via endocytosis and exocytosis (Brettschneider et al., 
2015) into extracellular spaces where pathology must diffuse spatially via the 
extracellular diffusion of transcripts, proteins, growth factors and other cues. 
 Absence of a distance-based effect in our results suggests that 
pathology spread must require long-range fiber projections rather than 
extracellular diffusion. In this, HD resembles Alzheimer’s and Parkinson’s 
disease, which too do not show strong evidence of distance-based spread. 
However, it is at odds with prior ex vivo cell culture work done in ALS, which 
shows that pathogenic proteins can diffuse into extracellular space without 
synaptic contact (Freundt et al., 2012). 
Spread along structural versus functional connections 
  Both structural and functional connectivity serve as equally good 
substrates for network diffusion, as their NDM models seeded at striatal 
regions achieve both high ultimate model performance and model 
improvement from baseline. Whether neurodegenerative pathology patterns 
are mediated by structural or functional connections is controversial 
(Brettschneider et al., 2015; Jones et al., 2016; Raj et al., 2012; Zhou et al., 
2012). Although misfolded proteins are known to spread along long range fiber 
projections (Jucker and Walker, 2013), it is also plausible that pathology 
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follows network dysfunction or cascading failures in brain activity (Jones et al., 
2016). Our NDM results do not favor either hypothesis over the other (4.4A). 
  However, we observe a significant relationship between a region’s 
structural connectivity to the striatum and its HD atrophy (r=0.24 p=0.03) 
(Figure 4.4C), but did not find similar effect for functional connectivity to the 
striatum (r=0.11, p=NS). Given that functional and structural connectivity in 
themselves are highly correlated, the most economical interpretation of our 
results is that the structural network mediates disease spread in HD (Greicius 
et al., 2009; Honey et al., 2009). The apparent mediation by the functional 
network might be a secondary, perhaps epi-phenomenon, a consequence of 
underlying structural topology. However, we think this notion warrants further 
investigation, as there could be additional underlying factors mediating 
functional network diffusion.  
 There is certainly mounting evidence from related cell culture and 
mouse studies that support our assertion that the structural network mediates 
pathology spread in HD. For example, both in-vitro and in-vivo transmission of 
pathology only occurred when a functioning synaptic network was in place 
(Gutekunst et al., 1999). Converging work in AD supports models of trans-
synaptic pathology spread mediated by structural connectivity. For example, 
classic studies identify the Locus Coereulus (LC) as the location where tau 
pathology is initially identified. However, the entorhinal region (EC), which is 
anatomically distant, but receives direct axonal projections from the LC, is the 
second region to develop tau pathology (Braak and Braak, 1996) (Pearson et 
al., 1985). Mouse studies using immunohistochemistry demonstrated 
relocation of tau from axons between the two regions to dendrites in the EC to 
lend further support to the notion of disease spread mediated by anatomical 
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connectivity (Liu et al., 2012). Overall, empirical data does not give 
overwhelming support to either cell autonomous or non-autonomous 
hypotheses explored so far in the investigation.   
Directional structural connectivity model  
 Having identified structural connectivity as the most likely mechanism of 
transynaptic pathology spread in HD, we sought to further improve our model 
by adding directionality. Trans-synaptic transmission can have a distinct 
directional bias, such that misfolded protein species might follow anterograde 
transport or signaling pathways. This is especially true in subcortical and 
striatal connections, which are known to be highly directional in comparison to 
corticocortical connections. Although little work has been done in HD, tau 
pathology in AD differentiates between efferent and afferent connections (Iba 
et al., 2015).  
 Hence, we tested the hypothesis that directional (specifically 
anterograde) process of spread along structural connectivity network will 
further improve model performance. The directional NDM results are shown in 
Figure 4.5. Overall, use of the directional structural connectome greatly 
improves model performance. As before, the striatum is again the most likely 
source of pathology origin (Figure 4.5A), but unlike the non-directional case, 
directional network diffusion does not dissipate into non-predictive patterns 
with low R; instead they seem to settle into highly predictive patterns with high 
R at large model times t, suggesting presence of a stable network attractor.  
 The model performance is highly significant (r=0.59, p < 1e-10), 
especially in comparison with random network scrambling of the directional 
structural connectome (Figure 4.6), confirming that network organization is 
integral to disease spread in HD. The Nucleus Accumbens is the most likely 
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region of pathology origin, and a significant relationship exists between 
anterograde connectivity to the Nucleus Accumbens and regional atrophy 
(r=0.66, p=7.38e-12). These results are superior to almost all previous models 
we have tested so far, save for PCA gene expression. 
 These data are complemented by strong evidence for heterogeneity of 
seeding and pathology origin in individual subjects. Although the majority of 
subjects give the striatum as the most likely region of origin, several subjects 
show occipital, parietal and temporal regions as seeds. This data converges 
with the emerging notion, especially in FTD, that a single disorder may have 
diverse anatomical and clinical manifestations, and uncertainty surrounds 
which aspect of proteinopathy drives that protein to select its unique anatomy 
in an individual patient (Seeley, 2017).  
Non-seeded anterograde NDM 
 Having established that directional structural connectivity is the network 
model that best recapitulates trans-synaptic HD progression, we sought to 
further elucidate the relationship between degeneration and intrinsic structural 
architecture. So far, the NDM model requires the extraneous assumption of an 
originating or seeding site. There is little evidence in the literature indicating 
that the striatum and specifically the Nucleus Accumbens has an etiologically 
or mechanistically privileged place in HD pathophysiology. Certainly, some of 
our gene expression results show moderate association with atrophy, but their 
striatal dominance is less a proof of striatal involvement than a tautology. The 
question remains: why is the striatum such a strong location for HD atrophy, 
even though HTT is not expressed especially strongly there, nor is there 
evidence of its network transmission to the striatum?  
 185 
 To address this, we sought to understand whether focal seeding was a 
necessary condition for anterograde transmission in HD, or whether diffuse or 
random seeding would perform just as well. We hypothesized the existence of 
intrinsic structural network epicenters or attractors, into which propagating HD 
pathology might accumulate. An indication that this might be so was already 
observed in the above directional NDM results (Figure 4.4A), where almost all 
seed locations produced R-t curves that eventually settled into a steady state 
with a high R value. As mentioned, this is indicative of a potential network 
attractor.  
 Using graph theory, previous work demonstrates that any (non-
directional) network diffusion process will eventually be dominated by the most 
persistent eigenmodes of the network, specifically the smallest eigenmodes of 
the graph Laplacian (Raj et al. 2012). Furthermore, eigenmodes were shown 
to form an effective basis on which baseline neurodegenerative atrophy data 
can be projected for prediction of a subject’s future atrophy. 
 Therefore, we hypothesized that the anterograde network Laplacian’s 
primary eigenmode (whose eigenvalue is zero) would resemble the 
topography of regional HD atrophy. This eigenmode hypothesis is independent 
of any specific starting or seed site. Intriguingly, the eigenmode’s spatial 
pattern was found to be strikingly similar to HD topography, with high values in 
the striatum and cuneus (Figure 4.8A). There was a significant relationship 
that appears to be related to disease severity. In pre-HD-A, this relationship is 
significant (r=0.53 p=1.96e-07) and the relationship strengthens as the highest 
disease severity group, HD-2 (r=0.64 p=1.98e-11) (Figure 4.8A1-2). This 
pattern is echoed, but to a much weaker extent in functional networks (Figure 
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4.8B1-3). To our knowledge, this is the first report of a directional human 
network eigenmode, and its link to anterograde pathology transmission. 
 As previously mentioned, the first anterograde eigenmode is a 
mathematically linear network attractor, a state into which any anterogradely 
diffusing pathology will increasingly accumulate, even if pathology seeding 
was random, diffuse or uniform. The above result therefore supports the idea 
that the prominent sites of HD atrophy may not be initiating sites, but rather 
the sites at which early pathology first accumulates beyond some threshold.  
 Subsequent network transmission will continue to exhibit similar 
topography, as shown earlier in Figure 4.4A on anterograde NDM from striatal 
seeding. Thus, network eigenmode presents a simple explanation of 
vulnerable “epicenters” whose healthy connectivity serve as a template for 
template-directed misfolding (Zhou et al., 2012). Eigenmodes anchor distinct 
networks and are hypothesized to give rise to different clinicoanatomical 
presentations in neurodegeneration (Seeley, 2017).  
 If this is so, then stereotyped progression in HD must imply stable 
primary eigenmode across individuals. Indeed, it was recently reported that 
the first few structural brain eigenmodes are stable across healthy subjects, 
and are relatively preserved even in diseases of extreme brain malformation 
such as agenesis of the corpus callosum (Wang et al., 2017).  
 Previous proposals involving network epicenters used resting state 
functional networks, which suggest that intrinsic topology of the functional 
network mediates template directed misfolding (Zhou et al., 2012). Our data 
somewhat replicate this in HD, as our functional eigenmodes also show a 
significant correlation with local degeneration in HD, which increases with 
disease progression (Figure 4.8B). However, this correlation is only about half 
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as strong as that of the structural eigenmode, which confirms our earlier 
conclusion that HD transmission is underpinned by structural rather than 
functional connectivity.  
 
Network-based anterograde accumulation of pathology from diffuse 
seeding 
 In order to confirm that accumulation of anterogradely diffusing 
pathology from non-focal seeding does indeed predict HD regional atrophy, we 
performed simulations of anterograde NDM from three diffuse seeding 
processes: a) seeding in proportion to HTT regional expression; b) uniform 
seeding in every location; c) random seeding. The results, contained in Figure 
4.9, show that although there are subtle differences in the intermediate time 
behavior of each seeding strategy, the eventual, steady state R value of 
around 0.59, as well as the spatial pattern, was very similar. The best result 
was obtained for seeding by PCA of all 12 HD-implicated genes, giving r=0.62, 
p < 1e-10. This result supports the notion that a focal or specific regional seed 
is not required for HD pathology, and that most kinds of diffuse seeding 
patterns will eventually result in observed HD atrophy pattern, purely as a 
result of anterograde network diffusion. In particular, HTT or gene PCA 
seeding of the anterograde NDM yields very strong correlations with atrophy, 
representing the closest match with empirical data contained in this paper. 
Concluding remarks 
 Collectively, these data show that the intrinsic architecture of the 
structural network mediates disease spread in HD, most likely via a process of 
trans-synaptic transmission. The success of the anterograde network model 
suggests a simple process whereby local production of HTT starts off a 
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process of pathology accumulation, followed by anterograde network 
transmission, which due to the nature of the network eigenmode, increasingly 
accumulates in striatal and occipital areas. The apparent selective vulnerability 
and early seeding of HD pathology in these areas might be explained purely in 
these terms, without requiring a privileged status for any brain region.  
Limitations 
Several methodological considerations should be taken into account when 
interpreting the current study. The first are limitations of the NDM. The NDM is 
a first-order, linear, parsimonious model of diffusive spread that assumes that 
the structural connectivity network remains unchanged over the duration of the 
longitudinal analysis. Though this assumption DTI data for individual subjects 
was not available in the current study, previous cross-sectional analysis in a 
subset of the current cohort shows rich club organizational changes in 
comparison to controls (McColgan et al., 2015). However, connectivity 
between HD stages and longitudinal connectivity remains unassessed. 
Similarly, the NDM model may not be the best fit for a resting state functional 
connectivity network, as neuroimaging work suggests the functional network is 
impeded by the presence of pathogenic proteins (Filippini et al., 2009). 
Moreover, individual subject genetic repeat length, medication history and age 
of symptom onset was not available. These variables could have implications 
in the individual group wise analysis, when identifying each subject’s seed 
region or determining individual rate of disease diffusion. Because this is the 
first study to empirically test multiple network models of pathology spread in 
HD, it will benefit from independent replication. Future work elucidating striatal 
vulnerability as well as the effect of repeat length on disease spread is 
necessary. 
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Chapter 5: 
Age-Related Changes in Topological Degradation of White 
Matter Networks and Gene Expression in Chronic 
Schizophrenia 
Introduction 
 Current models stipulate schizophrenia (SZ), a psychiatric disease 
characterized by hallucinations, flattened affect and cognitive disturbances, is 
a disorder of dysconnectivity arising not from focal pathophysiology, but rather 
from impaired neuroanatomical integration across the brain (O’Donoghue et 
al., 2017). Converging neuroimaging, physiological and molecular evidence 
suggest core symptoms of the disease are related to altered connectivity 
between distinct brain regions, causing inefficient information integration in the 
network (Pettersson-Yeo et al., 2011; van den Heuvel et al., 2010). 
Importantly, longitudinal evidence suggests SZ is not a static 
neurodevelopmental disorder, but rather an alteration in cortical plasticity that 
occurs over the lifetime of an individual (DeLisi et al., 1997). 
 A large number of diffusion MRI studies examining tract-level changes 
report findings reflective of altered white matter (WM) integrity in SZ (Kubicki 
et al., 2011, 2002; Luck et al., 2011; Price et al., 2008; Szeszko et al., 2008). 
Prior studies applying graph theory analysis to diffusion MRI data show 
abnormal pathlength, centrality and efficiency in frontal and temporal network 
structure as well as impaired efficiency and clustering coefficient in medial 
frontal, parietal/occipital and left temporal lobes (van den Heuvel et al., 2010; 
Wang et al., 2012; Zalesky et al., 2011).  While such studies elucidate 
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macrostructural changes in disease pathophysiology, age-related changes 
within and between WM networks with SZ progression remain incompletely 
understood (Gogtay, 2008). Furthermore, though WM abnormalities in SZ are 
shown to be highly heritable, the relationship between changes in network 
topology with age and its relationship to gene expression is largely 
uninvestigated (Ripke et al., 2014; Skudlarski et al., 2013). 
 The current study uses a cross-sectional design to test network models 
based on DTI and genetic expression data. We hypothesize network topology 
will degrade faster in SZ compared to controls, with a significant association 
between gene expression and topological abnormalities. To test this 
hypothesis, graph theory analysis is utilized to examine age-related patterns of 
global and local topological degradation. Additionally, we model the 
topological relationship to gene expression as measured by microarray data 
from healthy human brains from the Allen Brain Institute. The combination of 
multiple graph metrics in conjunction with gene expression data to examine 
questions of age-related organizational disturbances in SZ is unprecedented.   
 
Methods 
Subjects 
 DTI data were acquired from 24 individuals with chronic, treatment-
resistant SZ and 51 healthy controls. Patients were recruited from inpatient 
and outpatient units at the University College Hospital Galway (UCHG) and in 
the catchment area of HSE West of Ireland. All patients were diagnosed by 
experienced psychiatrists, using the Structured Clinical Interview for DSM 
disorders (SCID) (First and Pincus, 2002), as meeting the criteria for SZ per 
 197 
the DSM-IV-TR [Diagnostic and Statistical Manual of Mental Disorders, Fourth 
Edition].  
 Patients and control subjects were age and gender-matched (Table 
4.1). All patients with chronic SZ were treatment resistant at the time of 
scanning and being considered for treatment with clozapine, an atypical 
antipsychotic medication for treatment resistance. Treatment resistance was 
defined as failure to respond to at least 2 antipsychotic medications, one of 
which an atypical, with a prolonged period of moderate to severe positive 
and/or negative symptoms. At time of scanning, all patients were medicated 
with atypical antipsychotics, with some on 2 or more medications (Table 4.1). 
Mean Chlorpromazine equivalent dose was 247 mg. The control group 
consisted of 51 participants with no current or past axis I or II disorders (DSM-
IV-TR) and was screened using the SCID-Non-Patient Version (First and 
Pincus, 2002). Both the University College Hospital Galway and the National 
University of Ireland Galway Ethics committees granted ethical approval and 
written informed consent was obtained from each participant. 
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Table 5.1. Study participants. Demographic information of study participants. 
Characteristic Patients 
n=24 
Mean ± SD, range 
Controls  
n=31 
Mean ± SD, range 
t-test /x2 
vs. CON 
 
Age (years) 36.2 ± 10.02 
20-59 
34.4 ± 11.31 
19-57 
p=0.48 
Male/female (% male) 35/16 (46%) 17/7 (41%) p=0.41 
Duration of illness 
(years) 
14.42 ± 8.16 
4-39 
  
# psychotic episodes 4.8 ± 3.38 
2-20 
  
Medications    
Typical antipsychotics 12   
Atypical antipsychotics 24   
Clozapine 0   
Clinical scales    
Total PANSS  53.9(17.2)   
SAPS 27.9 (16.3)   
SANS 42.5(20.6)   
GAF 46.8(10.8)   
Abbreviations: PANSS, Positive and Negative Syndrome Scale (Scored on the 0-6 
scale); SANS, Scale for the Assessment of Negative Symptoms, SAPS, Scales for 
the Assessment of Positive; GAF, Global Assessment of Functioning.  
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Younger vs. Older 
 For reasons detailed in the results section, subjects were split into a 
“younger adult” or “older adult” group. For the younger adult group, there was 
no significant difference in gender composition between patients (n=14) and 
controls (n=30) (p=0.79). Furthermore, there was no significant difference in 
age between patients and controls in the younger adult group (p=0.11). The 
average age of a control subject in the younger adult group was 26.3 
(standard deviation: 5.45) and the average age of a patient in the same group 
was 29.1 (standard deviation: 5.18). For older adult subjects, there was no 
significant difference in gender composition between patients (n=10) and 
controls (n=21) (p=0.92). Similarly, there was no significant difference in age 
between patients and controls in the older adult group (p=0.90). The average 
age of a control subject in the older adult group was 45.9 (standard deviation: 
5.4) and the average age of a patient in the same group was 46.2 (standard 
deviation: 6.3).   
Image acquisition 
 Structural MR images were acquired on a 1.5T Siemens Magnetom 
Symphony MRI scanner, as detailed in (Holleran et al., 2014). For each 
individual, a two-dimensional midsagittal scan was used to position the subject 
so that the floor of the fourth ventricle was parallel to the y axis of the scanner 
coordinates system. The anterior–posterior (AP) axis was determined on the 
midsagittal slice using the anterior commisure–posterior commisure (AC-PC) 
line. Detailed high-resolution, wholehead contiguous axial slices (thickness 0.9 
mm, field of view 230x 230 mm) parallel to this axis were acquired using a set 
of three-dimensional (3D) T1-weighted magnetization prepared rapid gradient-
echo (MPRAGE) sequences (relaxation time (TR): 1140 ms; echo time (TE): 
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4.38 ms; inversion time (TI): 600 ms; flip angle 15°; acquisition matrix 256 x 
256, interpolated to 512 Å~ 512, pixel resolution of 0.45mm x 0.45 mm). 
 The diffusion sequence utilized Echo Planar Imaging (EPI)-based 
diffusion, 64 independent diffusion gradient directions at a b-value of 1300 
s/mm2 and 7 undirected images, TR=8100 ms, TE=95 ms, in-plane voxel 
resolution of 2.5 x 2.5 mm, slice thickness of 2.5 mm and SNR of b=1000 
s/mm2 images >20. After scout images, the total imaging time was 10.24 min 
for the diffusion MRI sequence. Diffusion parameters are further described in 
Holleran et al. 2014 utilizing methodologies recommended by (Jones et al., 
1999).  
Image preprocessing: Structural and diffusion MRI 
 Whole brain networks were constructed from 51 control and 24 
schizophrenic subjects, using previously described methodology (Iturria-
Medina et al., 2008; Raj and Chen, 2011). Briefly: T1-weighted MR images 
were processed using the FreeSurfer automatic volumetric pipeline to map 
and construct cortical volumes (Dale et al., 1999; Fischl et al., 2004a, 2004b, 
2002, 2001, 1999; Ségonne et al., 2004), (http://surfer.nmr.mgh.harvard.edu). 
Inspection of T1 data revealed 7 subjects (5 patients and 2 controls) had 
motion artifacts. These were excluded from analysis and not included in 
subject demographics. 
 Primary visual inspection did not indicate presence of major artifacts in 
any of the diffusion MRI data.  Slice-by-slice inspection showed motion was 
most evident in the frontal pole, but no major artifacts were detected that 
would result in additional exclusion from the study. Any potential confounding 
motion artifact was successfully addressed by eddy current and motion 
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distortion correction using methodology detailed in (Leemans and Jones, 
2009). 
 Cortical and subcortical volume mappings from the FreeSurfer 
aparc+aseg parcellation atlas were used to establish 86 region-of-interest 
nodes for tractography. The processed tissue segmentation defined the white-
gray matter interface, which was used to seed points for probabilistic 
tractography with 1000 streamlines drawn per seed voxel (Behrens et al., 
2007). Each streamline is assigned a probability score according to 
established criteria (Iturria-Medina et al., 2008). WM tracts are estimated by 
the connection strength of each ROI, which is obtained by summing the 
probabilities of the streamlines terminating between 2 regions.  
Graph theory analysis 
 Characteristic graph metrics to examine differences in network topology 
were calculated from undirected, weighted, non-thresholded structural 
connectivity matrices. Figure 5.1 depicts network construction. Network 
metrics including density, global efficiency, clustering coefficient, 
smallworldness, local connection strength, local efficiency and local modularity 
were computed in MATLAB using the Brain Connectivity Toolbox (BCT) as 
described in (Rubinov and Sporns, 2010). Additional metrics including power 
law alpha and largest eigenvalue of adjacency matrix were not available in the 
BCT and calculated using the igraph tool (Csardi et al., 2006). See below for 
definitions of additional network properties: 
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 Consider a network/graph 𝒢 = (𝒱, ℰ), with a set of 𝒩𝒱 nodes 𝒱 =
{ (𝓋𝑖)|𝑖 𝜖 1, … . , 𝒩𝒱} and the set of 𝒩ℰ edges where ℰ = {(ℯ𝑖,𝑗)| 𝑖𝜖𝒱, 𝑗𝜖𝒱}. 𝒩𝒱 
and 𝒩ℰ are notations for total number of nodes and edges in 𝒢 respectively.  
ei,j is the edge connecting the nodes iϵ𝒱 and  jϵ𝒱.  wij ϵ [0, ∞) is the weight 
associated with the edge ei,j, computed through fiber pathways measured 
through tractography. 
 Weight of the path P = < 𝓋1, 𝓋2, … … … , 𝓋k > is w(P)  =  ∑ w𝓋i,𝓋i+1
k
i=1 . 
Shortest path δ𝓋a,𝓋b between the nodes 𝓋a to 𝓋b has the weight:  
δ𝓋a,𝓋b =  {
min{w(P)|  P is the path from 𝓋a to 𝓋b} , If path exists
∞, otherwise
 
Adjacency matrix 𝒜𝒢 is defined as the 𝒩𝒱 × 𝒩𝒱  matrix where the non-diagonal 
entry is equal to wij, where iϵ𝒱 and jϵ𝒱. In the current study we work with 
undirected simple graphs, therefore diagonal elements of 𝒜𝒢 is equal to 0 and 
wij =  wji.  
 Power Law Alpha is the slope of the straight line that fits the log 
frequency distribution of node degree in the network. It is calculated by fitting 
the line to the equation:  
𝒴 =  βχ−α 
Here, 𝒴 is the degree distribution, β is the fitting constant and α is the value of 
power law alpha. 
 Largest Eigenvalue of Adjacency Matrix 𝒜𝒢 can be calculated with 𝓋 as 
a nonzero 𝒩𝒱 × 1 column vector, 𝐼𝒩𝒱  as the 𝒩𝒱 × 𝒩𝒱 identity matrix. Given 
𝒜𝒢, an eigenvalue λ and its associated eigenvector 𝓋 are a pair obeying the 
relationship: 
(𝒜𝒢 − λ 𝐼𝒩𝒱)𝓋 = 0 
From the spectra of all the obtained values of λ, largest computed value in 
magnitude is called as largest eigenvalue. 
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Figure 5.1. Brain network construction. A) T1 images were used to partition 
the brain into 86 cortical and subcortical areas with FreeSurfer B) WM fibers 
were arranged as determined by probabilistic tractography. Colors indicate 
directionality. Green is dorsal to ventral, red is left to right and blue is anterior 
to posterior. C) Individual structural connectivity matrices were created from 
probabilistic tractography D) Graph network analysis performed with nodes 
representing brain regions and edges representing the strength of WM tract 
connections 
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Genetic data 
 Microarray gene expression data from post-mortem healthy human 
brains were downloaded from the Allen Brain Atlas Institute and obtained as 
described in (Hawrylycz et al., 2012). The microarray data is composed of 926 
regions of the brain, each one belonging to a set of 58,692 probes that 
correspond to 29,181 distinct genes. Unique probe ID’s often represented the 
same gene and the average as used for analysis of the gene, as done by 
(Freer et al., 2016). For analysis, the 926 regions in the microarray data were 
mapped to 86 regions of the Desikan Atlas. Genes of interest implicated in SZ 
were selected from a DisGeNET database, which generates human gene-
disease associations from curated databases and text mining (Piñero et al., 
2015).  
Statistical analysis 
 Independent, two-sided t-tests were used to test for differences in 
characteristic graph metrics. All reported significant global p-values survived 
FDR correction for multiple comparisons and are FDR adjusted (Benjamini 
and Hochberg, 1995). When noted, permutation testing, randomly mixing 
group assignment, was performed to obtain a null-distribution of component 
size, independent of group status (5,000 permutations). Permutation tests for 
group differences in global network metrics were FDR corrected for multiple 
comparisons. Local metrics did not survive FDR corrections and local reported 
p-values are uncorrected. Using global metrics as dependent variables and 
age as independent variables, network degradation was modeled using 
regression analysis. The significance of regression model fits was evaluated 
using the F-statistic.  
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 Correlation analyses were carried out to determine whether identified 
brain topological changes were associated with gene expression. Correlations 
between a specific gene’s expression and a local graph metric were 
Bonferroni corrected across all three tested age ranges (p < 0.05/3). This 
Bonferonni correction method was applied in a manner suggested by (Mayo 
and Cox, 2006), which urges each experiment’s goals be considered when 
applying Bonferroni correction.  Specifically, the current study considers each 
gene and its relationship to age to represent its own experiment. Within each 
experiment exist 3 hypotheses (1 hypothesis for younger subjects, 1 
hypothesis for older subjects and 1 hypothesis for all subjects).  
 
Results 
White matter network topology in all subjects 
 First, we confirm results from our imaging pipeline reproduces 
numerous previously published data on altered global WM topology in SZ. We 
observe patients show significantly decreased density (p=0.02), global 
efficiency (p=0.01), clustering coefficient (p=0.01), largest eigenvalue of the 
adjacency matrix (p=0.02) and power law alpha (p=0.02) compared to 
controls. No significant difference in smallworldness is observed between 
patients and controls (p=0.38) (Figure 5.2). All reported global p-values 
survived FDR correction for multiple comparisons. To mitigate concerns of 
small sample, p-values were replicated with permutation testing (5,000 
permutations - FDR corrected, in Table 4.2).  
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Figure 5.2. Global metrics across all subjects. Boxplots of A) density, 
significant, p=0.018 B) global efficiency, significant, p=0.012 C) clustering 
coefficient, significant, p=0.012 D) largest eigenvalue of the adjacency matrix, 
p=0.016 E) power law alpha, p=.016 and F) smallworldness, not significant. 
Errors bars express standard deviation. 
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Table 5.2 Permutation testing of global metrics. Permutation tests of group 
differences in summary metrics (5,000 permutations). 
 
   All Subjects 
Metric FDR Corrected  
Raw P Value 
Raw P value  Permutation  
P Value 
Density p=0.018 p=0.0077 p=0.0078 
Global Efficiency p=0.012 p=0.0039 p=0.0044 
Clustering 
Coefficient 
p=0.012 p=0.0032 p=0.0044 
Largest Eigen 
Adj 
p=0.016 p=0.0029 p=0.0038 
Power Law 
Alpha 
p=0.016 p=0.0016 p=0.0016 
Small Worldness  p=NS p=0.3861 p=0.3934 
 
   Younger Subjects Under 37  
Metric FDR Corrected  
Raw P Value 
Raw P value Permutation  
 P value 
Density NS p=0.045 p=0.0474 
Global Efficiency p=0.0018 p=0.002 p=0.0022 
Clustering 
Coefficient 
p=0.0018 p=0.0009 p=0.0014 
Small Worldness  NS p=0.53 p=0.54 
 
   Older Subjects Over 37 
Metric FDR Corrected  
Raw P Value  
Raw P value Permutation  
P Value 
Density NS p=0.07 p=0.0678 
Global Efficiency NS p=0.33 p=0.3368 
Clustering 
Coefficient 
NS p=0.62 p=0.6098 
Small Worldness  NS p=0.08 P=0.0842 
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Age-dependent network degradation 
 To quantify changes in network topology with age, regression models 
were fit to each global metric over the age range of all subjects. Graphs fitting 
global network metric as a function age are hereby referred to as “age-
resolved” graphs and are depicted in Figure 5.3. Linear models were tested 
because prior work shows WM microstructure changes linearly with age in 
healthy control subjects (Hagmann et al., 2010). In addition, we hypothesized 
quadratic models may also capture network degradation as the current study 
encompasses a later, wider age range than prior work. To test these 
hypotheses, models fits were evaluated using significance of the F-statistic. 
We observe that in control subjects, all metrics degraded in a stereotyped 
manner. Density (p=0.02), efficiency (p=0.002), clustering coefficient 
(p=0.005) and power law alpha (p=0.05) degrade linearly with age (Figure 5.3) 
(Table 5.3). Interestingly, largest eigenvalue of the adjacency matrix degrades 
quadratically with age in controls (p=0.007).  
 In contrast, age-related network degradation patterns in patients do not 
follow similar, stereotyped trends trends. Density (p=0.076) and global 
efficiency (p=0.075) degrade in a moderate quadratic trend toward 
significance with age in patients (Figure 5.3A-B). However, neither linear nor 
quadratic fits accurately model age degradation patterns in clustering 
coefficient, power law alpha and largest eigenvalue of the adjacency matrix. 
The best regression equations for these age-resolved graphs are over-fitted, 
fifth degree polynomials, which are likely not generalizable (Table 5.3) (Figure 
5.3C). (Power law alpha and largest eigenvalue of the adjacency matrix not 
shown). Taken together, these data show that while controls show 
stereotyped, linear degradation of network organization with age, a 
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stereotyped network model for SZ is overall poor, as the best result shows 
merely a moderate trend toward significance (Figure 5.3A-B). Subsequent 
analysis splits patients into 2 separate age groups with the goal of elucidating 
the abnormal degradation trajectory observed in SZ. 
 
 
 
 
Figure 5.3. Age-resolved graphs. Best regression fits for age-resolved 
graphs of network metrics in all controls and patients. Global metrics in control 
subjects degrade in a significant linear, stereotyped manner. Patient networks 
do not exhibit the same trends.   
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Table 5.3. Model fits. p-values of F-statistics evaluating linear and quadratic 
regression model fit of global graph metrics vs. age.  
 
 
* indicates significant and moderate trends toward significance. 
 
 To further investigate age-related network degradation within SZ, 
regression was performed with patients split into a “younger adult” or “older 
adult” group. Age 37 was selected as the cut-off between “older” and 
“younger” subjects because visual inspection of SZ age-resolved graphs  
shows age 37 represents the peak of the parabolic age effect. Specifically, it is 
evident in Figure 5.3A-B that density and global efficiency continue to grow in 
the younger age range, before reaching a peak at age 37 then declining. This 
finding suggests a possible age-related topological change that warranted 
further analysis. Hence, to test this hypothesis, regression analysis was 
carried out separately in each age group. These individual regression fits are 
depicted in Figure 5.4. Due to the small sample size in each age group, 
permutation testing consisting of 5,000 iterations was carried out after the 
initial regression. In the younger adult group, degradation slopes of density, 
global efficiency, power law and largest eigenvalue of the adjacency matrix 
slopes do not significantly differ from 0. This result survived permutation 
testing (Table 4.4). In contrast, preliminary regression analysis shows all 4 of 
Metric Age (CON) Age2 (CON) Age (SZ) Age2 ( SZ) 
Density  p=0.024 *  p=0.03 p=0.12 p=0.076 *  
Global Efficiency p=0.002 * p=0.01 p=0.18 p=0.075 *  
Clustering 
Coefficient 
p=0.005 * p=0.02 p=0.91 p=0.47 
Power Law Alpha p=0.05 * p=0.06 p=0.32 p=0.28 
Largest 
Eigenvalue of 
Adjacency Matrix  
p=0.018 p=0.007 * p=0.11 p=0.13 
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those metrics degrade in a significant, linear manner in older adults (Figure 
5.4). However, only between the age effect of global efficiency and largest 
eigenvalue of the adjacency matrix survived permutation testing (Table 4.4). 
Clustering Coefficient did not follow this trend and does not degrade at a slope 
significantly different in either age group, suggesting a more sophisticated 
model may be necessary (data not shown).  
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Figure 5.4. Young vs. old age regression. p-values of linear regression fits 
for age-resolved graphs of global metrics for patients, divided into young 
(under age 37) and old (over age 37). A non-significant linear fit indicates the 
slope is not significantly different from 0.  
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Table 5.4. Regression permutations. Permutation analysis of age-resolved 
models. 
 
Metric Regression 
Young  
Regression 
Young 
 5000 
Permutations 
Regression 
Old 
Regression  
Old 
5000 
Permutations 
 
Density F = 0.898 
p=0.362 
 
p=0.300 F = 9.97 
p=0.013 * 
p=1 
Global 
Efficiency 
F = 0.24 
p=0.88 
p=0.745 F = 5.45 
p=0.048 * 
p=0.002 * 
Power Law 
Alpha 
F = 0.744 
p=0.405 
p=0.423 F = 6.53 
p=0.034 * 
p=1 
Largest 
Eigen Adj 
p=0.507 p=0.396 F = 7.40 
p=0.026 * 
p=0.010 * 
+ F represents F-statistic and p represents p-value.  
 
Note: Permutation tests do not calculate F-statistics, instead, calculates p-
value based on unique sums of squares (Type III SS) 
 
 
 
Younger adult vs. older adult global network analysis 
 Next, we examine network organization between patients and controls 
within the two age groups. Younger adult patients show significantly 
decreased global efficiency (p=0.002) and clustering coefficient (p=0.002) 
compared to age-matched controls (Figure 5.5B-C). Density (p=0.11) shows 
significant before multiple corrections, but does not survive FDR correction 
(Figure 5.5A). Similarly, power law alpha (p=0.11), largest eigenvalue of the 
adjacency matrix (p=0.11) also show significance before multiple corrections, 
but do not survive FDR correction (Data not shown). Smallworldness (p=0.55) 
is preserved between younger patients and controls (Figure 5.5D). No global 
graphic metrics are significantly different between older adult patients and 
age-matched controls (Figure 5.5E-H).  
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Figure 5.5. Young vs. old global metrics. Boxplots under age 37 of A) 
density, not-significant (NS) B) global efficiency, significant, p=.0018 C) 
clustering coefficient, significant, p=.0018 D) smallworldness, NS. Over age 37 
boxplots of E) density, NS F) global efficiency, NS G) clustering coefficient, NS 
F) Smallworldness, NS. Errors bars express standard deviation. 
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Relationship between gene expression & local network analysis 
 Due to the highly heritable nature of WM abnormalities in SZ, we 
investigated the relationship between changes in topological degradation and 
gene expression in both younger adult and older adult subjects. The current 
study’s 6 genes of interest include DISC1, DRD2, DTNB1, GRM3, COMT and 
BDNF. These genes were identified as the top genes reported to be 
associated with SZ from a GWAS database. Glass brains of healthy gene 
expression of DISC1 from post mortem brains are illustrated, as DISC1 the 
literature reports it as most associated with SZ (Figure 5.6). Figure 5.7 depicts 
glass brains of the additional regions of interest.  
 
 
 
 
Figure 5.6. DISC1 expression. Sagittal and axial glass brains of gene 
expression of DISC1 from post-mortem brains of healthy subjects. Gene 
expression data is logistic rescaled on a scale from 0 – 1 and nodal sizes are 
depicted to the same scale. 
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Figure 5.7. Expression of additional genes. Sagittal and axial glass brains 
of gene expression from healthy brains of additional genes of interest. All gene 
expression data is logistic rescaled on a scale from 0 – 1 and nodal sizes are 
depicted to the same scale. 
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 To pinpoint regional abnormalities, local network analysis of connection 
strength, efficiency and modularity was performed. Reported local effects did 
not survive FDR correction. Group analyses reveal reduced local connection 
strength between younger adult patients and age-matched controls in frontal, 
temporal and cingulate regions (Figure 5.8A). Specifically, the most drastic 
reductions in local connection strength of these regions are observed in the 
left caudal anterior cingulate cortex (p=0.00005), bilaterally in the superior 
temporal gyrus (p=0.0008, p=0.04), left pars triangularis (p=0.005), left 
transverse temporal gyrus (p=0.01) and right precentral gyrus (p=0.01) (Table 
4.5).  
 Older adult patients show only 3 nodes with altered local connection 
strength compared to age-matched controls, which include the right middle 
temporal gyrus (p=0.004), right hippocampus (p=0.009) and left nucleus 
accumbens (p=0.02) (Figure 5.8B) (Table 4.5). Interestingly, DISC1, DRD2, 
DTNBP1 and GRM3 show an age-related change in association between local 
connection strength and gene expression (Table 4.6). Age-related differences 
in the relationship between DISC1 and local connection strength disturbances 
appear to be driven by a significant correlation in younger subjects, an effect 
absent in older subjects (Figure 5.8C). Conversely, age-related differences in 
the relationship between DRD2 and DTNBP1 are driven by a significant 
correlation in older subjects and absent in younger subjects. We observe no 
age-related effect of connection strength disturbances and BDNF nor COMT 
expression.    
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Figure 5.8. Local connection strength. Coronal, sagittal and axial glass 
brains with decreased local connection strength in patients (blue nodes) and 
increased connection strength in patients (gold nodes) vs. controls. A) 
Younger subjects under age 37 and B) Older subjects over age 37. Node size 
represents t-statistic. Effects did not survive FDR correction. C) Correlation 
between differences in local connection strength (t-statistic) vs. healthy DISC1 
expression. Colors correspond to lobe.   
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Table 5.5. Local strength statistics. Nodes with significant (uncorrected) 
group effects in local connection strength. + denotes nodal metric is increased 
in SZ, lack of symbol denotes metric is decreased in SZ vs. CON.  
 
  
Region Lobe p value 
(uncorrected) 
Under Age 37   
Caudal Anterior Cingulate (L)  Cingulate F=.00005 
Superior Temporal Gyrus (L), (R)  Temporal p=0.0008, 
p=0.04 
Lateral Occipital Cortex (L)  Occipital  p=0.003 
Pars Triangularis (L)  Frontal  p=0.005 
Postcentral Gyrus (R), (L) Parietal p=0.007, p=0.02 
Thalamus (L)  Subcortical p=0.01 
Transverse Temporal Gyrus (L)  Temporal p=0.01 
Precentral Gyrus (R)   Frontal p=0.01 
Rostral Middle Frontal Gyrus (L)  Frontal p=0.02 
Medial Orbitofrontal Cortex (L) Frontal p=0.02 
Rostral Anterior Cingulate (L) Frontal  p=0.02 
Lateral Orbitofrontal Cortex (L), (R)  Frontal p=0.02, p=0.03 
Middle Temporal Gyrus (L)  Temporal p=0.02 
Paracentral Lobule (L), (R)  Frontal p=0.02, p=0.05 
Inferior Temporal Gyrus (L)  Temporal p=0.03 
Caudal Middle Frontal Gyrus (L)   Frontal  p=0.04 
Over Age 37   
Middle Temporal Gyrus (R) Temporal p=0.004 + 
Hippocampus (R) MTL  p=0.009 + 
Nucleus Accumbens (L) Medial Temporal  p=0.02 
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Table 5.6. Gene expression and connection strength. Age-related 
differences in the relationship between gene expression & local connection 
strength.  
 
Gene  
All 
Subjects 
Younger 
Subjects 
Older 
 Subjects 
Age 
Effect 
BDNF 
R = 0.05 
p=0.61 
R = 0.04 
p=0.71 
R = 0.19 
p=0.08 
-- 
DISC1 
R = -0.30 
p=0.005 * 
R = -0.32 
p=0.003 * 
R = -0.14 
p=0.21 
Driven by 
younger subjects 
COMT 
R = 0.07 
p=0.50 
R = 0.08 
p=0.47 
R = 0.03 
p=0.79 
-- 
DRD2 
R = -0.33 
p=0.002 * 
R = -0.26 
p=0.02 
R = -0.31 
p=0.004 * 
Driven by older 
subjects  
DTNBP1 
R = -0.26 
p=0.02 
R = 0.16 
p=0.15 
R = -0.30 
p=0.005 * 
Driven by older 
subjects 
GRM3 
R = -0.22 
p=0.04 
R = -0.09 
p=0.39 
R = -.30 
p=0.006 * 
Driven by older 
subjects 
* Survived Bonferroni correction significance threshold of p=0.05/3  
+ Blue highlight indicates age-related changes in the relationship between gene 
expression and WM fiber connection strength   
 
 
 Next, we examine local efficiency. We observe local efficiency is also 
reduced in younger adult patients compared to age-matched controls in 
frontal, temporal and cingulate regions (Figure 5.9A). The most significant 
reductions in local efficiency is observed bilaterally in the superior frontal gyrus 
(p=0.0005, p=0.003), bilateral caudal anterior cingulate (p=0.003, p=0.02), 
bilateral rostral middle frontal gyrus (p=0.004, p=0.02), left pars triangularis 
(p=0.01) and bilateral precentral gyrus (p=0.03, p=0.04) (Table 4.7). In 
contrast, older adult patients reveal only 2 nodes with abnormal local efficiency 
compared to age-matched controls, which include the right pars orbitalis 
(p=0.02) and left pericalcarine cortex (p=0.05) (Figure 5.9B) (Table 5.7). 
  Age-related differences in the relationship between DISC1 and local 
efficiency alterations appear to be driven by a significant correlation in younger 
subjects, an effect that is absent in older subjects (Figure 5.9C). There is no 
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relationship between DRD2, DTNBP1 and GRM3 (Table 4.8). BDNF and 
COMT were omitted from analysis due to lack of relationship to connection 
strength disturbance.  
 
 
 
 
 
Figure 5.9. Local efficiency. Coronal, sagittal and axial glass brains with 
decreased local efficiency in patients (blue nodes) and increased efficiency in 
patients (gold nodes) vs. controls. A) Younger subjects under age 37 and B) 
Older subjects over age 37. Node size represents t-statistic. Effects did not 
survive FDR correction. C) Correlation between differences in local efficiency 
(t-statistic) vs. healthy DISC1 expression. Colors correspond to lobe.   
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Table 5.7. Local efficiency statistics. Nodes with significant (uncorrected) 
group effects in local efficiency. + denotes nodal metric is increased in SZ, 
lack of symbol denotes metric is decreased in SZ vs. CON. 
 
Region Lobe p value 
(uncorrected) 
Under Age 37    
Superior Frontal Gyrus (R,L) Frontal p=0.0005, p=.003 
Caudal Anterior Cingulate (L), (R) Cingulate p=0.003, p=0.02 
Rostral Middle Frontal Gyrus (L), 
(R) 
Frontal p=0.004, p=0.02 
Lateral Occipital Cortex (L) Occipital p=0.005 
Postcentral Gyrus (L) Parietal p=0.005 
Pars Triangularis (L) Frontal p=0.01 
Supramarginal Gyrus (R) Parietal p=0.01 
Precentral Gyrus (L), (R) Frontal p=0.03, p=0.04 
Hippocampus (L) Subcortical p=0.03 
Caudal Middle Frontal Gyrus (L) Frontal p=0.03 
Superior Temporal Gyrus (L) Temporal p=0.03 
Over Age 37   
Pars Orbitalis (R) Frontal p=.02 + 
Pericalcarine cortex (L) Occipital p=.05 + 
 
 
 
 
 
Table 5.8. Gene expression and local efficiency. Age-related differences in 
the relationship between gene expression & local efficiency.  
 
Gene  All Subjects 
Younger 
Subjects 
Older 
Subjects 
Age 
Effect 
DISC1 
R = -0.23 
p=0.03 
R = -0.30 
p=0.005 * 
R = 0.02 
p=0.88 
Driven by 
younger 
subjects 
DRD2 
R = -0.20 
p=0.06 
NS  NS  --  
DTNBP1 
R = -0.21 
p=0.05 
NS  NS -- 
GRM3 
R = -0.08 
p=0.49 
NS NS -- 
* Survived Bonferroni correction significance threshold of p=.05/3  
+ Blue highlight indicates age-related changes in the relationship between gene 
expression and local efficiency   
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 Lastly, we investigate local modularity. Similarly, we observe decreased 
modularity in frontal, cingulate and temporal regions between younger adult 
patients and age-matched controls (Figure 5.10A). The most significant 
reductions in modularity occur bilaterally in the supramarginal gyrus (p=0.01, 
p=0.02), bilateral rostral middle frontal gyrus (p=0.01, p=0.03), bilateral frontal 
pole (p=0.01, p=0.03), bilateral caudal anterior cingulate (p=0.01, p=0.02) and 
bilateral transverse temporal gyrus (p=0.02, p=0.03) (Table 4.9). Older adult 
subjects display only 3 nodes with abnormal local modularity compared to 
age-matched controls, which include the right pars orbitalis (p=0.04) and 
bilateral nucleus accumbens (p=0.03) (Figure 5.10B) (Table 4.9). Older adult 
patients exhibit trends of increased modularity compared to controls.  Age-
related differences in the relationship between DISC1, DRD2, DTNBP1and 
local modularity appear to be driven by a significant correlation in older 
subjects, an effect that is absent in younger subjects (Figure 5.10C, Table 
4.10). BDNF and COMT were omitted from analysis due to lack of relationship 
to connection strength. Interestingly, there is an an age-related effect in the 
association between GRM3 expression and local modularity alterations. 
Specifically, younger subjects show a significant positive correlation between 
SZ disturbances in modularity and GRM3 expression, while older subjects 
show a significant negative relationship (Table 4.10).  
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Figure 5.10. Local modularity. Coronal, sagittal and axial glass brains with 
decreased local modularity in patients (blue nodes) and increased modularity 
in patients (gold nodes) vs. controls. A) Younger subjects under age 37 and B) 
Older subjects over age 37. Node size represents t-statistic. Effects did not 
survive FDR correction. C) Correlation between differences in local efficiency 
(t-statistic) vs. healthy DISC1 expression. Colors correspond to lobe.   
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Table 5.9. Local modularity statistics. Nodes with significant (uncorrected) 
group effects in local modularity. + denotes nodal metric is increased in SZ, 
lack of symbol denotes metric is decreased in SZ vs. CON. 
 
Region Lobe p value 
(uncorrected) 
Under Age 37   
Supramarginal Gyrus (R), (L) Parietal p=0.01, p=0.02 
Rostral Middle Frontal Gyrus (L), (R) Frontal p=0.01, p=0.03 
Frontal Pole (R), (L) Frontal p=0.01, p=0.03 
Caudal Anterior Cingulate (L), (R) Cingulate p=0.01, p=0.02 
Transverse Temporal Gyrus (R), (L) Temporal p=0.02, p=0.03 
Caudate Nucleus (R) Subcortical p=0.03 
Superior Parietal Lobule (R) Parietal p=0.03 
Caudal Middle Frontal Gyrus (L) Frontal p=0.03 
Superior Frontal Gyrus (L) Frontal p=0.03 
Paracentral Lobule (L) Frontal p=0.04 
Superior Temporal Gyrus (R) Temporal p=0.045 
Pars Opercularis (R) Frontal p=0.046 
Over Age 37   
Pars opercularis (R) Frontal  p=.04 +  
Nucleus Accumbens (R), (L) Medial 
Temporal 
p=.03 +, p=.03 +   
 
 
Table 5.10. Gene expression and local modularity. Age-related differences 
in the relationship between gene expression & local modularity.  
 
Gene  
All 
Subjects 
Younger 
Subjects 
Older 
Subjects 
Age 
Effect 
DISC1 
R = -0.25 
p=0.02 
R = -0.02 
p=0.87  
R = -0.26 
p=0.01 *  
Driven by older 
subjects 
DRD2 
R = -0.06 
p=0.57 
R = 0.18 
p=0.10 
R = -0.27 
p=0.009 * 
Driven by older 
subjects 
DTNBP1 
R = -0.23 
p=0.03 
R = 0.02 
p=0.85  
R = -0.31 
p=0.004 * 
Driven by older 
subjects 
GRM3 
R = 0.11 
p=0.33 
R = 0.33 
p=0.002 * 
R = -0.26 
p=0.01 * 
Sign of 
relationship 
changes with 
age 
* Survived Bonferroni correction significance threshold of p=.05/3  
+ Blue highlight indicates age-related changes in the relationship between gene 
expression and local modularity    
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Discussion 
 The present study uses DTI, advanced graph theory and post-mortem 
microarray data in a cross-sectional design to show novel alterations in age-
related topological network degradation and its relationship to gene 
expression in SZ. These findings support popular disconnection models 
suggesting WM disruptions underlie pathophysiology in SZ, which compromise 
network integration throughout the lifespan. 
 First, we replicate prior findings of disrupted global topology in SZ and 
preserved smallworldness between patients and controls across all subjects 
(Figure 5.2). Previous diffusion MRI and graph theory studies support these 
findings, which suggest a limited capacity of brain information integration in SZ 
(Bassett et al., 2008; Filippi et al., 2013; Pettersson-Yeo et al., 2011; van den 
Heuvel et al., 2010; Zalesky et al., 2011). It is believed such topological 
differences may be due to the outcome of different growth processes and that 
neurodevelopmental abnormalities in SZ that specifically impact large 
multimodal cortical organization (Bassett et al., 2008). 
 Because largest eigenvalue of the adjacency matrix (Figure 5.2D) and 
power law alpha (Figure 5.2E) are novel metrics in the context of DTI and SZ, 
they will be briefly discussed. Power law alpha is a derivative of degree, and 
follows previously published results of decreased degree in SZ compared to 
patients (Fornito et al., 2012). Eigenvalues are a set of characteristic roots 
associated with a system. Thus, reduced largest eigenvalue of the adjacency 
matrix (Figure 5.2D) across all patients compared to controls suggest a 
network more vulnerable to insult with decreased information flow and 
robustness (Navlakha et al., 2014; Restrepo et al., 2007). Because our study 
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is the first examining these metrics in the present context, these results will 
benefit from independent replication.  
 Regression analysis reveals control network topology degrades in a 
stereotyped manner, while corresponding patient networks do not (Figure 5.3, 
Table 4.3). Due to the small sample size arising from splitting up the patient 
group, permutation testing was carried out. Age-effects survived permutation 
testing with FDR correction in metrics largest eigenvalue of the adjacency 
matrix and global efficiency.    
 Prior graph theory analysis of network topology on diffusion MRI data in 
healthy networks shows a significant positive stereotyped, linear effect of age 
on network costs (Gong et al., 2009). This suggests the aging network 
experiences a linear reduction in overall cortical connectivity, causing it to 
become less connected. This result converges with our findings of linear 
degradation in global efficiency in control subjects because networks with 
higher costs tend to have lower efficiencies (Figure 5.3A).     
 Additional network modeling shows absence of significant network 
degradation in younger adult patients. In contrast, significant linear network 
degradation, which more closely resembles control networks, is observed in 
older adult patients (Figure 5.4). Interestingly, global network topology of 
younger adult patients is significantly compromised when compared to age-
matched controls (Figure 5.5A-D). This effect is not observed in older patients 
(Figure 5.5E-H). Local analysis reveals global network abnormalities in 
younger adult patients are driven by changes in frontal, temporal and cingulate 
regions (Figure 5.8A, Figure 5.9A, Figure 5.10A). These regional differences 
become markedly less pronounced in older patients when compared to age-
matched controls (Figure 5.8B, Figure 5.9B, Figure 5.10B).  
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 Observed local topology disruptions in younger patients converge with 
DTI studies examining WM integrity, as reflected by Fractional Anisotropy 
(FA). It is reported that patients with SZ show globally reduced FA, including in 
frontal, temporal and cingulate regions compared to controls (Kochunov and 
Hong, 2014; Kubicki et al., 2002; Luck et al., 2011; Mori et al., 2007; Price et 
al., 2008; Szeszko et al., 2008). Indeed, many of these changes are observed 
at the earliest stages of illness (Kuswanto et al., 2012; Samartzis et al., 2014). 
 
Model of age-related topological degradation in schizophrenia 
 Our age model of disrupted topology, presented in Figure 5.11 supports 
neurodevelopmental hypotheses of SZ, which postulate a neurodevelopment 
risk factor of SZ acts during adolescence, disrupting the synaptic 
reorganization and pruning stages later in life (Kochunov and Hong, 2014)). 
The current work shows younger adult patients (ages 20-37), show 
compromised topology but lack of network degradation, which we believe is 
evidence of compensatory rewriting, reflective of the dynamic nature of brain 
networks.  
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Figure 5.11. Model of topological degradation. Control networks degrade in 
a constant, linear manner. In SZ, network metrics are stagnant at a 
significantly compromised level throughout younger adulthood and begin to 
degrade linearly in old age.  
 
 There is support for rewiring and extended development into the third 
decade of life (Petanjek et al., 2011). Further evidence suggests homeostatic 
mechanisms can often compensate for one insult by shifting weights in parallel 
pathways (Marder and Goaillard, 2006; Tononi et al., 1999). Subsequently, 
older adult patients (ages 38-68) show linear degradation of global networks 
and less pronounced network differences between patients and controls. 
There is evidence for structural brain changes at different stages of the illness. 
In line with our results, several cross-sectional studies show WM deficits in 
chronic patients are either absent or less severe than in first episode patients 
(Friedman, et al., 2008; Kong et al., 2011). 
 
 Prior anatomical studies in SZ also support our age model. Graph 
network findings of anatomical architecture suggest topological differences 
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between divisions of normal cortex may represent the outcome of different 
growth processes in SZ, which impact cortical organization (Bassett et al., 
2008). Furthermore, in a 19-year longitudinal study of cortical thickness, brain 
developmental trajectory in patients normalizes with age in posterior regions, 
while remaining divergent in frontal and temporal regions (Greenstein et al., 
2006). Specifically, the diminished posterior anatomical differences represent 
attenuation of loss with age, and as a result healthy controls appear to ‘catch 
up’ with patients, as controls also have a parietal-frontal ‘wave of loss’ that 
characterizes normal development (Gogtay et al., 2004). 
 Similarly, diffusion MRI studies examining WM integrity (FA), support 
our age-related WM degradation model. It it is suggested that progressive 
brain abnormalities exist early in the disease and that ongoing brain changes 
occur in the initial years of diagnosis (Karlsgodt et al., 2008; Kyriakopoulos 
and Frangou, 2009; Pantelis et al., 2005). Patients early in the SZ disease 
process show decreased connectivity in structural networks compared to 
controls, with structural connectivity negatively correlating with illness duration 
(Zhang et al., 2015). 
  Prior literature shows differences in WM integrity (FA) of the frontal 
cortex between SZ patients and controls. Differences are most pronounced in 
the youngest subjects and disappear with increasing age, suggesting age-
related differences in WM maturation between groups (Jones et al., 2006). 
This result was recently replicated and extended in a 300-subject study 
examining the impact of age on WM integrity in SZ, the largest study of its kind 
to-date. It is reported that FA differences do not appear to progress with age. 
Converging with our data, controls show a gradual FA decline while patients 
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show a flat relationship in FA decline. Younger patients show lower FA than 
controls, a difference which disappears with age (Kanaan et al., 2017). 
 
Relationship between age-related topological changes and gene 
expression 
 Correlation analysis reveals age-related differences in the relationship 
between gene expression in our genes of interest and disturbances in logical 
topology. Though more than 108 common associated loci have been identified 
with schizophrenia, we specifically tested a priori hypotheses of the six most 
highly published genes associated with the disease (Ripke et al., 2014). 
  Remarkably, we show DISC1, a gene discovered and named for its 
causative implications in SZ, has an age-related effect across all three metrics 
of local connection strength, efficiency and modularity (Figure 5.8C, Figure 
5.9C, Figure 5.10C.) Though gene expression data was collected from healthy 
post-mortem brains, analysis was carried out on nodal metric t-statistics of 
patients vs. controls, suggesting DISC1 has a relationship with organizational 
disturbances. Though DISC1 was the only gene with a significant, age-related 
topological association with local efficiency, we observe DISC1, DRD2, 
DTNBP1 and GRM3 all show significant relationships with disturbances in 
modularity (Table 4.10).  
 Younger patients show decreased modularity compared to controls, a 
segregation metric similar to clustering coefficient, and a result replicated in 
other studies (van den Heuvel et al., 2010). Interestingly, later in the disease, 
this trend changes in older patients, showing increases in modularity. The 
corresponding significant relationships to gene expression experiences the 
same sign flip between younger and older subjects (Table 4.10). Because this 
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is the first study examining the relationship between modularity and gene 
expression in schizophrenia, this result will benefit from independent 
replication.  
 Because COMT and BDNF is reported to mediate WM microstructure 
disconnectivity in SZ, the lack of relationship between connection strength 
disturbance in COMT and BDNF is surprising (Table 4.6) (Chen et al., 2017; 
Poletti et al., 2016). However, it is not wholly unexpected as FA changes in the 
same subjects are not reported to be identical to connection strength 
measurements in SZ (van den Heuvel et al., 2010).   
 Prior work establishes a precedent that gene networks show 
associations with regional structural connectivity (Forest et al., 2017). 
Similarly, a recently published survey of 20,000 genes shows the average 
transcriptional profile of 85 SZ risk genes is associated with WM connectome 
disconnectivity (Romme et al., 2017). Dissecting these 85 risk genes into six 
functional classes such as neurodevelopment, synaptic function and 
glutamatergic neurotransmission illustrates only one gene class (calcium 
signaling) shows a significant relationship between connection strength in SZ. 
This study did not test age effects. Upon first survey of the entire subject age 
range of our genes of interest, we similarly observe nonexistent or weak 
correlations that didn’t survive Bonferroni correction. However, significant 
associations emerge when subjects are separated into the older and younger 
age range. Together, these results support age-related models of WM 
topological degradation in SZ while also informing genetic underpinnings of 
age-related changes in connectivity.   
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Limitations 
 Some points should be taken into account when interpreting our results. 
The first is that we acknowledge the possible confounding factor of 
antipsychotic medications on the observed findings. The current study 
includes a relatively homogenous group with a clinical profile of severe 
enduring schizophrenia despite being medicated with atypical antipsychotics. 
However, it remains possible that long term use of antipsychotic medications 
contributes to effects observed in older subjects. While the effect of 
antipsychotic medications on gray matter volume are well-documented, there 
is relatively little evidence to suggest antipsychotics changes WM 
microstructure (Navari and Dazzan, 2009). Additional analysis examining the 
relationship between medication strength and graphics metrics was not 
performed in the current study because prior work in these subjects suggests 
no relationship between medication strength and WM microstructure. 
Specifically, previous analysis carried out in this subject cohort shows no 
correlation between patient FA and chlorpromazine equivalents for each 
patient’s medication status (Holleran et al., 2014). The second point to take 
into account is that global graph metrics are not independent. Graph theory 
measures depend on the network density and thresholding of weak 
connections. In this study we chose not to vary the threshold to test for 
robustness because weak synaptic connections have been suggested to be 
critical for the expression of plasticity within a network (Poirazi and Mel, 2001).  
 Additional limitations of the study include the small patient sample size 
and that reported local effects did not survive FDR correction. The issue of 
small sample size was addressed by extensive permutation testing, which is 
applicable to very small sample sizes (Legendre et al. 2012). Due to the 
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multiple thousands of voxels that are tested, lack of survival of FDR correction 
is a frequently reported phenomenon in structural connectomics (Dennis et al., 
2013; van den Heuvel et al., 2010; Verstraete et al., 2011; Zou et al., 2008). 
While alternative correction methods to reduce family-wise error rate have 
been proposed, none have been extensively adopted (Zalesky et al., 2010).  
An additional limitation of the current study is its cross-sectional design, which 
does not control for age of onset and medication history between patients. 
However, all subjects were relatively homogenous with SZ diagnosis. All 
patients were chronic and treatment resistant, being considered for a trial of 
clozapine. It is our hope that these findings provide a basis for future studies 
involving a longitudinal experimental design.  
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Chapter 6: 
Toward an Umbrella Approach to Modeling 
Neurodegeneration: Clinical Implications, Future Studies and 
Conclusions 
 
 Recent advances in non-invasive neuroimaging technology and the 
application of graph theory to neural networks constitute a rapidly evolving 
field known as network neuroscience (Bassett and Sporns, 2017). Motivation 
behind the study of network neuroscience is rooted in the principle that 
illumination of higher brain function requires an understanding of brain network 
organization (Sporns, 2012; Sporns et al., 2005). A proliferation of studies 
have begun to unpack static states of brain network organization, both in 
healthy subjects and across a wide range of neural disorders (Bassett et al., 
2008; de Haan et al., 2009; Redcay et al., 2013; Wang et al., 2012). 
 A recent focus has been placed on the mechanistic role that structural 
brain networks have in shaping brain dynamics, which is broadly defined as 
how the brain changes with time (Sporns, 2014). Given the progressive, 
stereotypical patterns of disease progression related to clinical 
symptomatology, mapping brain dynamics of neurodegeneration is a critical 
area of research (Brettschneider et al., 2015). In line with the core tenets of 
network neuroscience, the brain can change on two previously described 
dimensions: 1) Dynamics on brain networks (functional and pathological 
consequences taking place atop a static structural network) and 2) Dynamics 
of brain networks (changing structural networks).  
 The current thesis applies graph theoretic approaches and machine 
learning to multimodal human neuroimaging data with the central aim of 
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constructing predictive models to elucidate mechanisms of neurodegeneration. 
To achieve this aim, four distinct, but related, studies were performed. In 
Chapter two, we examined both dynamics on networks and dynamics of 
networks using a predictive pathology spread model to assess whether the 
structural network undergoes degeneration in Alzheimer’s Disease (AD). 
Subsequently, in Chapter three, we showed a relationship between protein 
cerebrospinal fluid (CSF) biomarkers and atrophy and speed of disease 
progression. Chapter four focuses purely upon dynamics on networks by 
constructing several predictive models of pathology spread in Huntington’s 
Disease (HD) as the first work to empirically test HD neurodegeneration 
hypotheses in vivo. In Chapter five, we switched gears to analyze dynamics of 
networks by exploring age-related organizational structural changes and the 
relationship to gene expression in chronic schizophrenia (SZ). This final 
chapter integrates findings across all four original studies and discusses the 
therapeutic implications of the current thesis, methodological considerations 
and future work.  
 
Structural network mediates neurodegeneration and is preserved in 
Alzheimer’s Disease 
 The first study that we presented sought to test hypotheses of both 1) 
Dynamics on networks as well as 2) Dynamics of networks in AD. Popular 
models of AD hypothesize stereotyped disease progression occurs via white 
matter (WM) fiber connections, most likely through trans-synaptic transmission 
of toxic proteins (Jucker and Walker, 2013). Hence, an important question in 
the field is whether and how organization of fiber pathways is affected by 
disease. It remains unknown whether fibers act as mere conduits of 
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degenerative pathologies, or if they also degenerate with the gray matter 
network.  
 Because a large body of evidence shows that WM integrity is weakened 
in AD, we tested the hypothesis that a compromised WM network mediates 
neurodegeneration (Hasan et al., 2012; Lee et al., 2015; Nir et al., 2013; 
Rowley et al., 2013). In Chapter 2, Preserved Overall Network Organization 
in AD Spectrum Despite Loss of White Matter Tract Integrity, we tested 
our hypothesis using our group’s previously published Network Diffusion 
Model (NDM) as a tool. Graph theoretic analysis and the NDM were used in a 
longitudinal design of 124 subjects. We found that despite significant loss of 
WM integrity, the overall organization of the structural network remains intact.  
 Specifically, graph theory analysis showed preserved network 
organization in patients compared to controls. Topology is preserved on the 
global level (Figure 2.3), local level (Figure 2.4) and between distribution of 
hubs (Figure 2.5) in AD vs. age-matched controls. However, such results 
seemed to conflict with prior work, which report disturbances in AD structural 
network organization (Daianu et al., 2013; Lo et al., 2010; Prescott et al., 
2014). Puzzled, we sought to find the source of our conflicting results. We 
replicated well-published differences in tract-level density (Figure 2.6), 
confirming there was no issue in our subject data or preprocessing pipelines. 
 Examination of our thresholding strategy revealed that the fact that we 
did not perform previously employed thresholding and binarization steps was 
likely the source of our discordant results (Figure 2.7). A literature search also 
showed that prior studies used smaller network graphs, most of which did not 
include subcortical regions (Table 2.8). To probe the effect of a potentially 
compromised WM network on disease spread, we examined local 
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eigenmodes, a structural characteristic previously shown to govern disease 
spread (Raj et al., 2015a, 2012). We found eigenmodes were virtually identical 
in patients compared to controls (Figure 2.8). Furthermore, use of a diseased 
connectome in place of a template connectome did not improve prediction 
accuracy of the NDM (Figure 2.9).  
 These results suggest that, despite measurable changes in integrity of 
specific fiber tracts, overall WM network organization in AD is preserved. 
Further, there is no difference in the mediation of putative pathology spread 
between healthy and AD-impaired networks. This conclusion is somewhat at 
variance with previous graph theory results, which report global topological 
disturbances in AD (Daianu et al., 2013; Lo et al., 2010; Prescott et al., 2014). 
Our data indicate that the combined effect of edge thresholding, binarization 
and inclusion of subcortical regions to network graphs may be responsible for 
alterations found in previous reports. Taken together, data presented in 
Chapter 2 support hypotheses encompassing dynamics on networks in AD. 
We showed that the WM network, which has been previously shown to 
mediate disease spread, is not significantly compromised in AD. Our 
conclusion is that the static WM network does not undergo change as a result 
of disease and may likely simply serve as a conduit for neurodegenerative 
pathology.  
 
CSF biomarkers predict range of speed of neurodegeneration in AD 
 Having established that AD is indeed a disorder reflecting dynamics on 
networks, our next study sought to further understand the dynamics at play 
atop the static, preserved structural AD network. Biomarker hypotheses 
postulate that progression of AD pathology in the brain is related to and 
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proceded by protein biomarker changes in CSF (Jack and Holtzman, 2013) 
(Rosén et al., 2013). Numerous studies support this hypothesis, showing 
biomarker profiles related to AD, such as low AB and high Tau and pTau in 
CSF, are related to increased rates of global atrophy and cognitive decline 
(Barnes et al., 2013; Dickerson et al., 2012; Ewers et al., 2012; Schott et al., 
2010; Stomrud et al., 2010; Young et al., 2014).  
 Hence, we turned our attention to examining the relationship between 
CSF biomarkers and the speed of degenerative pathology spread. A recent 
focus has been placed on the prognostic ability of molecular biomarkers to 
predict clinical outcomes for practical purposes such as differential diagnosis, 
therapeutic treatment and clinical trial inclusion (Ewers et al., 2015; Mattsson 
et al., 2014; Shaw et al., 2011; Tosun et al., 2016). Still, current methods to 
assess rate of degeneration often require multiple, expensive brain scans that 
may not be readily available in all clinical settings. Current measures of 
atrophy rates further relies on global brain volumes, without regard to the 
process by which progression proceeds in the brain. Therefore, we proposed 
that the rate parameter in our NDM model would serve as a more effective and 
more mechanistically relevant measure of rate of progression in AD. We 
hypothesized a subject’s speed of degeneration could be predicted by 
baseline CSF metrics. In Chapter 3, “A New Network-Constrained 
Technique to Characterize Neurodegenerative Progression Rate in 
Alzheimer’s Disease,” we tested our hypothesis using graph theory and 
machine learning in longitudinal data from 810 ADNI subjects. Our group’s 
previously validated Network Diffusion Model (NDM), shown to accurately 
recapitulate patterns of AD spread, models a single parameter of disease 
progression rate based on a subject’s longitudinal MRI data.  
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 First, we show a significant correlation between a subject’s global 
atrophy speed and speed of degeneration as modeled from the NDM (Figure 
3.1). This suggests that our modeled beta parameter is indeed reflective of 
degeneration. Furthermore, we observe a significant effect of degeneration 
rate across diagnostic groups on the AD spectrum (Figure 3.2) in addition to 
an effect of APOE4 allele on degeneration rate (Figure 3.3). Interestingly, no 
significant relationships are found when modeling degeneration speed from 
baseline CSF metrics using regression or correlation analysis (Figure 3.4). 
However, hierarchical clustering shows three separate clusters emerge 
(Figure 3.5A), with significantly different rates of neurodegeneration as well as 
clinical severity across clusters (Figure 3.7). A K nearest neighbor classifier 
assigns subjects to clusters based on baseline CSF measurements with >90% 
high accuracy (Figure 3.5B). A range of degeneration speed can be inferred 
from cluster assignment. Furthermore, we illustrate that clusters have different 
profiles, with more pathogenic clusters characterized by classic disease-
related CSF biomarker profiles (Figure 3.6). The more pathogenic clusters 
show higher rates of pathology spread, cognitive impairments and frequency 
of putative APOE4 alleles (Figure 3.7) (Figure 3.8).   
 Together, our results demonstrate a subject’s range of degeneration 
speed can be predicted from baseline CSF biomarkers, which may be a 
practical, inexpensive screening tool for future prognostic applications. Note 
however that despite the predictability of range, it is still not currently possible 
to accurately predict the rate of an individual purely from baseline data. The 
addition of baseline atrophy somewhat improves the prediction of rate. 
Prediction accuracy is particularly high for the group of patients belonging to 
cluster 2, who are in the middle of their degenerative course. Overall, Chapter 
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3 lends further support to dynamics on networks, by elucidating the 
mechanisms atop the static structural network, further implicating the role of 
abnormal protein accumulation on the gray matter network, in 
neurodegeneration. 
 
Structural network mediates neurodegeneration in Huntington’s Disease 
 Thus far in the thesis, we have shown that a preserved structural 
network mediates disease spread in AD. We have also provided further data 
supporting the modeling of rate of degeneration from candidate CSF 
biomarkers. Next, we turn our attention to Huntington’s Disease (HD). HD is 
different than AD in that the two diseases show different aetiologies, 
histopathological hallmarks and clinical phenotypes. However, they are similar 
in that they both exhibit a progressive, stereotyped nature of brain changes 
and clinical phenotypes associated with disease severity (Brettschneider et al., 
2015).  
 Similar to AD, HD has a candidate misfolded protein species, mutant 
Huntingtin (HTT), which is hypothesized to flow trans-synaptically and 
pathologically throughout the network (Herrera et al., 2011; Lee et al., 2001; 
Tabrizi et al., 2016; Tan et al., 2015). Though several hypotheses of HD 
spread have been proposed, including distanced-based, activity-based and 
structural connectivity-based hypotheses, none have been evaluated 
empirically in vivo (Brettschneider et al., 2015). In Chapter 4, Structural 
Network Model of Pathology Spread Predicts Neurodegeneration in 
Huntington’s Disease, we test several proposed, but to-date untested, 
models of how HD pathology initiates and spreads throughout the human 
brain. A large dataset of 231 subjects from the Track-HD study is used to build 
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and evaluate the following hypotheses in a cross-sectional manner: 1) 
Different brain regions are selectively vulnerable to HD owing to the regional 
molecular composition patterns assessed via gene expression profiles (Figure 
4.3B-E); 2) HTT and downstream gene products are produced at local sites in 
proportion to their innate regional expression, but subsequently transmitted to 
remote sites via connectivity networks (Figure 4.3A); 3) HD pathology seeding 
is focal and independent of gene expression, but subsequently ramify 
throughout the brain via network connections (Figure 4.4A3); 4) HD pathology 
seeding is diffuse or random throughout the brain, but subsequent network 
transmission along a directional (anterograde) network can recapitulate both 
seeding and spread (Figure 4.5). 
 Since the process of trans-synaptic transmission of HTT is not 
conclusive in the literature, we also assessed a model of spatial spread, 
whereby 5) spread between brain regions is governed by the distance (rather 
than connectivity) between them (Figure 4.4A1). Following recent proposals 
that neurodegenerative vulnerability is a result of neuronal activity between 
brain regions, we also assessed whether 6) the NDM model of spread along 
the functional connectivity would fit empirical patterns better than NDM 
evolved on structural connectivity (Figure 4.4A) (Figure 4.8B). 
 Overall, our data show that even if HD pathology is diffuse or random 
throughout the brain, subsequent network transmission along a directional, 
anterograde structural network can recapitulate both seeding and spread 
(Figure 4.5). Specifically, we illustrate the striatum is the most likely source of 
pathology seeding in HD (Figure 4.6). Taken together, data presented in 
Chapter 4 utilizes graph theoretic approaches and predictive modeling as the 
first study to shed light on mechanisms of disease spread in HD using 
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hypotheses tested in vivo. Our data support models encompassing dynamics 
on networks implicated HD neurodegeneration, suggesting that, similar to AD, 
intrinsic structural architecture mediates disease spread in HD.  
   
Structural network organization changes with disease progression in 
Schizophrenia 
 After successfully constructing and evaluating models encompassing 
dynamics on networks in AD and HD, we switched gears to dynamics of 
networks. Though not traditionally characterized as a neurodegenerative 
disorder, Schizophrenia (SZ) represented an excellent disorder to model 
dynamics of networks due to the ongoing gray and WM brain changes 
associated with the disease, which some scientists in the field classify as a 
neurodegenerative process (DeLisi et al., 1997; Kochunov et al., 2013; 
Kochunov and Hong, 2014). Unlike AD and HD, a candidate protein is not 
implicated in SZ pathology spread and there is no homogenous clinical 
phenotype nor progressive nature of symptomatology (O’Donoghue et al., 
2017). Hence, it logically followed to evaluate SZ from a dynamics of network, 
rather than dynamics on network, perspective.  
 We hypothesized that we could recapitulate structural network 
degradation of SZ in a network model. The last presented study in the current 
thesis, Chapter 5, Age-Related Changes in Topological Degradation of 
White Matter Networks and Gene Expression in Chronic Schizophrenia, 
tests our hypothesis by modeling the change in structural brain architecture 
after disease onset and its relationship to gene expression in SZ. We apply 
graph theory analysis to diffusion MRI data from 75 subjects, including 24 
clinically heterogeneous subjects with chronic SZ. Genetic analyses were 
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performed with microarray data collected from healthy brains by the Allen 
Brain Institute (Oh et al., 2014).  
 First, we replicated prior work illustrating overall differences in global 
structural organization in patients vs. age-matched controls (Figure 5.2). 
Novel results show significantly altered age-related network degradation 
patterns in patients compared to controls. Specifically, controls show 
stereotyped, linear global network decline with age. In contrast, patients show 
non-linear network decline with age (Figure 5.3). Further analysis reveals lack 
of significant topological decline in younger adult patients, which is 
subsequently followed by stereotyped linear decline in older adult patients 
(Figure 5.4). Local and global analyses show significant topological differences 
in frontal and limbic regions of younger adult patients compared to age-
matched controls, which become less pronounced with age in older adult 
patients (Figure 5.5) (Figure 5.8A-B) (Figure 5.9A-B) (Figure 5.10A-B). Lastly, 
we show several gene expression profiles, including DISC1, are associated 
with age-related changes in WM disconnectivity (Figure 5.8C) (Figure 5.9C) 
(Figure 5.10C).  
 These findings provide novel WM topological and genetic support to 
neurodevelopmental hypotheses of SZ, suggesting network remodeling 
continues throughout the third decade of life before stabilizing. Overall, 
Chapter five offers additional evidence for the notion that structural networks in 
schizophrenia are dynamic. However, contrary to our hypothesis, structural 
architecture in schizophrenia appears to recapitulate a neurodevelopmental 
process, rather than neurodegeneration.  
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Treatment implications and future directions: Toward an umbrella model 
of neurodegeneration 
 The central aim of this thesis has been to build predictive models of 
neurodegenerative pathology spread. We examined models illustrating 
dynamics on networks as well as dynamics of structural networks. The last 
portion of this thesis will discuss treatment implications and future directions, 
with a dynamics on networks focus.  
 
Treatment implications: Dynamics on structural networks 
 In Chapter 2, we used the NDM to show that despite extensive 
neurodegeneration on the gray matter network, AD pathology spread is 
mediated by a preserved structural network. Similarly, in Chapter 4, we tested 
six separate versions of the NDM to show that HD disease spread was also 
mediated by the, likely preserved, structural network. Because the NDM is 
based on eigen decomposition of the connectome, we note the structural 
eigenmode plays a crucial role in governing disease spread from a baseline 
state. Eigenfunctions are omnipresent in classical mechanics, where for 
example, standing waves in continuous media are eigenfunctions. In structural 
biology, the “normal modes” that describe the degrees of freedom of large 
molecules are the eigenfunctions of the equations that capture the relationship 
between the atoms of the molecule (Heller, 1981). Furthermore, many 
phenomena related to graphs or networks can be described in terms of the 
constituent graph eigenmodes, a field known as spectral graph theory, which 
has thus far had limited application in network neuroscience (Ng et al., 2002; 
Wang et al., 2017). 
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 Conceptually, eigenmodes represent the orthogonal sub-networks of 
brain connectivity. Our lab has previously shown that the brain graph’s low 
eigenmodes act as network attractors (AD, Chapter 2) or sinks (HD, Chapter 
4) for neurodegenerative pathologies, brain activity and the spread of 
hyperactivity in epilepsy (Abdelnour et al., 2015a; Abdelnour et al., 2015b; Raj 
et al., 2015). Since these eigenmodes, or epicenters, have the lowest 
eigenvalues, linear dynamics will settle into those few modes. 
 Work conducted on both AD and HD leads us to conclude that disease 
spread in the two neurodegenerative pathologies is mediated by intrinsic 
structural network architecture, which remains the same, even in the diseased 
state. The discovery of preserved eigenmodes in the disordered brain is a 
result replicated outside of the present thesis. Recently, it was shown that 
structural eigenmodes are nearly identical between healthy subjects and even 
to a large extent conserved in severe neurodevelopmental brain malformations 
such as agenesis of the corpus callosum (Wang et al., 2017).  
 Our studies implicating the critical role of structural eigenmodes 
converge with prior work, which suggest neurodegenerative-associated 
networks contain vulnerable “epicenters” whose healthy connectivity serve as 
a template for template-directed misfolding (Zhou et al., 2012). These 
epicenters anchor distinct networks and are hypothesized to give rise to 
different clinicoanatomical presentations in neurodegeneration (Seeley, 2017). 
The connection between eigenmodes and brain epicenters is cemented by the 
high correlation between eigemode importance maps and structural edge 
density maps presented in Wang et al. 2017, which is a well-replicated result 
(Owen et al., 2016, 2015). 
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 Taken together, we conclude that intrinsic structural brain architecture 
can be used, in conjunction with a scan capturing baseline state, to construct  
predictive network models of the dynamic process of neurodegeneration. We 
propose our model can be extended outside of just AD and HD to perhaps all 
neurodegenerative disorders, which exhibit characteristics of dynamics on 
structural networks, such as stereotyped gray matter network brain changes 
linked to candidate misfolded proteins. From a treatment perspective, this 
conclusion has substantial treatment implications. Prior network studies have 
focused on detecting differences between groups of patients and controls at 
discrete time points (Bassett et al., 2008; de Haan et al., 2009; Redcay et al., 
2013; Wang et al., 2012). 
 While these studies are valuable in terms of finding relevant disease 
biomarkers, they are not sufficient for direct clinical diagnostic/prognostic 
adoption. The main reason is that many of these findings are statistically 
significant at the group level, but the individual discrimination ability of the 
proposed biomarkers is not typically evaluated (Arbabshirani et al., 2017; Rüb 
et al., 2001).  
 The NDM is a tool that can predict a single subject’s future state of 
neurodegeneration. Eventual clinical adoption of the NDM could have 
widespread diagnostic and prognostic implications on differential diagnosis, 
treatment interventions and clinical trial inclusion. Furthermore, the ability to 
predict a subject’s rate of pathology using CSF biomarkers, as performed in 
Chapter 3, could one day eliminate the need for multiple, time-consuming 
brain scans that require expensive equipment and processing. Clinical 
translation of work performed in Chapter 3 could result in the development of a 
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practical, inexpensive tool to predict neurodegeneration from a lumbar 
puncture, which could be used widely in all clinical settings.   
 
Future directions: Dynamics on structural networks  
 Future directions for expanding the NDM as a clinically relevant 
prognostic tool include expansion of current work within AD and HD as well as 
development of the model in other neurodegenerative disorders, such as 
Parkinson’s Disease (PD) and Amyotrophic Lateral Sclerosis (ALS). A future 
point of work as it relates to AD is to model protein biomarker dynamics of the 
disease. Chapter 3 shed light on the relationship between baseline protein 
biomarkers and prediction of a range of speed of neurodegeneration. The role 
of protein biomarkers in the etiology of AD is well-established (Andreasen et 
al., 2003, 2001; Hulstaert et al., 1999; Rosén et al., 2013; Tapiola et al., 2009). 
Specifically, it is known that the pathological processes in the brains of AD 
patients start more than a decade before the first symptoms are noticed (Jack 
et al., 2013; Price and Morris, 1999). However, biomarker data in the current 
subjects was gathered within a year of the baseline MRI scan, after subjects 
had already been diagnosed with dementia. Future work should focus on 
gathering CSF biomarker data in a longitudinal manner, before clinical 
manifestations of disease. Mapping the rate of neurodegeneration predicted 
by the NDM as a function of temporal dynamics of CSF biomarker profiles is 
critical. Such a work could potentially detect dementia long before clinical 
onset and could potentially lead to the development of preventative 
treatments.  
 In Chapter 4, we used the NDM as the first work to create a whole-brain 
predictive model of HD in vivo. A static, conserved WM network was assumed 
 257 
in NDM construction as WM data from subjects in the Track-HD study was not 
available for our use. Prior work in the Track-HD cohort shows there are 
differences in WM organization in HD, which target the rich club (McColgan et 
al., 2015). Though our AD work in Chapter 2 suggests the WM network in HD 
is conserved, this assumption needs to be empirically tested for future model 
development.  
 Furthermore, evaluation of the NDM is HD was performed in a cross-
sectional manner, because longitudinal data was not available to us. Our 
cross-sectional design was adequate to determine which seeding and 
transmission strategies were sufficient to recapitulate stereotyped patterns of 
HD atrophy. However, our model must be expanded to show it can reproduce 
longitudinal aspects of HD progression in a longitudinal study design.  
  Lastly, future work to expand the NDM in HD should include 
mathematically modeling the effect of genetic repeat length. A proliferation of 
work shows a significant association between the length of the trinucleotide 
CAG repeat and age of HD onset (Andrew et al., 1993; Chen and Wolynes, 
2017; Duyao et al., 1993). Significant associations between the rate of striatal 
atrophy and mutation length have also been reported (Aylward et al., 2000). 
Hence, precise prediction of a subject’s age of onset, with added granularity of 
how fast the brain will degenerate could offer significant clinical promise for the 
treatment of HD. 
 
Treatment implications and future directions: Dynamics of structural 
networks 
 Though our study examining dynamics of structural networks in SZ did 
not model neurodegenerative aspects of the disease, the impact of the work is 
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not diminished. In Chapter 5, we showed the presence of an extended 
neurodevelopmental period of WM network reorganization, which was 
associated with gene expression. There is a wide body of work providing 
insight into specific genes that may be involved in the aetiology of SZ.  
For example, the Schizophrenia Working Group of the Psychiatric Genomics 
Consortium examined over 150,000 cases to show 128 significant 
independent gene associations, spanning 108 loci (Ripke et al., 2014). 
Similarly, a study of 418 subjects revealed novel deletions and duplications of 
genes that were highly linked to SZ (Walsh et al., 2008). Fewer studies 
examine associations between SZ neuroimaging biomarkers and genes 
(Chavarria-Siles et al., 2016; Terwisscha van Scheltinga et al., 2013). 
 However, much of this work consists of large GWAS studies that do not 
specifically link the relationship between the brain’s local gene expression and 
structural architecture. Earlier this year, the relationship between local gene 
expression and connectome disconnectivity was established, as measured by 
fiber tract connectivity density (Romme et al., 2017). We extend prior reports 
as the first work utilizing multiple topological graph metrics to empirically 
evaluate the relationship between local gene expression and WM network 
organization. Treatment implications of our work are substantial. Discovery of 
candidate genes that may be linked specifically to structural network 
organization may one day elucidate the specific genes linked to the “split” 
(schizo) “mind” (phrenia) phenotype (Bleuler, 2010). It is our hope that 
discovery of such candidate genes will lead to treatment for the remediation of 
altered pathways, either in utero or in early development before disease onset.  
 Our work in Chapter 5 focused on the development of a network model 
to capture dynamics of structural networks in SZ. Going forward, the proposed 
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model must be validated. Unlike our studies in AD and HD, our SZ study had 
less than 100 subjects, which significantly limits model generalizability (Waller 
et al., 2017). Future work will validate our model in a significantly larger subset 
of clinically heterogeneous SZ subjects and ancestry-matched controls. 
 Further illumination of the relationship between structural network 
organization, gene expression and clinical severity is also critical. We did not 
have access to individual subject clinical profiles and were thus unable to build 
a more comprehensive model, which would illustrate clinical relevance. 
Inclusion of individual clinical profiles as well as inclusion of a less 
homogenous patient group into future models will shed light on potential SZ 
subtypes. It is well-documented that there exist subtypes of SZ, including 
schizoaffective, schizophreniform and schizotypal personality disorder, which 
show different clinical profiles, outcomes and neuroimaging biomarkers 
(Fenton et al., 1997; Takahashi et al., 2017; Weinberg et al., 2016). Expansion 
of the current work through validation and addition of clinical metrics will 
ultimately lead to the eventual construction of whole-brain predictive models of 
SZ. Such a model could lead to better characterization of subtypes and their 
associated WM network organization for differential diagnosis and targeted 
treatment for patients that may response to a specific drug class or type.  
 
Conclusion 
 Understanding network organization is critical to elucidating higher 
order brain interactions. Though studies examining static network differences 
in neurodegenerative pathology have been carried out at discrete time points, 
models of how the brain changes with disease progression are lacking. In this 
thesis, we elucidated mechanisms of neurodegeneration through the 
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construction and evaluation of whole brain predictive models. Using 
Alzheimer’s Disease and Huntington’s Disease, we show that prion-like 
disease spread in neurodegeneration is mediated by intrinsic structural 
network architecture. Models of Schizophrenia also illustrate the importance of 
structural architecture, as we show ongoing structural network remodeling 
associated with gene expression into the third decade. This process appears 
to be more neurodevelopmental than neurodegenerative. Going forward, we 
suggest the possibility for the creation of an umbrella model of 
neurodegeneration, which is is rooted in intrinsic structural network 
architecture in the Network Diffusion Model. We also suggest future studies 
that can validate the proposed neurodevelopmental model in Schizophrenia.  
It is our hope that the work presented in the present thesis is the basis of 
future work that leads to practical, prognostic and diagnostic clinical tools for 
the prediction of neurodegeneration on the single-subject level.   
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